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Abstract 
 
The liver plays an important role in drug toxicity, in part through its significant 
expression of drug-metabolising enzymes. For this reason, liver cells are often used in 
toxicity screening. Chronic liver injury is also a growing health concern, but its study 
in-vivo is limited by the severity of the bile duct ligation (BDL) animal model. In 
investigating ways to replace animals as a source of liver cells for toxicity screening and 
reduce and refine the BDL model, rat AR42J-B-13 (B-13) cells have been examined as 
an alternative to primary hepatocytes and chemical alternatives to BDL have been 
examined respectively. 
 
B-13 cells were readily converted by glucocorticoid treatment to hepatocyte-like (B-
13/H) cells, which expressed functional CYP1A and CYP3A sub-families whose 
expression could be induced in response to prototypical inducers. CYP2B1 could be 
induced at mRNA but not protein level. The CYP1A2 gene in B-13 cells was 
disrupted/non-functional, however stable introduction of human CYP1A2 showed B-13 
cells could be humanised and used for assessment of bioactivation-dependent 
genotoxins. Drug transporter mRNA expression was low in B-13 and B-13/H cells, but 
HNF4α overexpression enhanced transporter mRNA expression and function in B-13/H 
cells.  
 
The chronic administration of methapyrilene and α-naphthylisothiocyanate in rats and 
mice respectively, caused liver injury qualitatively equivalent to that seen after BDL but 
without the associated mortality or severity seen with BDL. 
  
These data suggest that B-13/H cells could be used as an alternative to primary 
hepatocytes for drug toxicity screening. Chronic administration of methapyrilene and α-
naphthylisothiocyanate could be used as alternative less severe models of periportal 
fibrosis in rats and mice respectively. Use of B-13/H cells would reduce the number of 
animals required for hepatocyte derivation and through refinement of the BDL model of 
periportal fibrosis, fewer rodents would be subject to the associated complications and 
high mortality rate of BDL. 
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1.1 The Liver 
 
1.1.1 Anatomy 
 
The liver is the largest internal organ in humans; it is located under the ribcage and 
below the diaphragm in the upper right region of the abdominal cavity. It is surrounded 
by the Glisson’s capsule, a collagenous tissue capsule similar to that which surrounds 
the kidneys and other organs. The liver is split into lobes of differing sizes; humans, 
mice and rats each have 4 liver lobes [1], although the number is variable in other 
animals. Blood is supplied to the liver from two sources. The portal vein carries in 
deoxygenated blood, rich in the products of digestion, direct from the gut, pancreas and 
spleen. The remaining blood is supplied from the hepatic artery which is fully 
oxygenated.  
 
1.1.2 Cellular composition, distribution and function 
 
Within the liver are at least 15 different cell types, as outlined in table 1.1. The bulk of 
the liver is composed of hepatocytes (80% of the liver by volume) which are 
responsible for the majority of liver functions [2]. However, although hepatocytes make 
up the bulk of the liver, the numerous other cell types are required for the liver to 
function correctly. 
 
Hepatocytes Progenitor cells 
          Oval cell (rodents)  
          Hepatoblasts (humans) 
Biliary epithelia Fibroblasts 
Endothelia 
         Sinusoids 
         Blood vessels (arteries and veins) 
         Lymphatics 
Smooth muscle cells (blood vessels) 
Sinusoids Mesothelia 
Blood vessels (arteries and veins) Nerves (unmyelinated) 
Lymphatics Neuroendocrine cells 
Kuppfer cells Hematopoetic cells 
Hepatic stellate cells (Ito cells) Blood (erythrocytes, leukocytes, etc.) 
Lymphocytes  
Table 1.1: Cell types found in the liver 
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The liver acts as the regulator of intermediary metabolism as well as the primary organ 
involved in metabolism of ingested xenobiotics. Its functions specifically include 
carbohydrate and protein metabolism, control of lipid uptake and metabolism, 
production of numerous serum proteins (such as albumin and clotting factors) and 
xenobiotic metabolism. 
 
At a structural level, the liver is composed of lobules (figure 1.1) – polygonal units that 
contain all hepatic cell types centred around points of blood entry and exit and bile exit. 
At a functional level, the liver is composed of acini which similar to lobules, are 
focused around the point of blood entry and exit. However acini take into account the 
heterogeneous conditions experienced by cells depending on their position along the 
porto-central axis as outlined in figure 1.3. 
 
 
Figure 1.1: The two principal models of liver structure. In the Kiernan lobule, A, blood flows toward 
the central vein within a lobule but also between lobules with oxygen and nutrient concentrations falling 
as blood flows away from the portal tract. In the Rappaport acinus, B, blood similarly flows from the 
portal tract to the central vein through zones 1-3. Blood however is restricted to a single acinus and is 
considered not to flow into adjacent acini. Abbreviations: PT, portal tract; CV, central vein; NPM, nodal 
point of Mall. 
 
Within the lobule or acinus, hepatocytes are organised into cell sheets flanked by 
sinusoids on either side. The hepatocytes are polarised so that on the sinusoidal surface 
(basolateral) they have numerous microvilli whereas on the lateral surface, they are 
bound by tight junctions to form canals (canaliculi) into which they secrete bile that 
drains into bile ducts located in portal tracts [2].  
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Between the hepatocytes and the sinusoid, fenestrated endothelial cells enclose an 
extravascular region called the space of Dissé. In this space are found hepatic stellate 
cells, which, in the absence of inflammation, are quiescent retinoid and vitamin A 
storing cells. The close proximity of hepatocytes to portal vein blood and the fenestrated 
nature of sinusoidal endothelial cells allows hepatocytes to carry out their 
aforementioned roles [2]. Since the liver is highly perfused with blood vessels and is the 
first organ exposed to absorbed compounds from the gut, it expresses proteins required 
for xenobiotic metabolism and clearance. The liver therefore acts as the primary site of 
ingested xenobiotic metabolism and can effectively metabolise xenobiotics absorbed 
from the gut before they reach distal organs through systemic circulation (referred to as 
first pass metabolism). The consequence of this is that because many xenobiotics are 
toxic, hepatocytes are particularly susceptible to necrosis and apoptosis in response to 
ingestion of toxic xenobiotics.  
 
1.1.3 The biliary system 
 
The biliary tree consists of specialised vessels which run the length of the liver and 
transport bile secreted by hepatocytes within the liver out through ever enlarging vessels 
to the gut as outlined in figure 1.2. In humans and mice, the gall bladder acts to store 
bile when it is not needed, but not in rats which lack a gall bladder. Cholangiocytes (bile 
duct epithelial cells) line all parts of the biliary tree. Bile facilitates the intestinal 
digestion and absorption of lipids and lipophilic vitamins. Bile acids, which are the 
primary constituents of bile, are synthesised by hepatocytes from cholesterol and 
pumped into the canaliculi which drain into bile ducts in portal tracts. Aside from its 
role in digestion, the bile is used as an important route of excretion of a range of 
xenobiotic metabolic products from hepatocytes that are too hydrophobic to be excreted 
via the kidneys.  
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Figure 1.2: The human biliary tree. Bile produced by hepatocytes is transported through the biliary tree 
which emerges from the liver as the common bile duct. From here bile either is stored in the gall bladder 
or released into the duodenum through the sphincter of Oddi. Most intestinal bile acids are recirculated 
back to the liver by enterohepatic recirculation via the portal vein. From Probert., (2011) [3]. 
 
1.1.4 Cells of the liver 
 
Hepatocytes - Hepatocytes make up the bulk of the liver and are responsible for most 
of its unique functions. They are appropriately specialised and, at the ultrastructure 
level, are packed with rough and smooth endoplasmic reticulum, mitochondria and 
glycogen granules. The tight junctions between adjacent hepatocytes on the lateral 
membrane act to form a barrier to blood and bile between the basal and apical 
membranes. Hepatocyte transporters also show polarised expression with specific 
transporters expressed on the basal and apical surfaces. The tight junctions and 
polarised expression of transporters allows for the partitioning of different substrates 
between the blood and the bile, aiding in the control of whole body homeostasis by 
hepatocytes. 
 
Cholangiocytes – Cholangiocytes, cuboidal epithelial cells that line the biliary tree, are 
responsible for regulating bile homeostasis. As a population they are heterogeneous – 
they show a different phenotype depending on their location within the biliary tree. In 
terms of morphology their size is directly correlated to the size of the vessels that they 
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line. Small cholangiocytes (i.e. those surrounding small bile ducts) do not significantly 
modify the contents of the bile. Large cholangiocytes, lining larger bile ducts, 
conversely secrete hormones and electrolytes and alkalinize the bile [4]. 
 
Hepatic stellate cells - Hepatic stellate cells under normal hepatic conditions are 
quiescent vitamin A storing cells that lie between sinusoidal endothelial cells and 
hepatocytes. Pro-inflammatory signalling from liver injury leads to the activation of 
hepatic stellate cells; they lose vitamin A and transdifferentiate to proliferative and pro-
fibrogenic contractile myofibroblasts [5]. As part of this phenotypic change they up-
regulate α-smooth muscle actin (α-SMA) expression. 
 
Portal tract fibroblasts - Fibroblasts within the portal tracts normally act to maintain 
extracellular matrix (ECM) within the portal tract. The portal tract fibroblast population 
is heterogeneous, however they can generally be considered to be composed of cells that 
do not express α-SMA (portal tract fibroblasts) and those that do (portal tract 
myofibroblasts) [6]. In response to biliary and periportal hepatic injury, differentiation 
of portal tract fibroblasts to a myofibroblast collagen secreting phenotype (α-SMA 
positive) may occur [7, 8]. However, evidence suggests that significant populations of 
portal tract fibroblasts can remain undifferentiated whilst still contributing to the 
fibrogenic deposition of fibrotic collagens [9, 10].  
 
Kuppfer cells - Kuppfer cells are the liver-resident macrophage population. They 
adhere to the sinusoidal side of endothelial cells and are found primarily in the 
periportal region of the liver [11]. The primary role of Kuppfer cells, under normal 
conditions, is to maintain blood homeostasis through the phagocytosis of large particles 
(>10nm) such as cell debris, damaged erythrocytes and microorganisms. In response to 
hepatic insult, they become activated and release a wide range of inflammatory 
mediators including cytokines through which they act to regulate liver-specific 
responses to inflammation and recruitment of extra-hepatic inflammatory cells [12]. 
 
1.1.5 Liver zonation  
 
Hepatocytes are morphologically the same but demonstrate different specialisations 
according to their position along the porto:central axis. Several functions of hepatocytes 
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appear uniform across all hepatocytes such as production of serum. However, as 
indicated in figure 1.3, numerous hepatic functions such as glucose, ammonia and drug 
metabolism show zonal localisation and this is a consequence of the proteins required 
for these processes being differentially expressed in the specific regions of the lobule. 
Zonation is a complex phenomenon with important ramifications on how the liver 
functions. 
 
Current evidence indicates that zonation is a consequence of Wnt signalling; Wnt up-
regulated genes are high in centrilobular regions and low in periportal regions (figure 
1.3) [13]. Liver-wide activation of Wnt signalling leads to a reprogramming of all liver 
hepatocytes to a centrilobular phenotype. Conversely, liver-wide inhibition of Wnt 
signalling leads to a phenotypic change of all hepatocytes to a periportal phenotype [13, 
14].  
  
 
Figure 1.3: Liver and hepatocyte zonation. As blood flows from the portal tract in zone 1 to the central 
vein in zone 3, the oxygen and glutathione concentration decreases and cytochrome P450 expression and 
Wnt signalling increases. Several hepatocyte functions are zonated in a process that appears to be 
controlled by a Wnt signalling concentration gradient which is high in centrilobular regions and low in 
periportal regions. The proteins involved in the indicated processes are shown. Genes down-regulated by 
Wnt signalling are blue and genes up-regulated by Wnt signalling are red. Adapted from Colnot et al., 
(2011) [15] and Wallace et al., (2008) [16]. 
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1.2 Xenobiotic metabolism 
 
1.2.1 The phases of metabolism 
 
The xenobiotic metabolising properties of the liver are due to the expression of drug 
metabolising enzymes (DMEs) in hepatocytes. These DMEs primarily act to modify 
lipophilic xenobiotics, absorbed from the gut, to create more water soluble metabolites 
that can be excreted via the bile or urine. The process of xenobiotic metabolism has 
historically been split into 3 distinct phases: phase I, phase II and phase III which 
correspond to xenobiotic modification, conjugation and cellular efflux respectively. 
Table 1.2 outlines the primary DMEs of phase I and II in humans. Phase I metabolism 
can involve hydrolysis, reduction and oxidation reactions, which permit the subsequent 
conjugation of hydrophilic groups by phase II conjugation enzymes. In humans, the 
majority of phase I reactions consist of mono-oxygenation reactions catalysed by 
cytochrome P450s (CYP450) and flavin-containing monooxygenases.  
 
Phase (I or II) Reaction type Enzyme family involved 
Number of human 
isoforms 
Phase I 
(modification) 
Mono-oxygenation 
Cytochrome P450s 
(CYP450s) 
57 isoforms classified into 
37 families 
Mono-oxygenation 
Flavin-containing 
monooxygenases (FMOs) 
5 isoforms 
Phase II 
(conjugation) 
Glucuronidation 
UDP glucoronosyl 
transferases (UGT) 
22 isoforms classified into 
8 families 
Sulphation 
Sulphotransferases 
(SULT) 
13 total, 6 expressed in the 
liver 
Glutathione conjugation 
Glutathione transferases 
(GST) 
17 isoforms divided into 8 
different classes 
Acetylation 
N-acetyl transferases 
(NAT) 
2 distinct isoforms with 
several genetic 
polymorphisms 
Methylation Methyl transferases 
10 distinct enzymes 
classified according to 
substrate 
Amino acid conjugation 
ATP dependent acid:CoA 
ligases and Acyl:CoA 
amino acid N-
acyltransferases 
2 known enzymes but 
more enzymes have been 
postulated 
Table 1.2: Major phase I and all phase II pathways of xenobiotic metabolism. Adapted from Apte et 
al., (2011) [17]. 
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Although most chemicals undergo modification followed by conjugation, some 
chemicals undergo conjugation directly followed by modification, or are directly 
conjugated and excreted. Gemfibrozil for example is conjugated (to glucuronic acid), 
prior to CYP2C8 mediated hydroxylation [18] and paracetamol, under normal 
conditions, is directly sulphated or glucoronidated prior to cellular elimination [19].  
 
1.2.2 Cytochrome P450s  
 
The CYP450 family is the largest family of DMEs and in humans consists of 57 
separate genes which in the liver are grouped into 4 main subfamilies (CYP1A, 2B, 3A 
and 4A). They are responsible for the majority of drug metabolising activity (~75% 
[20]) and although there are numerous human CYP450s, 2 isoforms, CYP2D6 and 
CYP3A4 metabolise over 50% of clinically administered drugs [21, 22]. CYP450s 
catalyse the mono-oxygenation of their substrates following the catalytic cycle shown in 
figure 1.4 in which they first bind their substrate followed by two stepwise electron 
reductions. Their ubiquity in drug metabolism is explained by their broad substrate 
specificity, afforded by a flexible active site which allows them to bind and modify 
numerous substrates [23, 24].  
 
 
 
Figure 1.4: The cytochrome P450 catalytic cycle. The first electron required for catalysis is donated by 
CYP reductase and the second electron may be donated by CYP reductase or cytochrome b5. Adapted 
from Apte et al., (2011) [17]. 
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1.2.3 Xenobiotic hepatic bioactivation & toxicity 
 
Although liver xenobiotic metabolism is considered a sequence of detoxification 
reactions, both modification and conjugation reactions can result in an increase in 
compound toxicity (a process referred to as bioactivation). The standard example for 
this is paracetamol overdose, in which CYP450s catalyse the production of the reactive 
metabolite N-acetyl-p-benzoquinoneimine (NAPQI) from paracetamol. Bioactivation 
reactions are generally associated with the production of reactive intermediates. These 
are normally generated electrophiles and radicals which are postulated to cause toxicity 
through modification of cellular macromolecules (including DNA) and oxidative stress 
[25].  
 
Bioactivation reactions cannot occur in the absence of functional DMEs and therefore 
the liver is susceptible to drug induced liver injury (DILI). Due to this susceptibility, 
hepatocytes contain particularly high concentrations of the cryoprotectant reduced 
glutathione, which is their main detoxification mechanism for reactive intermediates, 
including for NAPQI from paracetamol [19]. However, when detoxification pathways 
are saturated, then liver damage can occur unimpeded. 
 
DILI is a major cause of acute liver failure [26, 27]. Unexpected hepatotoxicity is also 
the leading cause of drug attrition during development and following approval [28, 29]. 
CYP450s, possibly because of their role in the metabolism of most xenobiotics and 
mechanism of catalysis, are the DME family most commonly implicated in drug 
bioactivation. Indeed, many structural alerts for toxicity (chemical groups associated 
with bioactivation), are such because they are bioactivated by CYP450s [20, 25] and 
reactive intermediates resulting from CYP450 metabolism are considered a major cause 
of DILI [30].  
 
1.2.4 CYP450 induction  
 
Due to the importance of CYP450s in xenobiotic metabolism, the liver has evolved 
robust mechanisms to control CYP450 expression; in response to specific compounds, 
CYP450 activity can be increased by either up-regulation of CYP450 expression or 
stimulation of existing CYP450 activity (homotrophic or heterotrophic induction 
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respectively). The induction of CYP450 expression is primarily regulated by the 
receptors described in table 1.3. The agonists of the receptors are frequently substrates 
of the CYP450s that the receptors act to up-regulate and the inductive property of 
CYP450s can therefore be considered a homeostatic mechanism to promote clearance of 
xenobiotics.  
 
Receptor Main rat 
CYP450 induced 
Prototypical agonists Response 
elements 
Aryl hydrocarbon receptor (AhR) CYP1A1 β-naphthoflavone, 3-
methylcholanthrene 
XRE 
Constitute androstane receptor 
(CAR) 
CYP2B1 Phenobarbital XREM & 
PBREM (DR-3, 
DR-4, ER-6) 
Pregnane X receptor (PXR) CYP3A1/23 Pregnane 16α-
carbonitrile, 
dexamethasone, 
rifampicin 
XREM & 
PBREM (DR-3, 
DR-4, ER-6, ER-
8) 
Peroxisome proliferator-activated 
receptor-α (PPARα) 
CYP4A1 Bezafibrate, clofibrate 
PPRE (DR-1) 
Table 1.3: CYP450 inducing receptors. Based on Tompkins, 2008 [31]. 
 
The aryl hydrocarbon receptor - the AhR is a basic helix-loop-helix receptor, a 
member of the PAS domain superfamily which, when activated, causes the up-
regulation of CYP1A1, CYP1A2 and CYP1B1 expression as well as the expression of 
several conjugating enzymes [32]. It is expressed in most tissues including liver and its 
prototypical ligands are polyaromatic hydrocarbons and heterocyclic amines such as β-
naphthoflavone (β-NF), 3-methylcholanthrene, benzo[a]pyrene and 2,3,7,8-
tetrachlorodibenzodioxin [33, 34]. Several dietary agonists have also been identified 
including curcumin and quercetin [35, 36].  
 
As illustrated in figure 1.5, under non-induced conditions, AhR is partitioned into the 
cytoplasm heterocomplexed to 90kDA heat shock protein (HSP90), hepatitis B virus x-
associated protein 2 (AIP) and p23. These protein chaperones (and potentially others to 
a lesser degree) act to fold and stabilise AhR, maintain ligand responsiveness and to 
retain the AhR in the cytoplasm [32, 37]. On binding of an agonist to AhR, AIP 
dissociates and the AhR translocates to the nucleus still bound to HSP90. Within the 
nucleus, AhR nuclear translocator (ARNT) binds to AhR in place of HSP90 and the 
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heterocomplex binds to XRE sites, recruiting coactivators and transcriptional machinery 
to up-regulate gene expression [32]. 
 
Historically, the evolution of the AhR has been viewed as an adaption to exogenous 
chemical insults as its identified ligands were essentially all xenobiotics. However, there 
is increasing evidence that the true physiological role of the AhR is concerned with 
regulation of endocrine and immunological functions and that induction with exogenous 
ligands may disrupt its normal function [32]. For example, AhR knockout mice 
demonstrate defective leukocyte, liver and vascular development [38, 39]. Female 
knockout mice are also poor breeders and this has been linked to the AhR regulating 
oestrogen synthesis via the ovarian CYP450 CYP19 [40]. In this study, it was shown 
that a AhR ligand could modulate AhR regulation of oestrogen synthesis suggesting that 
AhR agonists/antagonists could disrupt endocrine signalling. A further endogenous role 
of the AhR has been demonstrated by Opitz et al., [41]. In this work, kynurenine 
produced by tryptophan catabolism in tumour cells activated the AhR to promote 
tumour malignancy by suppression of immune responses and tumour cell death. The 
authors further showed that in human glioblastoma tissue, AhR activity was inversely 
correlated with a positive outcome.  
 
From a toxicological perspective, the induction of CYP450s by the AhR in response to 
exogenous compounds is the most important when considering drug development and 
potential DILI. However, it is clear that the AhR plays important roles regulating 
endogenous physiological functions that are yet to be fully elucidated and these may 
become increasingly important to take into account when designing drugs in terms of 
off target effects of AhR activators. 
 
The constitutive androstane receptor and pregnane X receptor - the CAR and PXR 
are orphan nuclear receptors that are almost exclusively expressed in the liver, with 
some overlap of ligands and response elements [42]. CAR is constitutively active in that 
it is able to bind response elements in the absence of ligand binding [42]; its activity can 
therefore be regulated by agonists and antagonists. mCAR prototypical activators 
include phenobarbital (PB), bilirubin and 1,4-Bis[2-(3,5-Dichloropyridyloxy)]benzene 
(TCPOBOP); androstane and androstenol are antagonists [42]. The mechanism of CAR 
activation differs between agonists as is illustrated in figure 1.5B-C: it can be activated 
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either directly or indirectly such as in the case of TCPBOP and PB respectively. In the 
cytoplasm, similar to AhR, CAR appears to bind HSP90 as a chaperone and additionally 
to the co-chaperone cytoplasmic CAR retention protein (CCRP) which is required for 
cytoplasmic retention [43, 44]. The mechanism of CAR inhibition appears to depend 
upon disruption of co-activator association with CAR. Androstane, for example, inhibits 
the interaction of hCAR with the co-activator SRC-1 [45]. 
 
In the case of direct ligand binding, such as by TCPOBOP, it is thought that the ligand 
binds within the ligand binding domain leading to the up-regulation of SRC-1 and 
protein phosphatase 2A (PP2A) association [44, 46]. Nuclear translocation requires 
dephosphorylation of threonine 38 of hCAR (threonine 48 in mCAR) and is aided by 
serine 202 dephosphorylation [47, 48]. PP2A may catalyse the dephosphorylation, 
although additional proteins are required for PP2A-mediated dephosphorylation of 
threonine residues. The dephosphorylation of threonine 38 and serine 202 leads to 
nuclear translocation and once within the nucleus, hCAR associates with co-activating 
proteins and heterodimerises with retinoic X receptors (RXR) to mediate transcription 
[42]. Within the nucleus it appears that phosphorylation of CAR or an associated 
protein is required for CAR transactivation, as inhibition of Ca
2+
/calmodulin-dependent 
kinase activity inhibits CAR mediated up-regulation of CYP2B10 but not nuclear 
accumulation of CAR [49]. 
 
PB is an indirect activator of CAR in that it is able to induce CAR transactivation but 
does not bind to CAR. Recently, pioneering work by Mutoh et al., [50], has 
demonstrated that PB activates CAR by preventing the activation of the epidermal 
growth factor receptor by epidermal growth factor (figure 1.5C). Activated epidermal 
growth factor receptor normally inhibits the interaction of receptor for activated C 
kinase 1 (RACK1) with PP2A and CAR by activating SRC kinase, which deactivates 
RACK1 through phosphorylation (of RACK1) at tyrosine 52. In-vitro 
dephosphorylation assays showed that RACK1 was required for PP2A mediated 
dephosphorylation of CAR at threonine 38. By inhibiting this activation of epidermal 
growth factor receptor, PB promotes the interaction of CAR, RACK1 and PP2A, 
dephosphorylation of threonine 38 by PP2A and subsequent nuclear localisation of 
CAR. Once in the nucleus, activated CAR may initiate gene expression similar to when 
it is ligand bound. In the ligand binding model of CAR activation, the involvement of 
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RACK1 is not known, but conceivably ligand binding of CAR may cause a 
conformational change allowing PP2A, CAR and RACK1 to associate; this would 
permit PP2A to dephosphorylate CAR at threonine 38 thereby promoting CAR nuclear 
translocation. 
 
PXR activation is similar to that of CAR. The PXR is activated by a wide range of 
prototypical activators in humans such as rifampicin and hyperforin  [42]. In humans in-
vitro, hPXR appears to be constitutively localised in the nucleus where, in the absence 
of ligand binding, it acts as a gene silencer through association with co-repressors and 
histone de-acetylases [51]. Binding of ligands leads to dissociation of co-repressors and 
the recruitment of co-activators, the same as those that associate with CAR, leading to 
transcriptional up-regulation of genes [42]. In mice in-vivo, mPXR appears to be 
localised in the cytoplasm (figure 1.5D) bound to HSP90 and CCRP [52]. Activation 
through ligand binding leads to association with co-activators and nuclear translocation, 
heterodimerisation with RXR and activation of gene transcription.  
 
Activated CAR and PXR both up-regulate the expression of a broad range of DMEs, 
many of which overlap. This is because CAR and PXR both bind to XREM and 
PBREM sites. The major genes they regulate include CYP3A4, CYP3A5 and CYP2B6 
as well as some hepatic transporters and phase II conjugation enzymes [42]. They also 
both have specific genes that they alone regulate. Although PXR and CAR bind at the 
same response elements, they have different affinities for the consensus motifs and 
therefore their binding affinity at different response elements varies. PXR therefore 
favours CYP3A regulation whereas CAR favours CYP2B regulation [42, 53, 54]. This 
system allows for fine control of gene regulation by the two receptors. 
 
The CAR and PXR play a significant role in the regulation of xenobiotic metabolism as 
they regulate the expression of CYP450s responsible for the metabolism of the majority 
of drugs [42, 55]. Similar to the AhR, however, they also have a range of endogenous 
physiological functions. These functions vary but both the PXR and CAR have been 
shown to regulate gluconeogenesis and endocrine signalling through modulation of 
steroid and thyroid metabolism [55]. In particular, an important role of the PXR is its 
regulation of bile acid homeostasis. The PXR is responsive to bile acid precursors and 
several secondary bile acids and its activation leads to significant up-regulation of 
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DMEs within hepatocytes, which promotes the detoxification of bile acids and their 
clearance back into the biliary tree [56-59]. PXR also inhibits CYP7A1, which catalyses 
the rate limiting step of bile acid synthesis, in order to reduce further bile acid 
accumulation within the liver [60]. The role of the PXR in this context is evident in 
PXR knockout mice that have undergone bile duct ligation which show a significantly 
greater hepatic injury than wild type mice subject to the same procedure [61]. CAR also 
appears to aid in regulation of bile acid and cholesterol homeostasis, although to a less 
marked extent [62]. 
 
The peroxisome proliferative activating receptor α - the PPARα, part of the nuclear 
receptor gene superfamily, is expressed in tissues associated with fatty acid catabolism 
including the liver, heart, kidneys and muscle [63]. PPARα has a range of synthetic and 
biological ligands; its biological ligands include fatty acids and metabolites from fatty 
acid anabolism and catabolism [63, 64]. Prototypical synthetic ligands are fibrate drugs 
such as clofibrate and bezafibrate. Unlike the AhR, CAR and PXR, PPARα activation 
does not lead to up-regulation of DMEs generally involved in clinical drug metabolism 
and bioactivation of xenobiotics by PPARα regulated DMEs is uncommon. In the 
absence of agonist activation, PPARα is localised to the nucleus where, heterodimerised 
with RXR, it inhibits transcription of target genes through recruitment of co-repressors 
at PPRE sites (figure 1.5E). Binding of ligands causes the release of co-repressors and 
the subsequent recruitment of co-activators which leads to the initiation of target gene 
transcription [63]. 
 
PPARα was first investigated when it was found that the chronic administration of anti- 
hyperlipidaemia drugs (later discovered to be PPARα agonists) caused peroxisomal 
proliferation, hepatomegaly and the development of liver tumours in rodents 
independent of any genotoxicity. Use of knockout mice demonstrated unequivocally 
that PPARα was responsible for the phenotype seen [65]. More generally, PPARα 
knockout mice show hepatic accumulation of lipids when fed a high fat diet or, when 
fasted, show hypoglycaemia and elevated concentrations of plasma free fatty acids. 
These are phenotypes indicative of disrupted fatty acid oxidation and gluconeogenesis 
[66]. Further work has demonstrated that the PPARα is a crucial regulator of fatty acid 
β-oxidation through which, particularly in the liver, it acts as a mediator of whole body 
energy homeostasis [63]. In response to high concentrations of fatty acids and their 
  Chapter 1. Introduction 
 
16 
 
intermediate breakdown products, the PPARα up-regulates genes associated with all 
three fatty acid oxidation pathways (mitochondrial, peroxisomal and microsomal)[63]. 
This negative feedback loop leads to a reduction of cellular fatty acid concentrations 
and plasma triglyceride and very low density lipoproteins levels. Synthetic PPARα 
agonists (mainly fibrates) have been used for years to effect these very changes in 
patients with hyperlipidemia and can be taken without risk of carcinogenesis. This is 
because the link between PPARα activation and carcinogenesis that is seen in rodents is 
not recapitulated in humans due to species differences in PPARα activity [67].  
 
In rodents, PPARα activation causes an increase in hepatocyte oxidative stress and 
hepatocyte size whilst also promoting proliferation and inhibiting apoptosis, responses 
not seen in humans [68]. In humans, PPARα is expressed at levels significantly lower 
than that seen in rodents (roughly one tenth of the level in rodents) and it does not 
regulate growth and apoptosis, unlike rodent PPARα [69]. The reduced sensitivity of the 
human PPARα and differences in transcriptional regulation are thought to be the 
primary reason for the species difference observed.  
 
In terms of the relevance of the PPARα to xenobiotic metabolism, PPARα is activated 
by environmental contaminants including herbicides and phthalate esters which humans 
may be exposed to via the diet [70]. In rodents, phthalate ester exposure leads to a 
typical peroxisomal proliferation response [71]. There is consequently a growing 
concern that chronic exposure of humans to these compounds may have toxicological 
consequences.  
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Figure 1.5: Mechanisms of A. AhR, B. direct CAR, C. indirect CAR, D. PXR and E. PPARα 
mediated CYP450 induction. D shows mPXR induction (cytoplasmic in absence of ligand binding). See 
text for details.  
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1.2.5 Drug transporters  
 
The transport of drugs and chemicals, both prior to and after metabolism, plays a 
fundamental role in determining the rate of xenobiotic clearance and route of excretion. 
Hepatocytes express a broad range of transporters as summarised in table 1.4. These 
transporters, due to the polarised nature of hepatocytes, are expressed either 
basolaterally or apically, and allow hepatocytes to selectively partition endogenous 
moieties or xenobiotics into general circulation or the biliary tree.  
  
Transporter Location Role Example substrate 
ATP 
dependent 
Solute carriers 
NTCP Basal Major influxer of bile salts 
Taurine and glycine 
conjugated bile acids [72] 
No 
OCTs Basal Influx of organic cations Choline No 
OATs Basal Influx of organic anions Salicylates [73] No 
OATP1s Basal 
Influx of organic anions, 
amphiphatic organic solutes 
and bile salts 
Dihydroxy bile salts [74] No 
OATP2A1 Basal 
Influx of prostaglandins and 
eiscanoids 
Prostaglandin E2 [75] No 
OATP2B1 Basal Influx of organic anions Atorvastatin [75] No 
ABC transporters 
BCRP Apical 
Efflux mainly of sulphate 
conjugates 
Gefitinib [76] Yes 
BSEP Apical 
Major effluxer of conjugated bile 
salts although may also pump out 
some xenobiotics 
Monovalent bile acids [72] Yes 
MDR1 Apical Efflux of cationic compounds Colchicine [77] Yes 
MDR3 Apical 
Efflux of phospholipids via flippase 
activity 
Phosphatidylcholine [77] Yes 
MRP1 Apical Efflux of glutathione conjugates LTC4 [78] Yes 
MRP2 Apical Efflux of organic anions and GSH Glucuronidated bilirubin Yes 
MRP3 Basal Efflux of glucuronidated conjugates Bilirubin diglucuronide Yes 
MRP4 Basal 
Efflux of glucuronide and sulphate 
conjugates 
Chenodeoxycholylglycine 
(+GSH) [79] 
Yes 
Table 1.4: Important hepatocyte transporters and their properties. Adapted from Arias, (2009) [80]. 
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Basolateral uptake transporters – Drugs or endogenous compounds may enter 
hepatocytes either by passive diffusion or basolateral transporter mediated active 
uptake. Uptake transporters are members of the solute carrier superfamily which power 
uptake through secondary active transport (electrochemical gradient dependent) [81]. 
The primary uptake solute carriers are the major organic anion transporting 
polypeptides (OATPs), sodium-dependent taurocholate co-transporting polypeptide 
(NTCP), major hepatic organic cation transporters (OCTs) and major hepatic organic 
anion transporters (OATs).  
 
Efflux transporters – The hepatic transporters involved in the efflux of xenobiotics, 
their metabolites and endogenous metabolism products belong to the ATP binding 
cassette (ABC) superfamily which catalyse the unidirectional export of substrates 
powered by ATP hydrolysis. The primary efflux ABC transporters are the multidrug 
resistance P-glycoproteins (MDRs), bile salt export pump (BSEP), multidrug resistance 
proteins (MRPs) and the breast cancer resistance protein (BCRP). The majority of these 
transporters are on the apical membrane and efflux substrates into the bile, however 
MRP3 & MRP4 are located on the basolateral membrane and pump water soluble 
conjugated-metabolites into the blood. 
 
Hepatobiliary transport - The transport of bile acids in hepatocytes is primarily 
mediated by NTCP, which uptakes bile salts from the blood, and BSEP, which exports 
bile salts into canaliculi. Other transporters including OATPs (particularly OATP1B1) 
and MRPs (particularly MRP2 and MRP3), also have a role in bile salt transport. The 
farnesoid-X receptor (FXR) transcriptionally regulates the expression of bile acid 
production and transport [82]. It is activated by a range of bile acids in response to 
which it induces BSEP expression whilst inhibiting the expression of NTCP and 
OATP1B1, and CYP7A1, the rate determining enzyme in bile acid synthesis [83]. This 
response acts to maintain bile acid homeostasis by promoting hepatocyte bile acid 
clearance. Under cholestatic conditions, this response acts to protect hepatocytes from 
toxicity resulting from intracellular bile acid accumulation. Although the FXR is the 
main regulator of hepatobiliary transport, the PXR and CAR also play a secondary role 
through similar regulation of bile acid transport and metabolism [84]. 
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1.3 Safety testing of drug candidates 
 
The further a potential drug candidate progresses through drug development, the greater 
the potential loss if its development is halted due to safety concerns; consequently, 
companies try to detect potentially toxic candidates early on during drug development 
using a range of toxicological endpoints [85].  
 
Important aspects of a candidate drug determined during the discovery phase include 
assessing whether a drug causes CYP450 or transporter induction or inhibition, forms 
adducts with proteins or DNA, and its route of metabolism [85]. Much of the discovery 
phase work of drug development is carried out in-vitro as it is cheaper, has higher 
throughput and requires smaller quantities of a drug candidate [86]. The proportion of 
this work carried out in-vitro will increase in the future as a consequence of the 
increasing public and legislative pressure to reduce animal use in research and 
promotion of the 3Rs principles of research; these encourage the refinement, reduction 
and replacement of animals in research [87]. 
 
The liver metabolises the majority of clinical drugs and it is hepatocytes that are 
primarily responsible for liver functionality. Hepatocyte function is therefore the 
determining factor that governs drug toxicity and pharmacokinetics. To this end, 
hepatocyte models are utilised in drug research for in-vitro assessment of candidate drug 
metabolic parameters in terms of routes of metabolism and potential DME 
induction/inhibition. These hepatocyte models are described below. 
 
1.3.1 Primary hepatocytes 
 
The gold standard model for in-vitro toxicity screening of novel drugs and chemicals 
are primary human hepatocytes. However, there are numerous issues associated with 
their sourcing and culture. Primary human hepatocytes for research are mainly sourced 
from liver excised as part of surgical procedures and the demand for donor tissue 
consequently outstrips the supply available. Beyond supply issues, as the donor liver 
comes from patients undergoing hepatic surgery, the tissue itself maybe diseased or 
proxy to diseased tissue and the liver has in most cases been exposed to a range of 
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therapeutic drugs taken by the patient. These issues can cause significant variability 
between donor samples [88].  
 
In culture, primary hepatocytes are non-proliferative and rapidly dedifferentiate to a 
more fibroblastic phenotype within a few days, losing the majority of relevant drug 
metabolising activity, particularly CYP450s [89, 90]. Their senescence prevents their 
expansion in culture and the rapid dedifferentiation means that all experiments must be 
carried out within a short period of time. The cause of hepatocyte dedifferentiation in-
vitro is thought to be related to the loss of ECM and ischemia experienced by 
hepatocytes during isolation. This leads to initiation of inflammatory (through NF-κB) 
and proliferative (through mitogen-activated protein kinase) signalling as outlined in 
figure 1.6 [86, 91]. This response has the effect of priming hepatocytes for division, 
increasing ribonuclease expression and repressing liver enriched transcription factors 
such as hepatocyte nuclear factor 1α (HNF1α) and 4α, and CCAAT/enhancer-binding 
protein α (C/EBPα) and C/EBPβ [92-94]. These transcription factors promote a 
hepatocyte phenotype and their repression is thought to lead to dedifferentiation and the 
gradual loss of DME expression [86, 95, 96].  
 
 
Figure 1.6: Factors contributing to dedifferentiation of hepatocytes. From Fraczek et al., (2013) [86]. 
 
The limited supply of human hepatocytes means that non-human hepatocytes are 
frequently used for in-vitro toxicity screening as an alternative. To enhance survival and 
maintenance of drug metabolising activity in hepatocyte cultures, numerous approaches 
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have been investigated. The most common approach is to sandwich hepatocytes 
between collagen and matrigel [89, 97]. Other approaches include supplementation of 
serum free medium with dexamethasone (DEX) or epigenetic modifying agents such as 
dimethyl sulfoxide (DMSO) and trichostatin A [98-100]. Although the use of these 
different techniques alone or in combination diminishes the rate of hepatocyte 
dedifferentiation, they have only limited effect and they introduce complications in 
examination of endpoints and results. 
  
1.3.2 Pluripotent stem cell-derived hepatocyte-like cells 
 
In an attempt to solve the problems of human hepatocyte availability, numerous groups 
have attempted to derive hepatocytes from pluripotent stem cells, usually human 
embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs). Hepatocyte-
like cells can be derived from either of these populations and a wide range of different 
techniques have been used, generally by attempting to recapitulate liver embryogenesis 
[101]. Specifically, this involves the application of growth factors at defined times in 
order to differentiate the stem cells from pluripotency to endoderm induction, hepatic 
lineage specification and finally maturation [102]. Hepatocyte growth factor, fibroblast 
growth factor 4, oncostatin M and activin A are used almost universally for these 
protocols although there is no universal protocol and methods used vary significantly 
[101]. To determine if hepatic differentiation of stem cells has been successful, a range 
of endpoints are commonly measured and the most common of these is the assessment 
of albumin, α-fetoprotein and α-1-antitrypsin expression by PCR and/or 
immunocytochemistry [102].  
 
Hepatocytes derived from pluripotent stem cells could solve many of the issues 
associated with the use of primary human hepatocytes. Pluripotent stem cells are 
proliferative so offer an unlimited source of hepatocytes for xenobiotic toxicity testing 
and if a standardised protocol was developed, variation seen in primary human 
hepatocyte preparations could be reduced. The use of hiPSCs as the pluripotent stem 
cells used for generation would be superior to the use of hESCs, as the ethics involved 
with their derivation are significantly more straightforward since hiPSCs are derived 
from somatic cells unlike hESCs which must come from fertilised embryos. 
Additionally, the use of hiPSCs could allow for hepatocytes with different drug 
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metabolising phenotypes to be generated from genetically distinct individuals, thereby 
improving the predictive capacity of toxicity screening. 
 
Although there are significant resources focused on this area of research, hepatocyte-
like cells generated using these protocols demonstrate substantial variability in terms of 
the percentage of cells differentiated to a hepatic lineage and the functionality of the 
“mature” hepatocyte-like cells. A review of the recent literature has showed that the 
number of derived hepatocyte-like cells expressing albumin varies between ~9-90% 
using different protocols [101]. Drug metabolism activity has been assessed in several 
experiments involving the generation of hepatocyte-like cells and this similarly shows a 
large variation. The hepatocyte-like cells have shown 0-100% of primary human 
hepatocyte CYP3A4 activity (the most commonly measured CYP450) and 4-100% of 
CYP1A2 activity [101]. Of recent studies, work by Chen et al., and Duan et al., using 
hiPSCs and hESCs respectively have shown promise in producing hepatocyte-like cells 
with physiologically relevant drug metabolising activity [103, 104]. Chen et al., 
demonstrated the generation of hepatocyte-like cells from hiPSCs that showed 
equivalent CYP3A4 expression to primary human hepatocytes and these cells, when 
injected, could rescue mice treated with a fatal dose of carbon tetrachloride (CCl4). 
Using hESCs, Duan et al., describe hepatocyte-like cells which showed similar levels of 
CYP3A4, CYP1A2 and CYP2D6 activity to primary human hepatocytes. Aside from 
assessment of a limited subset of genes, characterisation of hepatocyte-like cells derived 
from stem cells is incomplete, particularly in respect to conjugation and transporter 
activity. Importantly, it is suggested that hepatocyte-like cells derived from pluripotent 
stem cells are foetal like cells that require maturation for complete function, similar to 
hepatocytes following dedifferentiation [105]. To improve their function, methods will 
need to be devised so that the derived cells can be matured to fully functional 
hepatocytes. 
 
Although the work deriving hepatocyte-like cells from pluripotent stem cells is 
encouraging, their use for drug and chemical toxicity screening is currently limited. 
This is mainly because of the considerable variation in batch to batch differentiation and 
function and general lack of significant drug metabolising activity. They are however 
also expensive to generate due to the numerous growth factors required which would 
become particularly pronounced considering the huge numbers that would be required 
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for screening purposes. Finally, if physiologically relevant hepatocytes are generated 
from pluripotent stem cells, then it is likely that they would spontaneously 
dedifferentiate similar to primary hepatocytes, limiting their utility. 
 
1.3.3 HepG2 
 
The HepG2 cell line was derived from a male human hepatoblastoma in the 1970s and 
found to have a parenchymal hepatocyte morphology and express a range of liver 
synthesised plasma proteins whilst being proliferative and straightforward to culture 
[106, 107]. Although they are the most widely used alternative to primary human 
hepatocytes and consistently express a range of conjugating enzymes and a number of 
transporters, their expression of CYP450s is more varied and limited. In particular they 
generally express some CYP1A and, in most cases, low to undetectable levels of 
CYP2B/C and CYP3A. Although they express AhR, PXR and low levels of CAR, 
HepG2 cells induce CYP1A but usually not CYP2B/C or CYP3A in response to the 
different receptor agonists [93, 108-113].  
 
A consequence of their limited CYP450 activity means that un-modified HepG2 cells 
are generally not very predictive of toxicity when exposed to bioactivation dependent 
hepatotoxins compared to primary hepatocytes [109]. However, as they express 
machinery required for CYP450 function (particularly CYP reductase [113]), some 
success has been achieved using HepG2 cells stably expressing CYP450 variants [114, 
115] and these could potentially be used for drug and chemical toxicity screening. A 
disadvantage of this approach is that the potential for induction and therefore study of 
drug interactions is lost as the introduced genes are either constitutively expressed or 
tetracycline induced/inhibited.  
 
1.3.4 HepaRG cells 
 
HepaRG cells are emerging as a useful model of hepatocytes. They were derived from a 
human female hepatocellular carcinoma and under normal conditions they are 
phenotypically stable and proliferative with a non-hepatocyte phenotype [116]. When 
the cells are confluent they are treated with 2% DMSO which gives rise to two distinct 
populations, one of hepatocyte-like and one of cholangiocyte-like cells, within 7-10 
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days [116, 117]. Measurement of CYP450 expression shows that non-differentiated 
HepaRG cells (prior to DMSO treatment) express low to undetectable levels of a range 
of CYP450s including CYP3A4 and CYP2D6 similar to HepG2 cells. Following 
DMSO induced differentiation, CYP3A4 in particular was expressed at higher levels 
than in freshly isolated human hepatocytes. Other CYP450s measured were also up-
regulated though to a lesser extent but to levels greater than that seen in HepG2 cells 
[108]. Aside from CYP450s, they also express a number of conjugation enzymes and 
transporters required for phase II and III metabolism though their activity has not yet 
been determined [118].  
 
HepaRG cells express AhR and the nuclear receptors CAR and PXR; these receptors 
appear functional as induction of the CYP450s CYP1A2, CYP2B6 and CYP3A4 has 
been documented [108, 118]. Recent literature has assessed the potential of HepaRG 
cells for drug and chemical toxicity screening based on their similarity to primary 
human hepatocytes. In comparison to HepG2 cells and primary human hepatocytes, it 
has been shown that HepaRG cells were more comparable to HepG2 cells than primary 
hepatocytes in terms of their response to hepatotoxins; primary human hepatocytes were 
~42% sensitive, HepaRG cells ~12.5% and HepG2 cells ~6% sensitive to the 
hepatotoxins tested [109]. This data suggests that although they express a similar drug 
metabolising complement to primary human hepatocytes, this alone is not sufficient to 
confer similar sensitivity. Potentially this may be because HepaRG cells, as hepatoma 
cells, may be more resistant to apoptosis and necrosis than primary hepatocytes. 
 
1.4 AR42J-B-13 cells 
 
1.4.1 Isolation and properties 
The pancreatic acinar cell line AR42J was derived from a pancreatic adenocarcinoma in 
male Wistar rats treated with azaserine [119, 120]. They have been suggested to be a 
“cancerous version of primordial pancreatic ductular epithelium” as they express acinar 
markers (such as amylase) but also some neuroendocrine markers, as well as being 
highly proliferative [120]. In response to activin A and betacellulin in combination, or 
hepatocyte growth factor alone, it was shown by the Kojima lab that a proportion of 
AR42J cells began to produce insulin [121, 122]. These responsive cells were isolated 
and expanded to produce the AR42J-B-13 (B-13) cell line. In 2000, the Tosh group 
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demonstrated that treatment of B-13 cells with DEX caused them to flatten, cease 
proliferation and up-regulate the expression of liver specific markers including albumin, 
glucose-6-phosphatase and transferrin within 14 days [123]. The activation of C/EBPβ 
was shown in the same paper to be the crucial event inducing transdifferentiation as, in 
the absence of DEX, transfection of C/EBPβ was sufficient to induce 
transdifferentiation. Furthermore, use of the dominant negative form of C/EBPβ 
inhibited transdifferentiation [123]. 
 
Subsequent work has shown that hepatocyte-like cells derived from B-13 cells (B-13/H 
cells) express several CYP450 isoforms including CYP2C11, CYP2A and CYP2E1, 
most of which are up-regulated significantly by 5 days following initiation of DEX 
treatment and are expressed at similar levels to freshly derived hepatocytes [124, 125]. 
The up-regulation of CYP450s has been demonstrated to lead to similarly high levels of 
cell death in response to the hepatotoxin paracetamol to freshly isolated hepatocytes 
[124]. Cell death conversely was not seen in undifferentiated B-13 cells. 
 
1.4.2 Conservation of transdifferentiation of pancreas to liver 
 
Based on the observed transdifferentiation of B-13 cells to B-13/H cells, the effect of 
glucocorticoids on exocrine pancreatic tissue in-vivo has been investigated. Treatment 
of rats for 21 days with DEX led to a significant increase in the number of CYP2E1 
positive cells in the pancreas compared to control animals [126]. Similarly, in 
transgenic mice which have constitutively elevated levels of glucocorticoids, significant 
expression of CYP2E1 was seen in pancreatic exocrine tissue [127]. Removal of the 
adrenal glands of these transgenic mice inhibited the expression of CYP2E1 in the 
pancreas indicating that glucocorticoids were responsible for the CYP2E1 positive 
exocrine cells in the pancreas. Perhaps most importantly, hepatic markers could be 
detected in the pancreas of a human patient treated for over 20 years with glucocorticoid 
(prednisolone) [128]. Furthermore, culture of primary and immortal adult human acinar 
cells with high concentrations of DEX leads to expression of hepatic markers [128]. The 
ubiquitous nature of the transdifferentiation of pancreatic exocrine cells to hepatocyte-
like cells in response to glucocorticoid interspecies provides strong proof that rather 
than being an artefact of cell culture, the transdifferentiation response is a conserved 
pathophysiological response and is likely related to the similar developmental origins of 
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the liver and pancreas which are both foregut endoderm derived. It also suggests that 
glucocorticoids may play developmental roles in the specification of the liver and 
pancreas in the foetus [123]. 
 
1.4.3 Molecular basis of transdifferentiation 
 
The signalling pathway responsible for the transdifferentiation of B-13 cells to B-13/H 
cells is still being elucidated, particularly at the level of gene regulation. However 
significant progress has been made in linking the administration of glucocorticoids to 
the induction of C/EBPβ as outlined in figure 1.7 and it has become clear the that 
suppression of Wnt signalling is the crucial early stage event of transdifferentiation. The 
involvement of the canonical Wnt signalling pathway in the transdifferentiation 
response was first suggested when it was observed that, following DEX treatment but 
prior to any phenotypic changes, Wnt3a expression was significantly down-regulated 
and β-catenin cytoplasmic localisation, phosphorylation and degradation were 
significantly increased [129]. The role of β-catenin in the transdifferentiation response 
was confirmed when introduction of a mutant form of β-catenin, that cannot be 
phosphorylated, prevented DEX induced transdifferentiation [129]. Active β-catenin 
regulates gene expression through the T cell factor/lymphoid enhancer factor 
(TCF/LEF) family of transcription factors. Chemical activation of TCF/LEF inhibited 
transdifferentiation and its inhibition, using quercetin, potentiated transdifferentiation 
[129]. That TCF/LEF inhibition is not sufficient alone to induce transdifferentiation 
suggests that β-catenin does not act solely through TCF/LEF to repress C\EBPβ 
expression. 
 
Further up the signalling cascade, the glucocorticoid receptor has been shown to be 
required for glucocorticoid induced transdifferentiation in B-13 cells [130]. It has also 
been observed that transdifferentiation was associated with a significant up-regulation 
of serum/glucocorticoid inducible kinase 1 (SGK1) expression [130]. SGK1 knockdown 
was subsequently shown to inhibit transdifferentiation whereas SGK1 overexpression 
promoted it [130]. Importantly, evidence suggests that that SGK1C is able to 
phosphorylate β-catenin, providing a causal link between SGK1 activation and 
transdifferentiation [130]. The SGK1 promoter contains a glucocorticoid response 
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element, which the glucocorticoid receptor has been shown to bind in rat fibroblast and 
mammary cell lines [131, 132], allowing transcriptional regulation of SGK1 expression. 
 
The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B 
(PKB/AKT) pathway has been implicated in transdifferentiation because inhibition of 
PI3K using the small molecule inhibitor LY294002 inhibits transdifferentiation as does 
expression of a dominant negative form of PKB/AKT [130, 133]. PI3K can be activated 
by the glucocorticoid receptor leading to the downstream activation of 3-
phosphoinositide dependent protein kinase-1 (PDK1) [134] and this potentially may 
occur in B-13 cells following DEX treatment. Generally activation of PDK1 would be 
expected to enhance Wnt signalling as active PKB/AKT, activated by PDK1, can 
deactivate glycogen synthase kinase 3 (GSK3) through phosphorylation [135]. 
However, it has been more recently shown that PDK1 can activate SGK1C [136], which 
could lead to a net repression of Wnt signalling as SGK1C acts downstream of 
PKB/AKT. Potentially therefore, activation of the glucocorticoid receptor by DEX in B-
13 cells may lead to increased glucocorticoid receptor mediated SGK1 transcription and 
also the activation of a signalling cascade in which PI3K activates PDK1, which in turn 
activates SGK1C. Activated SGK1C may then inhibit Wnt signalling through the 
phosphorylation of β-catenin, causing the de-repression and subsequent up-regulation of 
C\EBPβ expression leading to transdifferentiation.  
 
Once C\EBPβ is activated, the mechanism of cellular reprogramming that causes 
transdifferentiation is unknown. Unpublished work from this lab suggests that DEX 
treatment is associated with major epigenetic reprogramming within hours of treatment 
which commit the cells to transdifferentiation, even when DEX is removed after only 6 
hours of treatment. C\EBPα and C\EBPβ are thought to be the first transcription factors 
induced, followed by the liver transcription factors HNF4α and RXRα [137]. Significant 
work is required however to elucidate the mechanism, though once established, it could 
be used to generate a human equivalent B-13/H cell which could be used for drug and 
chemical toxicity screening as an alternative to primary human hepatocytes.  
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Figure 1.7: Hypothesised signalling pathway linking DEX (and other glucocorticoids) to C/EBPβ 
activation and transdifferentiation. See text for details. Abbreviations: p, phosphorylated; GR, 
glucocorticoid receptor; LIP, C/EBPβ-liver enriched inhibitory protein. 
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1.5 Liver disease & fibrosis 
 
Liver disease is a significant worldwide cause of mortality; it is the 5
th
 most common 
cause of mortality in the UK, the 12
th
 in the USA and 14
th
 in the world overall [138]. 
The liver has the unique ability to regenerate when up to 70% of its mass is removed, 
restoring former mass and function within a relatively short period of time [16]. The 
liver can therefore regenerate in response to acute injury to restore full function. 
However, when the liver is challenged by chronic injury/insult, as from the diseases 
listed in table 1.5, the regenerative capacity of the liver results in the excess deposition 
of collagen I rich ECM. The unrestricted accumulation of this fibrotic matrix restricts 
liver regeneration and function [2, 16]. 
 
 
Disease 
Incidence 
Hepatitis B 370 million individuals worldwide [139] 
Hepatitis C 130 million individuals worldwide
 
[139] 
Alcoholic liver disease (ALD) 
Difficult to gauge, caused nearly 5,000 deaths in England and 
Wales in 2008 and death rates due to ALD have increased 69% in 
30 years [140] 
Non-alcoholic fatty liver disease 
(NAFLD) and non-alcoholic 
steatohepatitis (NASH) 
Possibly up to 60 million individuals worldwide and increasing due 
to a continual global rise in obesity [141] 
Primary biliary cirrhosis 
About 1 in 4000 individuals in England, lower in non-Western 
countries. Disproportionally effects women (only ~10% of sufferers 
are men)  [142] 
Table 1.5: Common causes of chronic liver disease and their incidence. Adapted from Probert (2011) 
[3]. 
 
1.5.1 Pathophysiology  
 
Chronic liver injury resulting from a variety of causative agents results in cell injury and 
death within the liver. The release of intracellular components resulting from cellular 
necrosis leads to activation of Kuppfer cells and initiation of an inflammatory response 
through the release of pro-inflammatory mediators [5, 16]. Exposure of collagen, a 
consequence of endothelium damage, also activates platelets which release pro-
inflammatory mediators [143]. These factors cause the recruitment of extra-hepatic 
leukocytes, which contribute to the inflammation, and the activation of fibroblasts (i.e. 
hepatic stellate cells and portal tract fibroblasts) causing them to replace the damaged 
liver parenchyma with fibrous matrix. In the context of wound healing, fibroblasts 
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deposit ECM which acts as a scaffold for regeneration. However, the constant pro-
inflammatory environment of chronically injured liver results in the prolonged 
activation and proliferation of pro-fibrotic myofibroblast cell populations leading to a 
net increase in ECM formation. This manifests as a reduction in “normal” matrix 
protein, mainly collagens IV and VI, and an increase in crosslinked fibrillar collagens I 
and III and fibronectin [5].  
 
Initially, the deposition of fibrous tissue within the space of Disse leads to a loss of 
endothelial fenestrations and hepatocyte microvilli in the sinusoids which retards 
metabolic exchange between hepatocytes and the blood resulting in attenuated hepatic 
function (figure 1.8)[5]. Over time, ongoing cycles of hepatic injury and scar tissue 
deposition may result in the development of cirrhosis. Cirrhosis is considered the final 
stage of fibrosis and is characterised by the development of regenerative and irregular 
hepatic nodules [144]. Initially the liver is able to functionally compensate for cirrhosis, 
however as the severity of fibrosis increases and portal hypertension develops, due to 
increased resistance faced by blood passing through the liver, cirrhosis may become 
decompensated, ultimately culminating in liver failure [5].  
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Figure 1.8: Changes in liver structure resulting from fibrosis. A. In normal liver hepatocytes are 
separated from the sinusoid by a thin-like basement membrane within the space of Disse and blood flows 
unimpeded through from afferent blood vessels in the portal tract to the central vein. B. In fibrotic liver 
metabolic exchange between hepatocytes and the blood is inhibited by the deposition of ECM within the 
space of Disse and loss of hepatocyte microvilli and endothelial fenestrate. ECM causes constriction of 
blood vessels causing portal hypertension. From Hernandez-Gea and Friedman, (2011) [5]. 
 
1.5.2 Liver fibrosis asymmetry 
 
Liver fibrosis develops in different regions of the liver lobule depending on the 
causative injury as outlined in figure 1.9. Hepatotoxins primarily target centrilobular 
regions due to the elevated expression of CYP450s and low concentrations of the 
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cyroprotectant glutathione in the region (because of liver lobule zonation). Conversely, 
viral hepatitis primarily infects periportal hepatocytes, at least during the early stages of 
the disease, due to their immediate proximity to the afferent blood supply.  
 
The asymmetric nature of liver lobule injury gives rise to asymmetric fibrosis: 
centrilobular liver damage causes centrilobular fibrosis and periportal injury leads to 
periportal fibrosis. The regulation of fibrogenesis varies depending on the location of 
lobule injury and this is in part due to the heterogeneity of hepatic (myo)fibroblast 
populations. The main sources of myofibroblasts in the liver are hepatic stellate cells 
and portal tract fibroblasts, which express both distinct and shared markers and 
demonstrate different behaviour in-vivo and in-vitro [145].  
 
Until recently, it was thought that fibrogenesis in centrilobular and perisinusoidal 
regions of the liver was mediated by hepatic stellate cells whereas, in periportal regions, 
it was mediated by portal tract fibroblasts [6, 16]. This was based on a number of 
studies including one by Beaussier et al., who showed that most myofibroblasts 
following bile duct ligation (BDL) were negative for the hepatic stellate cell marker 
desmin [146]. Furthermore, portal tract fibroblasts are activated, proliferate and deposit 
ECM during the early stages of liver injury following bile duct ligation prior to 
activation of hepatic stellate cells [145]. However, a recent study using lineage tracing 
suggests that the majority of myofibroblasts (>80%) in several murine models of liver 
disease including BDL are derived from hepatic stellate cells, which are also 
responsible for the majority of collagen production [147]. The role of portal tract 
fibroblasts and derived myofibroblasts in periportal fibrogenesis is therefore 
controversial; it is likely that, regardless of their apparently minor contribution to 
collagen deposition, they play a role in regulation of fibrogenesis, particularly during 
the initial phases and are an important determining characteristic of periportal 
fibrogenesis [145]. Their ablation would allow their absolute contribution to 
fibrogenesis to be determined. However this is prevented by the heterogeneous nature of 
portal tract fibroblast populations and lack of consistent markers to allow for their 
selective targeting compared to hepatic stellate cells [145].  
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Figure 1.9: Zonal nature of liver fibrosis. Different causative agents preferentially damage the liver in 
different regions. Based on Wallace et al., (2008) [16]. 
 
1.5.3 Ductular reaction and fibrogenesis 
 
Apart from differences in fibrogenic cell populations involved in fibrogenesis in 
different regions of the liver, other factors affect the development of fibrosis. Arguably 
the most important of these is the regulation of fibrogenesis by bile duct epithelia which 
is particularly pronounced during portal/periportal fibrogenesis due to the local 
activation of a ductular reaction. Ductular reaction describes the expansion of a 
potential stem niche within the small branches of the intra-hepatic biliary tree, such as 
occurs during chronic liver injury [4]. These stem cells are described as oval cells in 
rodents and hepatic progenitor cells in humans and have a cholangiocyte phenotype 
(cytokeratin-7 &-19 positive). They divide to form cords of bipotent cells, able to 
differentiate into hepatocytes or cholangiocytes, which stream out of the portal tract to 
aid in hepatic regeneration. A consequence of this reaction is an increase in the number 
of reactive biliary ductules within and around the portal tract. Although ductular 
reaction may be seen during chronic liver injury generally regardless of insult or 
localisation, it is particularly associated with portal and periportal injury [4].  
 
In terms of their ability to modulate fibrogenesis, in rats with biliary fibrosis following 
bile duct ligation, biliary epithelial cells have been shown to be able to release a range 
of pro-fibrogenic and inflammatory factors. These include including connective tissue 
growth factor, transforming growth factor β (TGFβ) -2 and platelet-derived growth 
factor [148-150]. There is also evidence for hedgehog mediated paracrine signalling 
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with myofibroblasts, in which cholangiocytes act to promote myofibroblast growth, 
which in turn promotes cholangiocyte proliferation [151].  
 
1.5.4 Modelling liver fibrosis 
 
Liver fibrosis is a complex disease involving the contribution of a range of cell types. 
The most straightforward modelling of liver fibrosis involves the in-vitro culture of 
hepatic stellate cells, isolated by collagenase and pronase digestion of the liver [152]. 
Hepatic stellate cells are isolated on the basis of their low density, a by-product of their 
high lipid content. This mechanism therefore primarily isolates quiescent cells which, 
on prolonged culture with plastic, rapidly acquire a myofibroblast phenotype similar to 
that seen in-vivo during chronic liver disease. Although useful for basic research, culture 
of single cell types fails to reflect the complexity of liver fibrosis, thereby necessitating 
the use of in-vivo models. The most common in-vivo models of liver fibrosis are 
detailed below: 
 
Carbon tetrachloride (CCl4) treatment - chronic administration of the hepatotoxin 
CCl4, particularly in rodents, is the most commonly used model of fibrosis. Most 
commonly it is dosed at 1ml/kg body weight twice a week by intra-peritoneal (i.p) 
injection for 4 to 8 weeks [153]. CCl4 is metabolised by hepatic CYP2E1 to form a 
reactive radical (trichloromethyl radical) which causes hepatocyte death through lipid 
peroxidation and alkylation of cellular components [154]. CYP2E1 is highly expressed 
in centrilobular hepatocytes and therefore CCl4 administration results in fibrosis that 
develops out of the central vein eventually forming central-central bridging fibrosis as 
shown in figure 1.10. Due to their low expression of CYP2E1, periportal hepatocytes 
are relatively unaffected [16]. 
 
Dimethylnitrosamine (DMN) administration - DMN is injected i.p in rats and mice to 
generate centrilobular fibrosis. Similar to CCl4, DMN is bioactivated by CYP2E1 to 
produce methanol and formaldehyde which through methylation of cellular components 
(particularly DNA) causes hepatocyte and endothelial cell apoptosis [155, 156]. It is 
commonly administered by i.p injection at 40-100mg/kg body weight 1 to 4 times a 
week for up to 15 weeks in rats. Mice are often treated by adding DMN to the drinking 
water at 0.1mg/L [153]. The progressive injury leads to centrilobular haemorrhagic 
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necrosis, coagulation and ultimately centrilobular and central-central bridging fibrosis 
[157]. 
 
Thioacetamide (TAA) treatment - thioacetamide is administered either by i.p injection 
or in the drinking water of rats and mice to generate primarily centrilobular fibrosis and 
eventually central-central bridge fibrosis [16]. Fibrosis is normally generated either by 
dissolving TAA in drinking water at 200mg/L or by i.p injection of 50-100mg/kg body 
weight 3 times a week for up to 12 to 16 weeks [153]. It is bioactivated by CYP2E1 
resulting in generation of the highly reactive sulfdioxide metabolite which, through 
covalent modification of cellular proteins, causes oxidative stress and necrosis in 
hepatocytes [158, 159].  
 
Bile duct ligation (BDL) - BDL is a surgical procedure involving the double ligation of 
the common bile duct for 3-4 weeks. This ligation causes cholestasis and the subsequent 
accumulation of bile acids within bile ducts. In bordering hepatocytes and 
cholangiocytes, these bile acids either cause apoptosis through disruption of 
mitochondrial function or, at higher concentrations, necrosis through solubilisation of 
the cell membrane [160]. Figure 1.10 shows that the location of the bile duct in the 
portal tract means that BDL causes periportal injury and fibrosis, leading to portal-
portal bridging fibrosis [161]. The severity of the injury induced by BDL however 
means that within 4 weeks, fibrosis is generally seen throughout the lobule [162]. 
 
 
Figure 1.10: Pattern of hepatic fibrosis induced by CCl4 and BDL. Adapted from Wallace et al., 
(2008) [16]. 
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1.5.5 Treatment of liver fibrosis 
 
Liver fibrosis, where the underlying causative agent is removed, has been shown to be 
reversible in many animal models of hepatic fibrosis and cirrhosis. In human patients, 
regression or complete reversal of fibrosis resulting from a range of diseases has been 
documented where the underlying insult has been treated [5, 163]. However, not all 
patients are responsive to treatment and therefore development of anti-fibrogenic drugs 
could be an important tool to treat fibrosis. Currently though, there are no approved 
anti-fibrogenic drugs in clinical use for the treatment of hepatic fibrosis as novel drugs 
tested clinically have generally failed due to lack of efficacy in human patients [143]. 
There is therefore an ongoing demand for models of fibrosis with which to develop anti-
fibrogenic drugs. 
 
1.6 Study objectives 
 
Development of novel drug treatments requires robust models with which to identify 
drug targets and consequently determine drug safety and efficacy. The rate of drug 
discovery and validation can be significantly limited by a shortage of robust, relevant 
and practical models. Application of the 3Rs principles of research to existing models 
can result in development of superior models for research whilst reducing animal usage 
The aims of this thesis were therefore to apply the 3Rs to two models within the field of 
liver toxicology and disease, primary hepatocytes and periportal fibrosis respectively, in 
order to develop more refined models and reduce animal usage. The aims specifically 
were to: 
 
 Investigate the expression and function of drug metabolising enzymes and 
transporters in B-13/H cells  
 
 Determine if B-13 cells can be humanised with human drug metabolising 
enzymes 
 
 Investigate if chronic administration of methapyrilene in rats and α-
naphthylisothiocyanate in mice could be used as alternative models of periportal 
fibrosis to BDL 
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2.1 Materials 
 
Unless otherwise stated, all materials were bought from Sigma-Aldrich at the highest 
purity available (Poole, UK). 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 
(PhIP) and 1-hydroxyestragole were kindly donated by Professor Nigel Gooderham 
(Imperial College London, UK) and Professor Ivonne Rietjens (Wageningen University 
and Research centre, Netherlands) respectively. Polyurethane 134 (PU134) coated slides 
were donated by Dr David Hay (The University of Edinburgh, UK). Professor Matthew 
Wright (Newcastle University, UK) provided the B-13 genomic sequence and DNA 
produced from rat liver and B-13 and B-13/H cells. Adenovirus constructs Ad-null, Ad-
C/EBPα encoding mouse C/EBPα, Ad-HNF1α encoding human HNF1α, Ad-HNF4α 
encoding human HNF4α, Ad-LAP encoding liver activatory protein of unknown species 
and Ad-LIP encoding liver inhibitory protein of unknown species were donated by 
Professor David Tosh (University of Bath, UK). Adenoviral construct Ad-EGFP, 
encoding green fluorescent protein, was donated by Dr Audrey Brown (Newcastle 
University, UK). 
 
2.2 Animals 
 
2.2.1 Housing and ethics 
 
Rats and mice were housed in the Comparative Biology Centre at Newcastle University 
and kept in accordance with Home Office guidelines. They were kept in separate rooms 
in an air-conditioned environment on a 12 hour light/dark cycle with regulated humidity 
(50% ± 10%) and temperature (23°C ± 1°C). Rats and mice were provided with food 
and water ad-libitum and kept no more than 5 (rats) or 6 (mice) to a cage. Experiments 
were performed under a UK Home Office licence (PPL 60/3907) and Newcastle 
University Ethics Committee permitted the use of animals for this project. Prior to a 
study starting, a protocol was prepared and approved by the Head Animal Technician. 
 
2.2.2 Rats 
 
Male Sprague-Dawley rats were purchased from Charles River (Margate, UK) and kept 
as per 2.2.1. Rats were between 200-300g body weight at the beginning of all 
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experiments.  
 
2.2.3 C57BL/6 mice  
 
 C57BL/6 mice (wild type) were either bred on site or purchased from Charles River and 
kept as per 2.2.1. Mice were at least 8 weeks old and between 15-22g body weight at 
the beginning of all experiments. 
 
 2.2.4 3x-κB-luc C57BL/6 mice (NF-κB –luc mice) 
 
NF-κB –luc mice [164] were re-derived from zygotes from Charles River. Mice were 
kept as per 2.2.1 and were at least 8 weeks old and between 15-22g body weight at the 
beginning of all experiments. 
 
2.2.5 PXR knockout mice 
 
PXR knockout mice [60] were bred on site and kept as per 2.2.1. They were at least 8 
weeks old and between 25-35g body weight at the beginning of all experiments. 
 
2.3 Cell Culture 
 
2.3.1 AR42J-B-13 
 
AR42J-B-13 cells (B-13s, rat pancreatic progenitor cells) were generously provided by 
Dr Karen Wallace (Aberdeen University, UK) and routinely cultured in low glucose 
Dulbecco’s Modified Eagle Medium (1g glucose/L, DMEM) supplemented with 10% 
foetal calf serum (v/v, FCS), 100U/ml penicillin, 100μg/ml streptomycin and 2mM L-
glutamine. Cells were incubated at 37°C in 95% air and 5% CO2. Medium was changed 
every 2-3 days. 
 
2.3.2 B-13
-TR/h1A2
 
 
B-13
-TR/h1A2 
cells (B-13 cells stably transfected with wild type human CYP1A2 and a 
tetracycline control vector) were cultured as per 2.3.1 but in medium additionally 
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supplemented with 250μg/ml geneticin (G418, Invitrogen, Paisley, UK) and 4μg/ml 
blasticidin (Invitrogen).  
 
2.3.3 HEK293 
 
HEK293 (Human embryonic kidney 293) cells were kindly provided by Dr Audrey 
Brown (Newcastle University, UK) and were routinely cultured as per 2.3.1. 
 
2.3.4 Isolation of Primary Rat Hepatocytes 
 
Primary rat hepatocytes were generously provided by Professor Loranne Agius 
(Newcastle University, UK) and were isolated following a conventional collagenase 
perfusion [165]. Viability was determined from an aliquot as described in 2.3.10. 
Assuming adequate viability (>75%), hepatocytes were seeded at 0.8 x 10
6 
per well of a 
6 well plate or snap frozen as day 0 (T0) samples. 
 
2.3.5 Primary rat hepatocyte culture 
 
Primary rat hepatocytes were initially cultured in low glucose DMEM (1g glucose/L) 
supplemented with 10% (v/v) FCS, 100U/ml penicillin, 100μg/ml streptomycin and 
2mM L-glutamine. After 4 hours, once hepatocytes had adhered to the culture vessel, 
the medium was replaced with low glucose DMEM (1g glucose/L) supplemented with 
100U/ml penicillin, 100μg/ml streptomycin and 2mM L-glutamine. Cells were 
incubated at 37°C in 95% air and 5% CO2. Medium was changed every 2-3 days.  
 
2.3.6 Cell passage 
 
When adherent cells reached 75-95% confluence they were subcultured. All medium 
was removed from cells and washed once in phosphate buffered saline (PBS, 137mM 
NaCl, 2.6mM KCl, 10mM KnHnPO4, pH 7.4) to remove all medium. After removal of 
the PBS, 1x trypsin-EDTA diluted in PBS was added to cells (5ml per T75
2
 flask and 
0.5ml per well of a 6 well plate) and the cells incubated at 37°C and 5% CO2 for 5-15 
minutes. The culture vessel was then tapped gently to promote cell detachment which 
was confirmed by light microscopy. Detached cells were then transferred to a 50ml 
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centrifuge tube (Fisher, Loughborough, UK) and an equal volume of complete culture 
medium was added to inhibit trypsin activity. Cells were then centrifuged at 800g for 5 
minutes. The supernatant was aspirated and the cells re-suspended in fresh medium. The 
cells were then seeded as required for cell maintenance or an experimental protocol. 
 
2.3.7 Long term cell storage 
 
Cell lines were regularly frozen down and stored at -80°C or in liquid nitrogen. Cells 
were detached from the cell culture vessel when 70-80% confluent and pelleted as 
outlined in 2.3.6. Following supernatant removal the pellet was re-suspended in freezing 
medium (10% (v/v) DMSO in FCS – normally 2ml per T752 flask). This was aliquoted 
into sterile cryovials (1ml/tube). Cryovials were placed in a Mr Frosty cooling device 
(Thermo scientific, Loughborough, UK) which was prefilled with isopropanol and pre-
chilled at -80°C. The Mr Frosty chills cells at ~1°C/minute for optimal cell survival. 
Cryovials were left overnight following which they were either left at -80°C or 
submerged in liquid nitrogen for long term storage. 
 
2.3.8 Cell stock revival 
 
Cryovials were removed from storage and placed in a water bath preheated to 37°C. 
Once thawed, 1ml of complete culture medium was added to the cryovial and the 
cryovial contents were carefully pipetted into 20ml of complete culture medium in a 
T75
2
 flask. The cells were incubated under normal conditions as outlined in 2.3.1 until 
cells had adhered to the culture flask (4-8 hours). The culture medium was then 
aspirated, fresh medium added and the cells returned to the incubator. Medium was 
renewed the following day.  
 
2.3.9 Determining cell number  
 
Following trypsinisation and pelleting as described in 2.3.6, cells were re-suspended in 
a defined volume of medium (1-10ml). An aliquot of 100μl of the cell suspension was 
then diluted 1:1 (v/v) in 0.4% (w/v) trypan blue in PBS. 50μl of the cell:trypan blue 
solution was then pipetted onto a haemocytometer counting grid. The number of cells in 
4-16 small squares was counted (depending on cell density). 3 counts were taken per 
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sample and averaged. The number of viable cells excluding trypan blue (i.e. colourless 
cells) per ml was then calculated as follows: 
 
                                        
  
                      
     
 
The cell suspension was then diluted as necessary based on the count. 
 
2.3.10 Measuring cell viability by trypan blue exclusion 
 
Trypan blue is excluded by cells with an intact plasma membrane (live cells), whereas 
compromised or dead cells fail to exclude the dye, turning them blue. Therefore, by 
counting the number of colourless and then blue cells, the viability of a cell suspension 
can be calculated. To measure cell viability, when trypsinising cells as in 2.3.6, instead 
of discarding the original culture medium, it was pipetted into a 50ml centrifuge tube. 
Following cell detachment using trypsin-EDTA, the detached cells were added to the 
original culture medium and centrifuged at 800g for 5 minutes. The supernatant was 
discarded and the pellet re-suspended in culture medium. Either an aliquot of this 
suspension or all was mixed 1:1 (v/v) with 0.4% (w/v) trypan blue in PBS and 50μl 
pipetted onto the grid of a haemocytometer. 4-16 small squares were counted in three 
different regions of the grid and the number of colourless (viable) and blue cells (non-
viable) counted. The viability was then calculated as follows: 
 
                 
                       
                 
  
 
2.3.11 B-13 transdifferentiation 
 
B-13 cells were cultured in 10nM DEX to transdifferentiate them to hepatocyte-like 
cells. DEX was added to their culture medium from a 1000x concentrated stock solution 
(10μM in ethanol). B-13 cells treated with DEX were cultured like normal B-13 cells as 
per 2.3.1 with medium and DEX changed every 2-3 days. Within 4-7 days hepatocyte-
like cells began to appear. B-13 cells were considered transdifferentiated to hepatocyte-
like cells (B-13/H) and ready for experiments following 14 days of culture in 10nM 
DEX unless otherwise specified.  
  Chapter 2. Materials and Methods 
 
44 
 
 
2.3.12 CYP450 induction 
 
For induction studies, cells were routinely dosed daily with inducing agents for 3 days, 
with a medium change every day. Cells were harvested on day 4 (24 hours after the last 
treatment with inducer). Inducers were used at the following final concentrations: β-NF, 
20µM; androstenol, 5µM; PB, 1mM; TCPOBOP, 1.5µM; DEX, 10µM; pregnenolone-
16α-carbonitrile (PCN), 2µM; bezafibrate, 250µM. 
 
2.3.13 Alvetex culture 
 
Alvetex scaffolds (AMS Biotechnology, Abingdon, UK) were briefly washed in 70% 
ethanol then PBS to prepare for cell seeding. 1 x 10
6
 cells were seeded onto the alvetex 
in a volume of 150μl and initially left for 1.5 hours for the cells to adhere. Following 
this incubation, 10ml of complete growth medium was added and the cells cultured as 
outlined in 2.3.1. Transdifferentiation was carried out by addition of 10nM DEX to the 
culture medium as outlined in 2.3.11.  
 
2.3.14 PU134 culture 
 
B-13 cells were seeded on to PU134 coated slides in 24 well plates at 3 x 10
4
 cells/well 
following which they were cultured as described in 2.3.1. 
 
2.4 Cell transfection, adenoviral titration and infection 
 
2.4.1 Effectene transfection  
 
For stable transfection, cells were transfected using effectene (Qiagen, Manchester, UK) 
in T75
2
 flasks essentially following the manufacturer’s guidelines under normal culture 
conditions. Effectene forms a cationic complex with DNA, promoting transfer through 
the cell plasma membrane facilitating transfection of DNA. Enhancer, EC buffer and 
plasmid DNA were mixed at a ratio of 10μl enhancer: 150μl buffer: 1μg DNA and 
briefly mixed using a vortex. Following a 5 minute incubation at room temperature, 
15μl of effectene was added per 1μg of DNA and vortexed again. After 15 minutes at 
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room temperature, the master mix was added dropwise to cells 60-70% confluent in 
fresh medium. Transfected cells were cultured for 48 hours under standard conditions 
after which they were washed in PBS and fresh medium added. 
 
2.4.2 Generation of stably transfected cell lines 
 
Transfected cells were cultured in medium containing the appropriate selection agent 
for 7-14 days until the majority of cells had died leaving small numbers of resistant 
colonies. For the cells transfected with the pcDNA6/TR vector (Invitrogen), selection 
was carried out by treating transfected cells with 8μg/ml blasticidin which was 
determined to be the optimal concentration (figure 2.1). B-13 cells transfected with 
human CYP1A2 (in the pT-REX-DEST30 vector, Invitrogen) were selected using 
400μg/ml geneticin which has been used previously in B-13 cells to select stable 
transformants (personal communication). 
 
 
Figure 2.1: B-13 blasticidin kill curve. B-13 cells were treated with the indicated concentrations of 
blasticidin for 3 consecutive days. Absolute viability was then determined for each treatment by trypan 
blue exclusion. Results are the mean and SD of 3 independent determinations from the same experiment. 
 
2.4.3 Adenovirus titration – plaque assay 
 
HEK293 cells were seeded into 6 well plates at 1 x 10
5
 cells/ well and cultured as per 
2.3.3 until approximately 80% confluent. Viral stocks to be titred were serially diluted 
between 10 x 10
-4 – 10-9. Medium was removed from the HEK293 cells and 300μl of 
each adenoviral dilution added to each well and the plate gently rocked to ensure 
coverage of all cells by the viral solution. Cells were then returned to the incubator and 
cultured per normal for 1 hour. During this incubation, a 5% agarose solution in PBS 
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was melted and cooled to approximately 45°C. Complete growth medium was pre-
heated to 45°C also. After the 1 hour incubation, the viral dilutions were aspirated from 
the cells. The 5% agarose solution was diluted to 0.5% in the complete growth medium 
and 2ml of this solution was added per well and left to set. Once set, 2ml of complete 
growth medium was added per well and the cells cultured as per 2.3.3 for 7-10 days. 
After this time the medium was removed and replaced with a 0.03% (w/v) solution of 
neutral red in PBS and incubated for 2 hours to stain living cells. The neutral red 
solution was aspirated and the number of plaques counted. The titre of the virus was 
then calculated using the following equation, from the dilution which gave between 15-
150 plaques per well:  
 
            
                     
        
 
2.4.4 Determining multiplicity of infection (MOI) 
 
Cultured cells were infected with Ad-GFP (adenovirus encoding green fluorescent 
protein) serially diluted over 3 logs (i.e. 10
0
 to 10
-3
). The following day, cells were 
imaged using a fluorescence microscope and the percentage of cells positive for green 
fluorescent protein (GFP) per field calculated. The number of plaque forming units 
(pfu) required for >85% infection efficiency was then calculated from this using the 
known viral titre, determined by a plaque assay (see 2.4.3), to give the MOI. 
 
2.4.5 Adenoviral infection of cells 
 
Per experiment, the number of cells in each well was calculated from a single well as 
per 2.3.9. Using this and the known MOI of the cell line, the volume of virus to be 
added per well was calculated. This was then added per well and the cells cultured as 
per normal for 24 hours. At this point the medium was changed to remove all virus and 
the cells cultured as normal (5% CO2 and 37°C) until required. Ad-SGK1F encoding 
human SGK1F and Ad-FOXA2, encoding human forkhead box protein A2, were from 
Vector Biosystems (Philadelphia, USA). For all adenoviral constructs used, 
overexpression of the virus encoded protein coding sequence in infected cells was 
driven by a linked constitutively active promoter. 
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2.5 Plasmid DNA constructs and sequencing  
 
2.5.1 Competent cell transformation 
 
Plasmid DNA was replicated in TOP10 cells (Invitrogen). When required, TOP10 cells 
were thawed on ice and 2μl of TOPO cloning reaction was added to the vial after which 
the cells were incubated on ice for 30 minutes. The cells were then heat shocked in a 
water bath, equilibrated at 42°C, for 30 seconds without shaking. Heat shocked cells 
were transferred to ice and 250μl of super optimal broth (20mM glucose, 10mM NaCl, 
2.5mM KCL, 10mM MgCl2, 10mM MgSO4, 2% tryptone and 0.5% yeast extract) added 
to the vial. The vials were then placed in a 37°C incubator shaking at 200rpm for 1 
hour. The transformed cells were spread onto 2 agar plates containing the appropriate 
selection agent (kanamycin 25μg/ml or ampicillin 100μg/ml); one plate was spread with 
20μl and the other with 200μl. The plates were incubated overnight at 37°C. 
 
The next morning a colony was picked and placed into 5ml of Luria-Bertani medium 
(LB, 10g/L NaCl 10g/L tryptone and 5g/L yeast extract) with antibiotics as required and 
incubated overnight at 37°C shaking at 220rpm. The following day the cells were either 
mini- or maxi-prepped or frozen down as outlined in 2.5.2, 2.5.3 and 2.5.4 respectively. 
 
2.5.2 Mini-prep isolation of plasmid DNA 
 
Isolation of plasmid DNA was carried out using Qiagen Qiaprep Miniprep spin columns 
to rapidly isolate pure plasmid DNA from ~5ml of bacteria in LB. The purification 
works by the alkaline lysis of bacterial cell walls followed by the adsorption of plasmid 
DNA onto a permeable silica membrane under high salt conditions [166]. 
Contaminating RNA is removed by RNAse in buffer P1. 
 
DNA was isolated essentially as per the manufacturer’s protocol. 5ml of culture was 
centrifuged in eppendorf tubes at 16,000g for 1 minute. The supernatant was discarded 
and the pellet re-suspended in 250μl of buffer P1 following which 250μl of buffer P2 
was added (salt solution with sodium dodecyl sulphate). The tube was inverted to 
produce a clear solution to which 350μl of buffer N3 was added (containing acetic acid 
to neutralise alkaline lysis buffer) and rapidly inverted. The cloudy solution was 
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centrifuged for 10 minutes at 16,000g to pellet cell debris and genomic DNA. The 
supernatant was pipetted into a Qiaprep spin column and centrifuged for 1 minute at 
16,000g. The flow through was discarded and 500μl of buffer PB added to the column 
which was then centrifuged again as before. The flow through was discarded and 750μl 
of buffer PE added to the column which was centrifuged at 16,000g for 1 minute. The 
flow through was discarded and the column centrifuged once more for 1 minute to 
remove residual residue. The column was transferred to a nuclease free eppendorf and 
50μl of nuclease free water added directly to the column membrane. The column was 
left to stand for 1 minute then centrifuged for 1 minute at 16,000g to elute the plasmid 
DNA. Plasmid DNA was then quantified spectrophotometrically as described in 2.6.2. 
 
2.5.3 Maxi-prep isolation of plasmid DNA 
 
To purify large quantities of plasmid DNA (up to 500μg), a maxi-prep was carried out 
using the Qiagen Maxiprep kit. It is based on the same theory as the miniprep but 
designed to produce larger yields.  
 
250ml of overnight culture in a 1L Erlenmeyer flask was decanted to 50ml centrifuge 
tubes and centrifuged at 6,000g for 10 minutes at 4°C. The pellets were re-suspended 
and combined in 10ml of buffer P1 (RNase containing) and 10ml of buffer P2 was then 
added and mixed by inversion. This solution was left to stand for 5 minutes following 
which 10ml of buffer P3 was added (pre-chilled on ice) and mixed by inversion. This 
was left on ice for 20 minutes and subsequently centrifuged at 6,000g for 30 minutes at 
4°C. The supernatant was then applied to a Qiagen-tip 500 column that had been 
equilibrated by the addition of 10ml of buffer QBT left to drain through. The 
supernatant was left to enter the column after which the column was washed 2 times 
with 30ml of buffer QC. The flow through was discarded. The plasmid DNA was eluted 
by the addition of 15ml of buffer QF into a 50ml centrifuge tube and precipitated by the 
addition of 10.5ml of absolute isopropanol. The sample was inverted to mix then 
centrifuged at 6,000g for 30 minutes at 4°C. The supernatant was discarded and the 
pellet washed with 70% ethanol. After another centrifugation step (6,000g for 30 
minutes at 4°C), the supernatant was all removed and the DNA pellet left to air dry for 
10 minutes. The pellet was then re-suspended in nuclease free water and quantified as 
per 2.6.2. 
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2.5.4 Storage and thawing of transformed bacteria 
 
TOP10 cells transformed with plasmid DNA were stored long term as glycerol stocks at 
-80°C. 500μl of an overnight culture, picked from a single colony, was diluted 1:1 (v/v) 
with sterile LB containing 30% (v/v) glycerol then transferred to a cryovial, labelled and 
frozen long term at -80°C. 
 
When required, previously stored bacteria were thawed and a small volume (20-30μl) 
streaked out on an agar plate supplemented with the appropriate antibiotic to select for 
transformed bacteria. The glycerol stock was then returned to the -80°C freezer for 
storage. After incubation overnight at 37°C, a single colony was picked from the plate 
and grown up overnight in LB, with antibiotics as required, and plasmid DNA purified 
using a miniprep (2.5.2) or maxiprep (2.5.3). 
 
2.5.5 DNA extraction from agarose gel 
 
DNA subject to agarose gel electrophoresis (see 2.6.8) was imaged using a UV light 
box and the band of interest excised using a sterile scapel blade, weighed and placed 
into a nuclease free eppendorf tube. The DNA was then extracted using a QIAquick gel 
extraction kit (Qiagen) which, similar to the miniprep system, utilises the adsorption of 
DNA onto a silica membrane under high salt concentrations. 3 volumes of buffer QG 
was added to the plasmid DNA in an eppendorf. This was placed in a heat block set at 
50°C for ~10 minutes until melted. One volume of absolute isopropanol was then added 
and mixed and the entire solution applied to a gel extraction column. The column was 
centrifuged at 16,000g for 1 minute and the flow through discarded. 750μl of buffer PE 
was then added to the column and centrifuged again as before to wash the DNA. The 
flow through was discarded and the column centrifuged dry at 16,000g for 1 minute to 
remove residual buffers. The DNA was eluted by the application of 30μl of nuclease 
free water to the centre of the silica membrane. After standing for 1 minute the column 
was centrifuged at 16,000g for 1 minute. The flow through was then reapplied to the 
membrane and centrifuged once more to increase yield. The eluted DNA was quantified 
as detailed in 2.6.2. 
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2.5.6 TOPO cloning 
 
DNA was cloned into a gateway vector (pENTR/D-TOPO) using the TOPO cloning 
system (Invitrogen) as outlined in figure 2.2. This system utilises Vaccinia 
topoisomerase I which cleaves the phosphodiester backbone of duplex DNA at 5´-
(C/T)CCTT-3´ sequences and binds the 3′ thymidine [167]. The DNA sequence to be 
cloned was amplified using primers that add a 5′ complementary sequence (CACC). 
The vector contains an overhang which binds the DNA in only one orientation 
facilitating directional cloning into the vector. The topoisomerase can then ligate the 
DNA and plasmid together using the energy stored from the original cleavage.  
 
 
Figure 2.2: TOPO cloning system. From 
http://tools.invitrogen.com/content/sfs/manuals/pentr_dtopo_man.pdf 
 
Following insertion into the gateway vector, the insert was transferred to a destination 
vector using a LR recombination reaction (Invitrogen). This reaction utilises LR clonase 
to directionally transfer DNA between the gateway restriction sites attL1 and attL 2 to 
the destination vector with corresponding attR1 and attR2 sites in a single quick 
reaction. 
 
Target DNA sequences (containing the nucleotide sequence 5′-CACC-3′ in the required 
orientation) were prepared by reverse-transcription polymerase chain reaction (RT-
PCR) and cloned into the gateway pENTR/D-TOPO vector following the 
manufacturer’s instructions. Briefly, DNA was mixed at a 1:1 molar ratio with the 
gateway vector (1μl of vector/reaction). 1μl of salt solution (1.2M NaCl and 60mM 
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MgCl2) was then added to the DNA followed by nuclease free water up to a final 
volume of 6μl. The reaction was mixed and incubated for 30 minutes at room 
temperature following which the vector was transformed as described in 2.5.1.  
 
To transfer the DNA insert from the gateway vector to the destination vector (pT-REX-
Dest30), 150ng of the pENTR/D-TOPO containing insert was mixed with 150ng of pT-
REX-Dest30 and Tris-EDTA buffer pH 8.0 (10mM Tris, 1mM EDTA pH 8) up to 8μl. 
LR Clonase II enzyme mix (Invitrogen) was thawed on ice briefly then vortexed twice. 
2μl was then added to the reaction and vortexed twice to mix. The reactions were 
incubated for 1 hour at 25°C then terminated by the addition of 1μl of proteinase K. The 
reaction was then transformed into TOP10 cells as per 2.5.1. 
 
2.5.7 Restriction digests 
 
Restriction of plasmid DNA was carried out essentially following the restriction enzyme 
manufacturer’s guidelines (New England Biolabs, Hitchin, UK). Briefly, the reaction 
mixture was composed of 2μl 10x reaction buffer (optimal buffer determined based on 
restriction enzymes being used), 0.2μl of acetylated bovine serum albumin (BSA, 
10μg/μl), up to 1μg of plasmid DNA, 0.5μl of restriction enzyme(s) and nuclease free 
water up to 20μl. This was incubated for 1 hour at 37°C. The samples were then mixed 
with DNA loading buffer and subjected to agarose gel electrophoresis as outlined in 
2.6.8 to determine the size of fragments produced. 
 
2.5.8 Sequencing and analysis 
 
Miniprepped plasmids were sequenced by DNAseq (Dundee, UK) using either M13 or 
sequence specific primers. Sequencing chromatograms were analysed using Sequence 
Scanner Software v1.0 (Applied Biosystems, Paisley, UK). 
 
The B-13 genomic sequence was analysed using the Integrative Genomic Viewer 
software [168]. The sequence was aligned to the Wistar rat genome reference assembly 
RN4. 
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2.6 Isolation of RNA and quantification 
 
2.6.1 RNA isolation 
 
Total RNA, from cell and tissue samples, was isolated using TRIzol (Invitrogen) 
essentially following the recommended protocol. TRIzol is a monophasic solution of 
guanidine isothiocyanate and phenol which allows for the 3 step isolation of RNA by 
isolation, precipitation and washing. The underlying principal is based on acid 
guanidinium thiocyanate-phenol-chloroform extraction [169]. 
 
To extract RNA from cells, after a PBS wash, cells were scraped and centrifuged at 
16,000g for 1 minute to pellet after which 1ml of TRIzol was added and pipetted up and 
down. If the cells were cultured in 6 well plates, after the PBS wash, 1ml of TRIzol was 
added directly to the cells in the well and left on an orbital shaker for 5 minutes. The 
TRIzol was then transferred to RNAse free eppendorf tubes. After a 5 minute 
incubation, 200μl of chloroform was added and mixed by inversion. This was then 
centrifuged at 16,000g for 15 minutes to promote the formation of an aqueous phase, 
interphase and organic phase. RNA partitions in the aqueous phase whereas DNA and 
proteins are localised to the interphase and organic phases. The aqueous phase was 
transferred to a fresh tube and 500μl of isopropanol was added to precipitate the RNA. 
The tube was then mixed by inversion and left to stand on ice for 15 minutes. To pellet 
the RNA the tube was centrifuged at 16,000g for 10 minutes. The isopropanol was 
aspirated off and 1ml of 70% ethanol used to wash the pellet. The samples were 
centrifuged again as before and all the ethanol removed. After 5-10 minutes of air 
drying at room temperature the pellets were re-suspended in RNAse free water. The 
RNA was then quantified as per 2.6.2 and frozen at -80°C until needed. 
 
Tissue preparations were carried out following the same protocol but were prepared 
differently; tissues were snap frozen in TRIzol (in liquid nitrogen) immediately after 
culling and when needed were thawed on ice. The samples were then homogenised 
using a hand homogeniser and then briefly sonicated if required prior to RNA 
extraction.  
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2.6.2 RNA and DNA quantification 
 
The peak absorbance of RNA and DNA is at 260nm. The optical density (OD) at 
260nm using a 1cm pathlength is 1.0 for double stranded DNA at 50μg ml-1 and 40μg 
ml
-1 
for single stranded RNA. The concentration of nucleic acids in a pure solution can 
therefore be easily calculated by UV spectrophotometry.  
 
To determine the quantity of RNA and DNA in samples, their absorbance at 260nm was 
measured using a Nanodrop 2000 spectrophotometer (Thermo Scientific) using RNAse 
free water as the blank. The purity of samples was measured by calculating the 
OD260/OD280
 
ratio. For pure nucleic acid samples this should be between 1.8-2.1. Lower 
ratios suggest contamination, likely by phenol or protein. A peak absorbance at 270nm 
rather than 260nm indicates significant phenol contamination [170]. 
 
2.6.3 DNAse I treatment of RNA 
 
To remove contaminating genomic DNA from TRIzol purified RNA, samples were 
routinely treated with RQ1 RNAse-free DNAse (Promega, Southampton, UK). DNAse 
selectively hydrolyses the phosphodiester backbone of single and double stranded DNA 
to degrade DNA whilst leaving RNA intact. 
 
8μl of RNA was added to 1μl of 10x RQ1 buffer (400mM Tris-HCl pH 8.0, 100mM 
MgSO4 and 10mM CaCl2) and 1μl of RQ1 RNAse free DNAse. The reactions were 
mixed by pipetting and incubated at 37°C for 30 minutes. 1μl of stop solution (20mM 
EGTA pH 8.0) was then added and incubated at 65°C for 10 minutes to deactivate the 
DNAse. 
 
2.6.4 RNA cleanup using RNeasy columns 
 
To remove contaminating DNAse from samples following DNAse treatment for PCR 
array plates (see 2.6.11), samples were cleaned using RNeasy columns (Qiagen). 
RNeasy columns utilise the selective binding of mRNA (>200 base pairs in length) to a 
silica membrane under high salt conditions. 
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Following DNAse treatment of RNA (as detailed in 2.6.3), the RNA solution was made 
up to 100μl with RNAse free water, following which 350μl of buffer RLT was added 
and mixed. 250μl of absolute ethanol was added and mixed by inversion. The RNA 
solution was then transferred to an RNeasy spin column, incubated for 2-5 minutes then 
centrifuged at 16,000g for 15s and the flow through discarded. 500μl of buffer RPE was 
added to the column which was centrifuged for 15s at 16,000g and the flow through was 
discarded. This step was then repeated to remove any residual buffer. The RNeasy spin 
column was transferred to a fresh RNAse free eppendorf and 30μl of RNAse free water 
applied directly to the membrane to elute the RNA. This was left to stand for 1 minute 
then centrifuged for 1 minute at 16,000g. The RNA was then quantified as per 2.6.2 and 
frozen at -80°C until needed. 
 
2.6.5 1
st
 strand synthesis and reverse transcription of RNA 
 
Reverse transcription was carried out using Moloney Murine Leukemia Virus reverse 
transcriptase (M-MLV), a RNA-dependent DNA polymerase, essentially following the 
manufacturers guidelines (Promega). Briefly, DNAse treated RNA was diluted to 
200ng/μl and 5μl (i.e. 1μg total) transferred to a 200μl reaction tube. 1μl of 50ng/μl 
random primers (Promega) were added to each tube, mixed by pipetting and incubated 
at 90°C for 3 minutes. Incubation at 90°C melts the RNA secondary structure and 
following this, the temperature was brought down quickly to 4°C to allow annealing of 
the random primers to the RNA. 
 
To the 1
st
 strand synthesis reactions on ice was added 14μl of reverse transcription 
mastermix. This was composed of 2μl 10mM dNTPs (Promega), 4μl of 5x M-MLV 
buffer (50mM Tris-HCl pH 8.3, 3mM MgCl2, 75mM KCl, and 10mM DTT), 7μl of 
nuclease free water and 1μl of M-MLV. The reverse transcription reactions were 
incubated for 1 hour at 42°C after which they were diluted accordingly (usually to 10-
20ng/μl) with nuclease free water and frozen at -20°C 
 
2.6.6 Polymerase chain reaction (PCR) 
 
PCR is a technique which uses thermostable DNA polymerases and thermal cycling to 
rapidly and accurately amplify target DNA sequences. As summarised in figure 2.3, 
  Chapter 2. Materials and Methods 
 
55 
 
during a cycle of PCR, double stranded DNA is separated at high temperatures (95°C) 
then short ˊ5-3ˊ oligonucleotides (upstream and downstream primers) anneal 
complementary cDNA at a target sequence to be amplified. Thermostable DNA 
polymerase then binds and elongates the DNA strand 5ˊ-3ˊ. In principle, the abundance 
of the target sequence (the amplicon) should double every cycle (i.e. exponentially) 
meaning that, very rapidly, a huge amount of amplicon is generated which can be 
visualised by agarose gel electrophoresis (detailed in 2.6.8) 
 
 
Figure 2.3: The events of a PCR cycle. From 
http://www2.le.ac.uk/departments/emfpu/genetics/explained/images/PCR-process.gif 
 
Semi-quantitative PCR was routinely carried out using GoTaq green 2x mastermix 
(Promega), which contains Taq polymerase. For cloning work, Pfu DNA polymerase 
(Promega) was used as this has 3′-5′ exonuclease proofreading capability. The mutation 
rate of Taq is approximately one error per 2.0 x 10
5
 base pairs whereas for Pfu the error 
rate is only one error per 1.6 x 10
6
 base pairs, due to its proofreading activity [171].  
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Using GoTaq green, the reaction mix for PCR, made up on ice, was as follows: 10-40ng 
of cDNA was added to 10μl of GoTaq green 2x mastermix, 2μl each of upstream and 
downstream primers (from 10μM primer stocks, 1μM final concentration) and nuclease 
free water up to 20μl.  
 
For Pfu, the reaction was composed on ice as follows: 40-100ng of cDNA was added to 
5μl of 10x Pfu buffer (200mM Tris-HCl (pH 8.8 at 25°C), 100mM KCl, 100mM 
(NH4)2SO4, 20mM MgSO4, 1% (v/v) Triton X-100 and 1μg/μl BSA), 1μl 10mM 
dNTPs, 5μl of forward and reverse primers (from 10μM primer stocks, 1μM final 
concentration) and nuclease free water up to 49.3μl. 0.7μl Pfu was then added and 
mixed by pipetting. 
 
Once samples were prepared, thermal cycling was carried out using a Px2 (Thermo 
Scientific) thermocycler. The programme used varied according to the primers used 
(listed in appendix A) but was essentially as follows: 
 
Initial denaturation  -   95°C   1 minute 
 
Then 30-35 cycles of: 
Denature   -   95°C   1 minute 
Anneal   -   X°C   30s 
Elongate   -   72°C   1 minute per Kbp (GoTaq) 
       2 minutes per Kbp (Pfu) 
 
Final elongation -  72°C   5 minutes 
Hold    -  4°C  ∞ 
 
Annealing temperature was optimised according to individual primer pairs but was 
55°C in most cases. After the run was complete samples were stored at 4°C. 
 
2.6.7 Fusion PCR 
 
To amplify sequences greater than 1Kbp using Pfu, which would not amplify in a single 
reaction, both halves of the sequence were amplified in separate reactions then fused in 
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a third reaction as illustrated in figure 2.4. The primers were designed so that the 5ˊ-3ˊ 
sequence of the 1
st
 fragment was complementary to the 3ˊ-5ˊ sequence of the 2nd 
fragment. Following amplification of a fragment by Pfu, the PCR products were 
separated using agarose gel electrophoresis (see 2.6.8) and the correct size product gel 
purified (see 2.5.5). When both fragments were amplified and purified, fusion PCR was 
run using Pfu DNA polymerase as before but using a modified method. Specifically, 
Pfu reactions were set up using equimolar amounts of the DNA sequences to be fused 
(50ng total) and run for 10 cycles without either the forward or reverse primers to allow 
the fragments to anneal at their complementary ends and prime one another for 
elongation by the polymerase. After 10 cycles the primers were added and the PCR run 
for another 25 cycles. Agarose gel electrophoresis and gel extraction was used to 
separate and purify the completed sequence from any fragment left over. 
 
 
Figure 2.4: The steps of fusion PCR. First the two halves of the complete sequence are amplified in 2 
separate reactions using primers that give complementary ends. The 2 fragments are separated using 
electrophoresis and purified. In the fusion PCR reaction, the two fragments anneal and are amplified to 
produce a complete sequence. 
 
2.6.8 Agarose gel electrophoresis 
 
When DNA is placed within an electric field, it migrates towards the positive electrode 
because the sugar phosphate backbone of DNA is negatively charged. All DNA 
migrates towards the anode, but larger fragments experience more resistance in a 
polymerised agarose matrix and therefore migrate at a slower rate. This is exploited in 
agarose gel electrophoresis to separate DNA fragments by size. PCR reactions were 
routinely separated in 1-2% agarose (1-2% (w/v) agarose and 5μg/ml ethidium bromide 
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in TAE (40mM Tris, 20mM acetic acid, 1mM EDTA)). The gels were prepared by 
boiling the TAE and agarose together in a microwave until dissolved then left to cool. 
Once cool enough to hold, the ethidium bromide was added. Gels were then cast in a 
casting stand and a comb added to form wells. This was then left to set prior to 
electrophoresis. To resolve amplicons greater than 400bp, a 1% agarose gel was used; 
for amplicons smaller than 400bp, a 2% agarose gel was used.  
 
Prior to electrophoresis, 9μl of 6x DNA loading dye (Promega) was added per Pfu PCR 
reaction and mixed. This was required so that samples sank to the bottom of the wells. 
GoTaq PCR reactions did not need DNA loading dye added because the mastermix 
already contained it. 10μl of reaction was generally loaded into an agarose gel alongside 
100bp or 1Kbp DNA ladder (New England Biolabs) and separated for 30-45 minutes at 
90V. TAE, sufficient to cover the gel, was used as the running buffer. Once amplicons 
were resolved, they were imaged using a G:BOX transilluminator and bundled software.  
 
2.6.9 Quantitative real-time PCR 
  
In principle, per PCR cycle, each template of DNA produces 2 copies. This principle is 
utilised in real-time PCR to quantitatively measure the amount of target DNA in 
different samples. SYBR green is a dye that is fluorescent when bound to double 
stranded DNA and therefore, by measuring its fluorescence, the amount of target DNA 
can be measured in real time during PCR. 
 
A quantitative real-time PCR (qPCR) mastermix was prepared by mixing 6.5μl of 
SYBR Green JumpStart Taq ReadyMix, forward and reverse primers to final optimised 
concentration (between 125-250nM) and nuclease free water up to a volume of 12μl per 
well. 12μl of mastermix was added per well of an optical 96 well reaction plate 
(Applied Biosystems) and 1μl of cDNA added (usually from a 10ng/μl stock). The 
plates were sealed using optical film (Applied Biosystems) and centrifuged at 300g for 
1 minute to collect samples at the bottom of the wells. Plates were then either run 
immediately or stored at -80°C for up to a week. Plates were run in a 7500 Fast real-
time PCR thermocycler (Applied Biosystems) using the included software (SDS 2.0.6). 
The run method was as follows: 
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Initial denaturation  -   95°C   5s  
 
Then 40 cycles of: 
Denature   -   95°C   5s 
Anneal   -   X°C   30s 
Elongate   -   72°C   30s 
        
The annealing temperature was optimised for each primer pair. Following the cycling, 
melt curve analysis was run using the default software programme. SYBR green 
fluorescence was measured during the extension phase of cycling. Once the run was 
complete, the cycle threshold (CT) was set manually by setting the threshold in the 
lower half of the exponential phase of amplification. 
 
Relative amounts of target DNA were calculated using the comparative ΔΔCt method 
using 18S ribosomal RNA (18S rRNA) as the housekeeping control. Relative 
expression was calculated as follows: 
 
Δ                           
 
ΔΔ   Δ           Δ           
 
                ΔΔ   
 
Standard deviation was calculated as described by Yuan et al., (2006) [172] from the 
ΔΔCT values as follows:  
 
                       ΔΔ          ΔΔ                     
                                   ΔΔ          ΔΔ         
 
2.6.10 Primer design 
 
Nucleotide sequences were downloaded from the NCBI database 
(www.ncbi.nlm.nih.gov) and primer-blast was then used to design primer sequences for 
RT-PCR. In general, primers were designed so that they had minimal complementarity 
with themselves and their pair. They were 18-25 bases in length, with 40-60% guanine 
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and cytosine content and with an annealing temperature within 1-2°C of one another. 
Where possible, they were also designed to span an exon-exon junction. For normal 
PCR, primers were designed to amplify a sequence of 200-600bp whereas for qPCR the 
target amplicon size was 50-200bp. 
 
2.6.11 PCR array plates 
 
PCR arrays (SAbiosciences, Crawley, UK) were used to perform rapid quantitative RT-
PCR screens for related transcripts. The arrays were used as outlined in the 
manufacturer’s protocol, firstly by preparing cDNA using the RT2 first strand kit 
(SAbiosciences). Briefly, 1μg total RNA was added to 2μl of genomic DNA elimination 
buffer and water up to 10μl. This was then incubated at 42°C for 5 minutes then placed 
on ice. A reverse transcription mastermix was prepared by combining 4μl of 5x buffer 
BC3, 1μl of control P2, 2μl of RE3 reverse transcriptase mix and 3μl of water per 
reaction. 10μl of this mix was added to the DNA eliminated RNA solution and mixed 
by pipetting. The reaction was subsequently incubated at 42°C for 15 minutes, then the 
reverse transcriptase deactivated by incubation at 95°C for 5 minutes. Finally 91μl of 
nuclease free water was added and mixed. The qPCR mastermix was then immediately 
prepared by mixing 102μl of cDNA, 1350μl of 2x RT2 SYBR green mastermix 
(SAbiosciences) and 1248μl of RNAse free water. This was mixed by pipetting and 
25μl added to each well of the PCR array plate which was sealed with optical film and 
centrifuged at 300g for 1 minute. The plate was run in a 7500 Fast themocycler using 
the included software with the following settings:  
 
1 cycle of: 
Initial denaturation   -   95°C   10 minutes  
 
Then 40 cycles of: 
Denature    -   95°C   15s 
Anneal and elongate  -   60°C   60s 
Followed by melt curve analysis 
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Following the end of the run the CT values were calculated as described in 2.6.9 and the 
excel-based PCR array data analysis template used to analyse the data (available at 
http://www.sabiosciences.com/pcrarraydataanalysis.php). 
 
2.7 Protein isolation and analysis 
 
2.7.1 Cell lysate preparation 
 
Cultured cells were washed once in PBS then scraped into 1ml of ice cold PBS. The 
samples were centrifuged at 16,000g for 1 minute and the pellet re-suspended in an 
appropriate volume of 20mM Tris (pH 7.5). Samples were then quantified by Lowry 
assay (2.7.3) and frozen as aliquots at -80°C until required. 
 
2.7.2 Tissue lysate preparation 
 
Tissue from culled animals was flash frozen in liquid nitrogen then stored at -80°C until 
needed. When required, it was thawed on ice and rinsed in PBS to remove any blood. 
The tissue was then homogenised by hand and sonicated in 20mM Tris (pH 7.5). 
Samples were quantified by Lowry assay (2.7.3) and frozen at -80°C until required. 
 
2.7.3 Lowry assay 
 
The Lowry assay was used to determine protein concentration [173]. The mechanism is 
that, under alkaline conditions, copper reacts with peptide bonds. Folin-ciocalteu 
reagent is then added which is reduced, through a poorly understood mechanism, to 
produce a blue colouration. The intensity of colour is proportional to the amount of 
protein present at 750nm. With the use of protein standards, the concentration of protein 
in samples can therefore be easily calculated. 
 
Assay buffers were prepared fresh each time. Buffer ABC was made up as follows: 
Lowry A (2% (w/v) Na2CO3 and 4% (w/v) NaOH), Lowry B (2% (w/v) sodium tartrate) 
and Lowry C (1% (w/v) CuSO4) were combined at a ratio of 100:1:1 (v:v:v). Folin-
ciocalteu was diluted 1:1 in distilled water prior to use. BSA was used as the protein 
standard and was made up in 20mM Tris (pH 7.5) in concentrations ranging from 0-
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20mg/ml. To 5μl of standard or protein sample was added 50μl of distilled water and 
1ml of buffer ABC. This was briefly vortexed and incubated at room temperature for 10 
minutes. 100μl of diluted folin-ciocalteu reagent was added and mixed then incubated 
for 15-20 minutes until blue colouration was visible. The samples were then transferred 
to 1cm plastic cuvettes and OD750 measured using the 0mg/ml standard to blank. The 
OD750 of the standards was plotted against concentration and used to calculate the 
protein concentrations of samples using the equation y = mχ + c.  
 
2.7.4 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
In 1970 Laemmli first described the use of SDS-PAGE to separate proteins based on 
their molecular weight [174]. This system of electrophoresis utilises sodium dodecyl 
sulphate (SDS), an anionic detergent. When a potential difference is applied to SDS 
bound polypeptides, they migrate towards the anode (due to the binding of negatively 
charged SDS) through the polyacrylamide gel at a rate proportional to their molecular 
weight, which allows for separation of proteins in a solution. The proteins are initially 
denatured to polypeptide chains by heating in the presence of SDS and the reducing 
agent DL-dithiothreitol (DTT) which reduces thiol groups, so that they lose their 
secondary, tertiary and quaternary structure which would otherwise interfere with 
migration.  
 
SDS-PAGE was carried out using the Bio-Rad protean minigel system (Hereford, UK). 
Briefly, front and back glass plates (0.75mm) were clamped and petroleum jelly applied 
to the underside to prevent leakage. The polyacrylamide gel used is composed of a 
resolving gel and a stacking gel in which samples are loaded. Use of a stacking gel 
improves resolution as proteins accumulate at the stacking/resolving interface. 
Resolving gel acrylamide percentage varied according to the molecular weights of the 
proteins of interest but 9% was most commonly employed (optimally resolves ~20-
100kDa). The stacking gel was always 4%. A 9% resolving gel was composed of 9% 
acrylamide/bis (w/v) (using acrylamide/bis-acrylamide, 37.5:1 ratio), 375mM Tris-HCL 
(pH 8.8), 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate and 0.05% (v/v) 
tetramethylethylenediamine (TEMED) The ammonium persulphate and TEMED were 
added last as they catalyse the polymerisation of the acrylamide. 200μl of isopropanol 
was layered over the resolving gel whilst it set to create a level interface for the stacking 
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gel. Once the resolving gel had set (within 1 hour), the isopropanol was washed off with 
distilled water. The stacking gel consisted of 4% acrylamide/bis (w/v), 125mM Tris (pH 
6.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate and 0.1% (w/v) TEMED. 
This was immediately poured over the resolving gel and a comb inserted into the 
polymerising gel to form wells. Once set, the glass plates were unclamped and either 
stored in electrode running buffer (25mM Tris, 0.1% (w/v) SDS and 192mM glycine, 
pH 8.3) at 4°C for 2-3 days or placed in a gel tank filled with electrode running buffer 
for immediate use. 
 
Samples for SDS-PAGE were diluted at least 1:1 (v/v) in reducing loading buffer 
(120mM Tris (pH 6.8), 20% glycerol (v/v), 3.9% (w/v) SDS, 0.74% (w/v) bromophenol 
blue and 20mM DTT) and heated at 95°C for 5 minutes. Typically 20μg of protein was 
loaded per well alongside a ladder containing coloured proteins of known molecular 
weights (ColorBurst Electrophoresis Marker, molecular weight 8-220kDa). 
Electrophoresis was run at 100V until the migrating front reached the stacking/resolving 
interface at which point the voltage was increased to 160V. When the migrating front 
reached the bottom of the gel, the proteins were transferred to nitrocellulose for Western 
blotting (detailed in 2.7.5). 
 
2.7.5 Western blotting 
 
Western blotting describes the detection of specific proteins separated using SDS-
PAGE using immunodetection. Whilst samples were being separated by electrophoresis, 
filter paper and nitrocellulose membrane (Fisher) were cut to size and incubated in pre-
chilled transfer buffer (25mM Tris, 192mM glycine and 20% (v/v) methanol, pH 8.3). 
Following the end of SDS-PAGE, the plates were removed and the gel transferred to the 
nitrocellulose membrane. The gel and nitrocellulose membrane were sandwiched 
between filter paper and a scouring pad on both sides in a transfer cassette with the 
nitrocellulose membrane closest to the anode. A roller was used to remove air bubbles 
between the gel and nitrocellulose membrane. The cassette was placed in a tank filled 
with pre-chilled transfer buffer and an ice pack. Transfer was run for 2 hours at 100V.  
 
After transfer, the nitrocellulose membrane was removed from the cassette and transfer 
buffer washed off by a rinsing in TBS-T (200mM NaCl, 20mM Tris (pH 7.4) and 
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0.05% (v/v) Tween 20, pH 7.4). The membranes were then blocked in 3% (w/v) 
skimmed milk powder in TBST-T for 1 hour at room temperature or 16 hours at 4°C to 
block non-specific antibody binding. After blocking, membranes were given 3 washes 
with TBS-T followed by 2 incubations in 10ml of TBS-T for 10 minutes. The 
membranes were then incubated in primary antibody (diluted in 0.3% (w/v) skimmed 
milk powder in TBS-T, see table 2.1 for dilutions) for 1 hour at room temperature or 16 
hours at 4°C. The primary antibody solution was removed and then membranes washed 
as before. The appropriate secondary antibody (horseradish peroxidase (HRP) bound, 
diluted in 0.3% (w/v) skimmed milk powder in TBS-T) was added and left for 1 hour at 
room temperature. The secondary antibody was removed and the membrane was finally 
washed again as before. 
 
To detect bound secondary antibody by HRP catalysed chemiluminescence, Pierce ECL 
Western blotting substrate (Thermo scientific) was used. 0.75ml of reagents 1 and 2 
were added to the membrane and mixed briefly by rocking. The membrane was then 
blotted with tissue paper and sandwiched between saran wrap in a film cassette. CL-
Xposure film (Thermo scientific) was exposed to the membrane in a dark room for 
varying degrees of time (dependent on antibodies used) then developed using an 
automated developer (RP X-OMAT, Kodak, Hertfordshire, UK). Following 
development, the position of the ladder proteins was marked on the film.  
 
Nitrocellulose membranes in some cases were re-probed for an additional protein. After 
the initial probing, membranes were stripped by washing for 1 hour at room temperature 
in TBS-T, changing the TBS-T every 10 minutes. The membranes were then blocked 
and probed again as before.  
 
2.8 Histochemistry and immunostaining 
 
2.8.1 Paraffin embedded section preparation 
 
Tissue from freshly culled animals was fixed in 10% buffered formalin (3.7% (v/v) 
formaldehyde in PBS) for 24 hours then transferred to 70% ethanol for at least 24 hours. 
Fixed tissue was then processed and embedded and sequentially cut by microtome into 
5μm sections onto Superfrost Plus slides (Fisher) and stored.  
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2.8.2 Haematoxylin and eosin staining (H&E) 
 
Prior to staining of sections, they were first dewaxed by incubation in xylene for 10 
minutes then rehydrated by incubation in 100% then 95% ethanol. Sections were 
incubated in haematoxylin for 1 minute which stains nuclei blue. The blue colour of 
haematoxylin was developed by incubation in Scott’s tap water (2% (w/v) NaHCO3 and 
0.35% (w/v) MgSO4 in distilled water) for 10s. After a wash in tap water, sections were 
stained in eosin for 15 seconds then again washed in tap water. Sections were 
dehydrated by incubation in an increasing ethanol gradient (50%, 75%, 90% and 100% 
(v/v)) each for 5 minutes followed by a 10 minute incubation in xylene. Sections were 
mounted using DPX and allowed to dry overnight prior to imaging.  
 
2.8.3 Sirius red staining of collagen 
 
At acidic pH, sirius red F3B specifically binds to basic amino acids in collagen due to 
its 6 sulphonic acid groups [175]. Fibrotic ECM is primarily composed of collagen; 
sirius red staining is therefore used to easily visualise fibrosis in tissue sections. 
Following dewaxing and dehydration as outlined in 2.8.1, sections were incubated for 1 
hour in sirius red (0.001% (w/v) direct red 80 (Fisher) in saturated picric acid). The 
stain was then fixed by 2 washes in 0.5% (v/v) acetic acid in distilled water. 
Dehydration and mounting was then carried out as described in 2.8.2. 
 
2.8.4 Immunohistochemistry 
 
Following dewaxing and dehydration as described in 2.8.2, endogenous peroxidase 
activity was quenched in sections by an incubation in hydrogen peroxide (3% H2O2 
(v/v) in absolute methanol) for 15 minutes. After a wash in PBS for 5 minutes, sections 
were then subject to antigen retrieval which was either sodium citrate heat based (see 
2.8.5) or trypsin protease based (see 2.8.6). Antigen retrieval was required because 
fixation can lead to cross-linking of amino acids, thereby masking the epitope. Antigen 
retrieval reverses some of this cross-linking improving the efficacy and specificity of 
immunostaining.  
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After antigen retrieval, a hydrophobic pen was used to outline the sections to keep 
solutions localised over the section. Sections were then blocked in 20% (v/v) FCS in 
PBS for 20 minutes at room temperature to block non-specific binding of antibodies 
followed by 3 PBS washes, each for 5 minutes. The primary antibody was incubated 
overnight at 4°C and was diluted in 0.05% (v/v) FCS in PBS (see table 2.1 for antibody 
details). To control for non-specific secondary antibody binding, a no primary antibody 
control (no primary) section was routinely stained alongside other sections and treated 
the same except that, during this primary antibody incubation period, it was incubated in 
diluent (0.05% (v/v) FCS) alone. The primary antibody was then washed off and the 
sections washed 3 times in PBS each for 5 minutes. The secondary antibody, diluted as 
for the primary antibody, was incubated for 1 hour at room temperature. This was then 
removed and washed as before with PBS. Antibody binding was detected using 3,3'-
diaminobenzidine (DAB, Dako, Ely, UK) which is oxidised, in a peroxidase conjugated 
reaction, to a brown insoluble product, which can be imaged microscopically. The DAB 
substrate solution was made up by combining 1ml of substrate buffer with a drop of 
DAB+ chromagen solution. 200μl of this solution was added per section. The time for 
development varied depending on the antibody combination used and was optimised for 
each combination. Generally it was between 1 to 3 minutes. After the required 
development time, the sections were washed in a large volume of distilled water then 
counterstained in haematoxylin for 1 minute. Sections were then incubated in Scott’s 
tap water for 10s, washed in tap water and dehydrated and mounted as previously 
described in 2.8.2.  
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Antigen 
Approximate 
molecular weight 
(kDa) 
Antibody 
raised in 
Dilution Source 
Primary antibodies 
α-SMA 42 Mouse 1/250 IHC Abcam (ab134813) 
Albumin 60 Rabbit 1/3000 WB Unknown 
Amylase 55 Rabbit 1/3000 WB Abcam (ab21156) 
β-actin 44 Mouse 1/3000 WB Sigma (A1978) 
BrdU n/a Mouse 1/50 ICC 
BD bioscience 
(347580) 
CK-19 40 Rabbit 1/250 IHC Abcam (ab84632) 
CPS-I 160 Rabbit 1/1000 WB Abcam (ab3682) 
CYP reductase 70 Rabbit 1/3000 WB Santa Cruz (sc13984) 
CYP1A1/ 
1A2 
56 Goat 1/3000 WB Daiichi 
CYP2B1/ 2B2 56 Mouse 1/1500 WB Abcam (ab22721) 
CYP2C11 57 Goat 1/3000 WB Daiichi 
CYP2E1 50 Rabbit 
1/3000 WB 
1/150 ICC 
Abcam (ab28146) 
CYP3A1 51 Mouse 1/3000 WB Abcam (ab22724) 
CYP4A1 50 Rabbit 1/1500 WB Abcam (ab3573) 
HNF4α 50 Goat 1/1500 WB Santa Cruz (sc6556) 
γH2AX (S139) 17 Rabbit 1/1000 WB Abcam (ab2939) 
MRP2 185 Mouse 1/100 WB Santa Cruz (sc59608) 
NTCP 38 Rabbit 1/200 WB Abcam (ab85611) 
PCNA 29 Mouse 1/300 IHC Abcam (ab2426) 
PMP70 70 Rabbit 1/3000 WB Abcam (ab3421) 
SGK1 50 Rabbit 1/1500 WB Sigma (S5188) 
Vimentin 58 Rabbit 1/250 IHC Abcam (ab92547) 
Secondary antibodies 
Anti-mouse 
FITC 
n/a Rabbit 
1/50 Comet 
staining 
Sigma (F9137) 
Anti-mouse 
HRP 
n/a Goat 
1/3000 WB 1/200 
IHC 
Dako (P0447) 
Anti-goat HRP n/a Rabbit 1/200 WB Sigma (A5420) 
Anti-rabbit 
FITC 
n/a Sheep 1/200 ICC Dako (F7512) 
Anti-rabbit HRP n/a Goat 
1/3000 WB 1/200 
IHC 
Dako (P0448) 
Table 2.1: Details of antibodies used (abbreviations: ICC - immunocytochemistry, IHC – 
immunohistochemistry, WB – Western blot)  
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2.8.5 Sodium-citrate antigen retrieval 
 
Sections were placed in 10mM sodium citrate pH 6.0 in a plastic rack then microwaved 
at high power for 20 minutes. The sodium citrate was topped up every 5 minutes to 
replace that lost by evaporation. After microwaving the sections were cooled down by 
slowly adding distilled water to the sodium citrate buffer. Once at room temperature 
immunostaining was continued. 
 
2.8.6 Trypsin antigen retrieval 
 
For protease antigen retrieval, a trypsin solution (0.1% (v/v) trypsin-EDTA in PBS) was 
pre-warmed at 37°C. Sections were then incubated in this solution for 30 minutes at 
37°C prior to continuation of immunostaining. 
 
2.8.7 Fluorescence immunocytochemistry 
 
Cells in 6 well plates were washed twice in PBS then permeabilised with 2ml of ice 
cold absolute methanol at 4°C for 10 minutes. This was then aspirated off and the cells 
washed twice with PBS. 2ml of fixative solution (0.2% (v/v) glutaraldehyde and 2% 
(v/v) formaldehyde in PBS, pH 7.4) was then added and left for 15 minutes at room 
temperature. Following removal of fixative, non specific binding sites were blocked by 
incubation in 5% (v/v) FCS in PBS for 10 minutes. The cells were washed twice in PBS 
and the primary antibody added (diluted in PBS, see table 2.1 for antibody details). To 
control for non-specific secondary antibody binding, no primary antibody control (no 
primary) cells were routinely stained alongside other cells and treated the same except 
that, during this primary antibody incubation period, they were incubated in diluent 
(PBS) alone. After 1 hour incubation at room temperature, the cells were washed twice 
in PBS then incubated in the appropriate secondary antibody for 1 hour at room 
temperature. Cells were then incubated in 4',6-diamidino-2-phenylindole (DAPI, 6μg/ml 
in PBS) for 20 minutes to label DNA. DAPI is a fluorescent cell permeable dye that 
binds in the minor groove of DNA at AT rich clusters allowing for specific fluorescent 
detection of DNA [176]. The DAPI solution was aspirated off and the cells washed 3 
times with PBS before being stored in 5ml of PBS at 4°C in the dark prior to 
visualisation. 
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2.8.8 Transmission electron microscopy 
 
Cells were suspended in 10mM EDTA in PBS, pelleted then fixed in 2% glutaraldehyde 
in Sorenson’s phosphate buffer (0.1M sodium phosphate, pH 7.2). The fixed cells were 
then processed and embedded in resin by the Newcastle University Electron 
Microscopy Research Service. Samples were viewed using a Philips CM100 
transmission electron microscope. 
 
2.8.9 Image analysis 
 
Stained slides were imaged using a Lecia bright field microscope (Milton Keynes, UK) 
using the accompanying software, setting the white balance as required. Fluorescently 
stained cells were imaged using either a Zeiss fluorescence (Cambridge, UK) or a Nikon 
SP2 laser scanning confocal (Kingston-upon-Thames, UK) microscope. Qwin software 
(Leica) was used to assess the percentage staining of immunostained sections. The 
threshold for positive staining was specified manually and kept constant for each batch 
of stained slides. 70kDa peroxisomal membrane protein (PMP70) fluorescence from 
cells was determined using ImageJ [177], by applying a threshold, kept constant, to 
images to remove the background. The analyse particle mode, with particle size set to 
exclude background staining, was used to count the number of positive staining foci. 
This was divided by the cell number to give mean relative normalised PMP70 staining. 
 
2.9 Enzyme activity assays 
 
2.9.1 Rat liver microsome preparation 
 
The majority of hepatic CYP450s are located in the endoplasmic reticulum in 
hepatocytes. Microsomes are therefore often used to assess drug bioactivation and 
metabolism. Liver from a freshly culled rat was chopped roughly in ice-cooled TKMS 
buffer (50mM Tris; 25mM KCl, 5mM MgCl2 and 250mM sucrose, pH 7.5). The tissue 
was then homogenised using a dounce homogeniser in 5 times the volume of tissue on 
ice, filtered through bolting cloth and centrifuged at 12,000g for 20 minutes at 4°C 
(pellets nuclei, mitochrondria and lysosomes). The top layer of fat was removed and the 
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supernatant transferred to a fresh centrifuge tube and the samples centrifuged again at 
12,000g for 20 minutes at 4°C. The supernatant was aliquoted into ultracentrifuge tubes 
and centrifuged at 100,000g at 4°C for 1 hour. The supernatant was removed and the 
pellet (microsomes) washed in fresh TKMS buffer. The pellet was re-suspended in 
TKMS buffer once more then transferred to a fresh ultracentrifuge tube. This was 
centrifuged in an ultracentrifuge as before. Following the spin, the supernatant was 
removed and the pellet re-suspended in 1ml of microsome buffer (10mM KnHnPO4, 
1mM EDTA and 20% (v/v) glycerol, pH 7.2). The microsomes were then aliquoted and 
stored at -80°C. The protein concentration of samples was calculated by Lowry assay 
(2.7.3). 
 
2.9.2 Resorufin based probe assays (EROD, MROD and PROD) 
 
CYP1A1, CYP1A2 and CYP2B1 activities were determined in cellular lysates, using 7-
ethoxyresorufin, 7-methoxyresorufin and 7-pentoxyresorufin respectively. These 
modified forms of resorufin that are not fluorescent are metabolised to resorufin which 
is highly fluorescent. Different CYP450 enzymes specifically metabolise these different 
substrates as summarised in figure 2.5 and therefore they can be used to measure the 
activity of these enzymes [178-180]. 
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Figure 2.5: Metabolism of 7-ethoxyresorufin, 7-methoxyresorufin and 7-pentoxyresorufin. 
 
Following treatment, cells were washed once in PBS then scraped using a rubber 
policeman into fresh PBS and transferred into an eppendorf tube. The cells were 
centrifuged at 16,000g for 30s and the supernatant discarded. The pellets were then re-
suspended in TM buffer (50mM Tris-HCl, 25mM MgCl2 pH7.5). 50μl of the cell lysate 
was added to 100μl of either 4μM 7-ethoxyresorufin, 2μM 7-methoxyresorufin or 20μM 
7-pentoxyresorufin in TM buffer depending on the CYP450 being measured. This was 
then prewarmed at 37°C for 15 minutes after which 50μl of 500μM nicotinamide 
adenine dinucleotide phosphate (NADPH) was added per well to initiate the reaction. 
Immediately after NADPH addition, fluorescence was measured (λexcitation: 522nm, 
λemission: 586nm) routinely every 1 minute for up to 20 minutes at 37°C. A resorufin 
standard curve was prepared fresh for every assay on the same plate with concentrations 
ranging from 0-32pmol/well resorufin in TM buffer. Following the end of the assay, 
fluorescence readings were plotted against time and a line of best fit fitted to the linear 
region of activity to give a rate of change in fluorescence. The amount of resorufin 
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produced was then calculated from the standard curve and normalised to protein 
concentrations measured by Lowry assay (detailed in 2.7.3) to give an absolute rate of 
activity. 
  
2.9.3 Luciferin-IPA CYP3A1 assay 
 
To measure CYP3A1 activity in cell lysates, luciferin-IPA (Promega) metabolism was 
measured which, in rats, is primarily catalysed by CYP3A1 (personal communication 
with Promega). The metabolism of the proprietary substrate yields D-luciferin which is 
then catalysed by luciferase to produce light which can be measured as outlined in 
figure 2.6. 
 
 
Figure 2.6: Metabolism of luciferin-IPA by CYP3A1 and luciferase 
 
To measure luciferin-IPA metabolism, cell pellets or microsomes were re-suspended in 
TM buffer as described in 2.9.1. A fourfold concentrated reaction mastermix was 
prepared by mixing 0.05μl of 3mM luciferin-IPA, 22.5μl of distilled water and 5μl of 
1M potassium phosphate buffer. 27.5μl of mastermix was added to each well with 5μl 
of each cell sample in 96 well white walled plates. Plates were pre-incubated for 10 
minutes at 37°C then the reaction started by addition of 17.5μl of 4.3mM NADPH (final 
concentration of 1.5mM). Reactions were incubated for 30 minutes at 37°C then 50μl 
luciferin detection reagent added per well. Plates were tapped to mix then luminescence 
determined using a Tecan infinite 200 plate reader (Männedorf, Switzerland) using a 1 
second integration time. 
 
2.9.4 Dye retention assays 
 
Efflux transporter activity was determined using dye retention assays. As outlined in 
figure 2.7, if cells are cultured in a medium containing a lipophilic compound, the 
compound will enter cells and over time equilibrium is reached between its entry and 
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exit. Transporter efflux determines the accumulation of the compound and their 
inhibition causes enhanced retention of the dye. Through the use of specific compounds 
and transporter inhibitors, the relative activity of transporters can be determined.  
 
 
Figure 2.7: Principal of fluorescence transporter efflux assays. 
 
The specific fluorophores and inhibitors used to determine the activity of different 
transporters is detailed in table 2.2. 
 
Table 2.2: Substrates and inhibitors used to measure indicated transporter activity. CMFDA was 
from Life technologies (Paisley, UK). 
Transporter 
activity 
measured 
Substrate Inhibitor 
Fluorescent read 
settings 
Excitation Emission 
MDR 1μM Hoechst 33342 (H33342) 5μM Cyclosporin A 355nm 455nm 
BCRP 1μM H33342 1μM Ko143 355nm 455nm 
MRP 
1μM 5-chloromethylfluorescein 
diacetate (CMFDA) 
10μM MK571 490nm 520nm 
BSEP 
1μM dihydrofluorescein diacetate 
(H2FDA) 
100μM Troglitazone 
50μM Glibenclamide 
490nm 530nm 
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To determine activity, cells were first incubated with the respective inhibitor or vehicle 
in serum free medium for 30 minutes at 37°C. After this incubation, the medium was 
replaced with serum free medium containing both the inhibitor and the appropriate 
fluorescent substrate for a further 30 minutes at 37°C. The cells were then washed twice 
with ice cold PBS. After the final wash, ice cold PBS was added to each well and 
fluorescence read using the settings shown in table 2.2. Gain was optimised individually 
for each substrate and inhibitor combination per day then kept constant between 
different plates to ensure results could be directly compared. Background readings were 
subtracted from all values which were then normalised to protein concentration as 
calculated by Lowry assay (see 2.7.3). Values were expressed as percentage change in 
fluorescence relative to vehicle treated controls.  
 
2.10 Measurement of DNA damage 
 
2.10.1 The single cell gel electrophoresis assay (comet assay) 
 
DNA damage was routinely measured by the alkaline comet assay [181]. Essentially, 
cells are embedded in agarose and proteins and membranes removed with a lysis 
solution. A strong basic solution is then used to denature and unwind the DNA, 
following which a potential difference is applied. Damaged DNA with breaks is more 
mobile than unbroken DNA and therefore migrates further towards the anode. The 
amount of DNA migration (“the tail”) from the nucleus (the “head”) can be determined 
using a DNA intercalating dye and used as a measure of DNA damage. 
 
Treated cells were detached using trypsin as described in 2.3.6 then centrifuged at 600g 
for 5 minutes to pellet the cells. The cells were re-suspended in a small volume of ice 
cold medium and counted by haemocytometer, following which cell density was 
adjusted to 1 x 10
6
 ml
-1
. Cell viability was also measured by trypan blue exclusion (as 
outlined in 2.3.9) and cells with viability less than 80% were discarded. 6μl of the cell 
solution was added to 54μl of low melt point agarose (0.9% (w/v) in PBS), which had 
been melted in boiling water then equilibrated to 37°C. 50μl of this mix was then 
immediately pipetted onto slides pre-coated with agarose (0.75% (w/v) in PBS). The 
embedded cells were incubated in a fridge for 10 minutes to harden the agarose then in 
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comet lysis buffer (10 mM Tris, 2.5M NaCl and 100 mM EDTA pH 10.0 supplemented 
on the day with 2% (v/v) DMSO and 1% (v/v) triton X-100) for 1 hour at 4°C, which 
lyses the cell membranes. Slides were briefly washed in PBS then were incubated for 30 
minutes in electrophoresis buffer (0.3 M NaOH, 1 mM EDTA pH>13). 
 
Electrophoresis was run at 30V (~0.9V/cm) 300mA for 30 minutes at 4°C. The 
embedded cells were incubated in neutralisation buffer (0.5M Tris pH 7.5) for 15 
minutes then washed in PBS. Slides were incubated for 5 minutes in 1x SYBR gold 
nucleic acid stain (Invitrogen) in PBS. Finally, they were washed twice in distilled 
water and left to air dry in the dark at room temperature overnight. Slides were stored 
long term at 4°C in the dark. SYBR staining was imaged by fluorescence microscopy 
using the fluorescein isothiocyanate (FITC) filter and comets measured using 
CometScore software (http://www.autocomet.com). DNA damage was expressed as the 
olive tail moment, a parameter which takes into account the comet tail length and the 
percentage of DNA in the comet tail. 
 
2.10.2 DNA diffusion assay 
 
Following preparation, embedding and lysis of cells as described in 2.10.1, slides were 
incubated in comet lysis buffer for 1 hour then 0.5M Tris pH 7.4 for 5 minutes. They 
were then washed and stained with SYBR gold as previously outlined in 2.10.1. Slides 
were visualised using a fluorescent microscope.  
 
2.10.3 Assessment of cell proliferation 
 
To check that DNA damage caused by treatments was not due to DNA replication, cells 
were labelled with the thymidine analogue BrdU (bromodeoxyuridine) which is 
incorporated by cells into their DNA during S-phase of the cell cycle. Cells, the 
morning after treatment, were treated with 15μM BrdU for 2 hours. Cells were then 
subjected to the comet assay as described to 2.10.1 but following incubation in the 
neutralisation buffer, cells were incubated with anti-BrdU (see table 2.1 for details) 
diluted in 0.5% (v/v) FCS in PBS for 1 hour at room temperature. Slides were washed 
three times in PBS then incubated with a FITC conjugated secondary antibody in 0.5% 
(v/v) FCS in PBS for 1 hour at room temperature. This was then washed off and slides 
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were soaked in 6μg/ml DAPI for 15 minutes to stain DNA followed by a 15 minute 
wash in distilled water. Slides were air dried overnight at room temperature in the dark 
and imaged the following day. 
 
2.11 Spectrophotometric CYP450 assays 
 
2.11.1 Total CYP450 dual-beam spectroscopy 
The haem bound in cytochromes demonstrates different absorbance properties 
depending on its oxidation and ligation state and can be used to identify specific 
cytochrome concentrations in a solution. Reduced CYP450 has a characteristic 
absorbance peak at 450nm and therefore, by measuring the absorbance difference 
between reduced and oxidised samples, the concentration of total CYP450 in a sample 
can be measured [182]. 
 
To measure total haem-bound CYP450 concentrations in samples, cell pellets were re-
suspended in 2ml of TST buffer (20mM Tris, 250mM sucrose and 0.01% (v/v) triton X-
100 pH 7.4). 5μl was removed to measure total protein concentration by Lowry assay as 
described in 2.7.3. 1-5mg of sodium dithionite was added to the sample and inverted to 
mix. The reduced solution was then split into 2 cuvettes. Carbon monoxide was bubbled 
through one cuvette for 30s at about 1 bubble per second. The absorbance difference 
between the two cuvettes was then measured between 400-500nm. The total haem 
bound CYP450 concentration was then calculated using the following equation, where 
91,000 M
-1
 cm
-1
 is the extinction coefficient of CYP450 [182]:  
 
                                
            
            
 
 
2.11.2 Total cytochrome b5 dual beam spectroscopy 
 
The concentration of total cytochrome b5 in a sample can be calculated similar to 
CYP450, however the reduced absorbance peak is at 424nm [182]. Cell pellets were re-
suspended in 2ml of TST buffer and 5μl taken to measure total protein concentration by 
Lowry assay (see 2.7.3). The solution was split equally between 2 cuvettes and one 
solution reduced by addition of 50μg of nicotinamide adenine dinucleotide (NADH). 
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The absorbance difference of the oxidised and reduced solutions was measured between 
400-460nm. The total cytochrome b5 concentration was then found using the following 
equation, where 18,500 M
-1
 cm
-1
 is the extinction coefficient of cytochrome b5 [182]: 
 
                                 
            
      
 
 
2.12 Serum activity assays 
 
Blood was collected from animals by tail vein bleeding or after culling and was left to 
clot at room temperature (~1 hour). Blood was centrifuged at 16,000g for 5 minutes and 
the serum transferred to a fresh tube. Analysis of alanine transaminase (ALT) and 
alkaline phosphatase (ALP) serum activities, biomarkers of hepatocyte and 
cholangiocyte injury respectively, was carried out by the Royal Victoria Infirmary 
Clinical Biochemistry Department in Newcastle Upon Tyne.  
 
2.13 Hydroxyproline assay 
 
The hydroxyproline content of the liver is proportional to the severity of fibrosis due to 
the abundance of hydroxyproline specifically in collagen [183]. The Quickzyme 
hydroxyproline assay (2B Scientific, Upper Heyford, UK) was used to calculate total 
hydroxyproline content of rat liver samples, essentially following the recommended 
protocol. Briefly, 100μl of 6M hydrochloric acid was added per 10mg of liver tissue 
(wet weight) and incubated overnight at 110°C. The samples were then centrifuged at 
16,000g for 15 minutes and 35μl of the supernatant added to 75μl of included assay 
buffer then incubated for 20 minutes at room temperature. Whilst incubating, the 
detection reagent was prepared by mixing detection reagent A and B at a ratio of 2:3. 
75μl of detection reagent was added to each sample and these were then incubated at 
60°C for 60 minutes and then the OD570 measured. A series of hydroxyproline standards 
were run alongside samples ranging from 0 to 300μM diluted in 4M hydrochloric acid 
to generate a standard curve which was used to calculate hydroxyproline content of 
samples using a line of best fit and y = mχ + c. Sample readings were normalised to 
protein concentration as calculated by Lowry assay (outlined in 2.7.3). 
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2.14 Luminescent imaging of mice 
 
NF-κB –luc mouse luminescence was detected and quantified using the Xenogen IVIS 
(in-vivo imaging system) 200 Spectrum imaging system using the bundled Living Image 
4.0 software (Caliper Life Sciences, Hopkinton, USA). Prior to imaging, mice were 
anaesthetised with isoflurane and their abdominal fur shaved off. The mice were then 
given an intra-peritoneal (i.p.) injection of 200μl D-luciferin (Caliper Life Sciences) at 
15mg/ml in PBS. Mice were typically imaged 0, 5 and 10 minutes following D-luciferin 
injection using a 1 minute integration time. Following imaging, mice were either 
returned to their cages or culled by cervical dislocation. The major organs of culled 
mice were quickly excised and imaged in the IVIS again using a 1 minute integration 
time to determine the source of luminescence. From captured images, regions of interest 
were manually specified using the Living Image 4.0 software to calculate total flux 
values (photons/s).  
 
2.15 Statistics 
 
Statistically significant differences between groups were determined by the Student’s 2-
tailed t-test unless otherwise specified. Regardless of hypothesis test used, significance 
was achieved where p<0.05. 
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Chapter 3. Expression and induction of drug metabolising enzymes in 
B-13/H cells 
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3.1 Introduction 
 
Hepatic bioactivation is implicated in the toxicity of numerous drugs [30]. Hepatocytes 
are the primary defining cell type of the liver and are responsible for most of its 
functions, including drug and chemical metabolism. Hepatocytes, particularly human 
hepatocytes, are consequently the gold standard for novel drug and chemical toxicity 
screening to assess for potential toxicity. However, as outlined in the introduction, there 
are numerous problems associated with the sourcing and culture of primary hepatocytes 
for screening purposes, meaning that alternatives are sought. 
 
Functional hepatocytes produced from the B-13 cell line could be an alternative to 
primary hepatocytes; the cells are easily expanded in standard culture medium and 
consistently, when treated with nanomolar concentrations of DEX, transdifferentiate to 
hepatocyte-like cells. B-13 cells also have a stable phenotype in that, although they have 
an abnormal karyotype, they have maintained the ability to transdifferentiate and, unlike 
tumorigenic cells, do not grow in soft agar [184]. 
 
To date, although the expression of some drug metabolising enzymes has been 
demonstrated in transdifferentiated B-13 cells [124, 125], their drug metabolising 
properties remain poorly characterised as does their ability to induce CYP450s, a 
physiologically important response. To this end, the aim was to fully characterise the 
expression of drug metabolising enzymes, particularly CYP450s in B-13/H cells, and to 
investigate their potential for induction in response to the relevant AhR, CAR, PXR and 
PPARα ligands. The hypothesis was that B-13/H, but not B-13 cells, would express a 
similar range of functional CYP450s to rat hepatocytes with a similar capacity for 
induction. 
 
3.2 B-13 cells undergo transdifferentiation in response to DEX treatment 
 
B-13 cells were routinely transdifferentiated to B-13/H cells by 14 days treatment with 
10nM DEX. As shown in figure 3.1A, DEX treated B-13 cells flattened and spread. 
When proliferation was measured (figure 3.1B), it was observed that DEX treatment 
arrested proliferation of B-13 cells compared to vehicle treated cells as has been 
documented previously [124]. B-13/H cells also expressed a range of hepatic markers 
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including carbamoyl phosphate synthetase 1 (CPS-1), CYP2E1 and CYP reductase, 
similar to rat liver, that were not expressed in untreated B-13 cells (figure 3.2). B-13/H 
cells retained expression of amylase following transdifferentiation as has been 
previously shown [124]. CYP450s contain a haem cofactor required for function. Split 
beam spectrophotometry demonstrated that B-13/H but not B-13 cells contained haem 
bound CYP450 as has been documented previously (figure 3.3A & B) [184]. CYP 
reductase is the main electron donor for CYP450s. However cytochrome b5, which also 
contains haem, can also act as an electron donor to CYP450s and its addition to 
microsomes has been shown to enhance their metabolic capacity [185]. Measurement of 
haem bound cytochrome b5 showed that B-13/H but not B-13 cells contained an 
equivalent amount of haem bound cytochrome b5 to freshly isolated hepatocytes (figure 
3.3C & D).  
 
 
Figure 3.1: B-13 cells change morphology and cease proliferation in response to DEX. A. Change in 
morphology in response to DEX. Representative brightfield and transmission electron 
photomicrographs at 100x and 34000x magnification respectively. B. Proliferation of vehicle and DEX 
treated cells. The total number of cells treated with vehicle (0.1% (v/v) ethanol) or 10nM DEX were 
counted per field of view per time point. Results are the mean and SD of 3 independent determinations 
from a single experiment, typical of at least 3 separate experiments. Statistical analysis was not 
performed. 
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Figure 3.2: B-13/H cells express hepatic markers. A. Western blot for the indicated proteins in B-13 
and B-13/H cells and control rat liver. Lysates were prepared and quantified by Lowry assay. 20μg of 
protein/well was separated by SDS-PAGE and transferred to a nitrocellulose membrane which was 
blocked and probed. Antibody binding was detected using ECL Western blot substrate. B. CYP2E1 
immunostaining in B-13 and B-13/H cells. Fixed cells were blocked then immunostained for CYP2E1, 
using DAB to detect bound antibody before counterstaining with haematoxylin. Cells were analysed 
using a Leica upright microscope. Scale bar indicates 100μm. Results are typical of at least 3 separate 
experiments.  
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Figure 3.3: B-13/H cells contain haem-bound CYP450 and cytochrome b5. A. Total CYP450 
absorbance spectrum. Lysates prepared from B-13 and B-13/H cells were re-suspended in TS buffer 
containing sodium dithionite and then split into 2 different cuvettes. Carbon monoxide was bubbled 
through one of the paired cuvettes and then the absorbance difference measured between the reduced and 
oxidised samples between 400nm and 500nm. B. Quantified total CYP450 content in B-13 and B-13/H 
cells. The OD450-OD490 was calculated from the absorbance difference spectrum as in A and the total 
CYP450 content calculated using the extinction coefficient as outlined in the methods. CYP450 content 
was normalised to protein concentration. C. Total cytochrome b5 absorbance spectrum. Lysates from 
B-13 cells, B-13/H cells and freshly isolated primary rat hepatocytes were re-suspended in TS buffer and 
split into 2 cuvettes. 50μg of NADH was added to one of the paired cuvettes and absorbance difference 
measured between the reduced and oxidised samples between 400nm and 460nm. D. Quantified total 
cytochrome b5. The OD424-OD409 was calculated from the absorbance difference spectrum as in C and the 
total cytochrome b5 content calculated using the extinction coefficient as outlined in the methods. 
Cytochrome b5 content was normalised to protein concentration. For A and B, results are the mean and 
SD of 3 independent determinations from a single experiment, typical of 2. Statistical analysis was not 
performed. For C and D, results are the mean and SD of 3 separate experiments. There was no significant 
difference between B-13/H cells and rat hepatocytes. 
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3.3 B-13/H cells express male CYP450 isoforms 
 
Several DMEs, including some CYP450 isoforms, are sex specific; their expression is 
dependent on specific patterns of growth hormone (GH) release from the pituitary 
gland, which may be influenced by the actions of gonadal hormones such as 
testosterone or oestrogen [186]. In adult male rats GH is released in an ultradian manner 
every 3.3 hours. Between these pulses the basal blood plasma level of GH is less than 
5ng/ml [187]. Conversely, in adult female rats, GH peaks are on average lower than in 
males, but they occur more frequently and the basal level of plasma GH is generally 
greater than 5ng/ml [188]. To determine the expression of sex-dependent CYP450s in 
B-13 cells, which are male cells [128], RT-PCR was carried out. As shown in figure 
3.4A, B-13/H cells expressed all CYP450 transcripts measured with the exception of 
CYP3A2.  
 
To quantitatively determine the expression of the expressed CYP450s, qPCR was 
carried out on B-13 and B-13/H cells, and male and female rat liver (figure 3.4B). 
CYP2C11 is the main CYP450 in male rats, making up around 50% of total CYP450 
content [189]. Conversely, in female rats, CYP2C12 is the dominant CYP450 isoform, 
making up around 40% of total CYP450 content [190, 191]. B-13/H cells expressed 
about 10 times less CYP2C11 mRNA than male rat liver but around 10 times more than 
that expressed in female rat liver (figure 3.4B). In contrast, CYP2C12 mRNA was, as 
expected, highly expressed in female rat liver with significantly reduced expression in 
male liver and even lower expression in B-13/H cells. 
 
Analysis of the expression of other sexual-dimorphic CYP450s showed that B-13/H 
cells expressed greater mRNA levels of the male specific isoform CYP2C13 compared 
to female liver but 100 fold less than that seen in male liver (figure 3.4B) [186]. The 
mRNA expression of male isoforms CYP3A2 and CYP3A18 was significantly higher in 
male liver than in B-13/H cells or female liver. B-13/H cells expressed equivalent levels 
to that seen in female rat liver. Expression of CYP2A mRNA, a female predominant 
CYP450 [192], was significantly higher in female liver than male liver. B-13/H cells 
showed expression significantly lower than male liver. CYP2C7, which has been 
previously reported as a female predominant isoform [193], showed equivalent mRNA 
expression in male and female rat liver samples. Considering that the expected 
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difference between male and female rat liver expression of CYP2C7 is only 2-3 fold, 
the small sample sizes in this work may explain the lack of significant difference. B-
13/H cells expressed significantly lower levels of CYP2C7 mRNA than male liver. 
CYP2C6, which is not generally considered sex-dependent [194], was expressed at the 
level of mRNA at similar levels by male and female rat liver. B-13/H cells expressed 
significantly greater levels than male liver and B-13 cells expressed only around 1/300
th
 
of that expressed in B-13/H cells. 
 
The pattern of mRNA expression of the main sexual-dimorphic CYP450s, CYP2C11 
and CYP2C12, suggests that B-13/H cells recapitulate a male pattern of CYP450 
expression. This is essentially supported by the pattern of mRNA expression of the 
other sexually dimorphic CYP450s. In culture, primary hepatocytes rapidly lose 
expression of CYP3A2 and this may explain why B-13/H cells expressed only similar 
levels to female liver [195]. Previous work also suggests that CYP3A2 takes longer than 
14 days following transdifferentiation to be expressed [124]. These reasons may also 
account for the low expression of CYP3A18 mRNA observed. Western blotting for 
CYP2C proteins essentially supports the transcript data. Figure 3.4C indicates that there 
was no detectable CYP2C protein in B-13 cells whereas B-13/H cells expressed 
immunodetectable protein. 
 
To establish whether the CYP2C11 expressed in B-13/H cells was functional, B-13 and 
B-13/H cells were treated with methapyrilene, which some evidence suggests is 
activated to a toxic product by CYP2C11 [196]. Figure 3.5 shows that the viability of B-
13 cells was unaffected by methapyrilene exposure at concentrations of up to at least 
500µM whereas methapyrilene treatment caused a dose-dependent loss of viability in B-
13/H cells, with an EC50 concentration of approximately 20µM.  
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Figure 3.4: B-13/H cells partially recapitulate a male pattern of CYP450 expression. A. RT-PCR for 
the indicated transcripts in B-13 cells, B-13/H cells, male rat liver and female rat liver. Total RNA 
was extracted from samples using TRIzol and cDNA produced which was used as the template for PCR. 
Following PCR, samples were separated by agarose gel electrophoresis and visualised by UV 
transillumination. B. qPCR for sex-dependent CYP450s. Total RNA was extracted from B-13 cells, B-
13/H cells, and male and female rat liver samples using TRIzol and reverse transcribed. The cDNA was 
used as template for qPCR to measure the expression of the indicated transcripts. Readings were 
normalised to 18S rRNA expression and fold change expressed relative to male rat liver. Bars are the 
mean and SD of 3 independent determinations from a single experiment, typical of at least 3 separate 
experiments. *significantly different to male liver at p<0.05. C. Western blot for CYP2C11. Lysates 
were prepared and quantified by Lowry assay. 20μg of protein/well was separated by SDS-PAGE and 
transferred to a nitrocellulose membrane which was blocked and probed. Antibody binding was detected 
using ECL Western blot substrate. Blot is representative of at least 3 separate experiments. 
 
 
  Chapter 3. Results 
 
87 
 
 
 
Figure 3.5: B-13/H cells are sensitive to methapyrilene. B-13 or B-13/H cells were treated with 
different concentrations of methapyrilene and their viability assessed by trypan blue 24 hours later. EC50 
was calculated using GraphPad Prism. Additional statistical analysis was not performed. Results are the 
mean and SD of 3 independent determinations from the same experiment, typical of at least 3 separate 
experiments. 
 
3.4 B-13/H cells are not receptive to GH 
 
GH control of sex-dependent CYP450 expression in hepatocytes is regulated by the 
growth hormone receptor (Ghr) acting through the JAK/STAT signalling pathway 
(particularly requiring JAK2 and STAT5b) [186]. To determine if B-13/H cells would 
be sensitive to GH, mRNA expression of JAK/STAT signalling components was 
investigated by qPCR array. Figure 3.6 shows that both B-13 and B-13/H cells 
expressed the majority of pathway components including JAK2, STAT5b and Ghr, 
which were expressed at similar mRNA levels in both cell types.  
 
To determine if expression of CYP2C11 could be induced in B-13/H cells, B-13/H cells 
were cultured either serum-free or in serum-containing media and were treated with 
different concentrations of GH (human growth hormone (hGH)). CYP2C11 mRNA 
expression in these cells did not significantly change following treatment suggesting 
that, at least under the conditions tested, B-13/H cells do not respond to GH (figure 
3.7A). To confirm the qPCR, CYP2C11 was probed by Western blotting which 
similarly indicated that GH had no effect on CYP2C11 protein expression (figure 3.7B). 
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Figure 3.6: B-13/H cells express signalling machinery required for JAK/STAT signalling. 
JAK/STAT signalling qPCR array. Total RNA was produced from B-13 and B-13/H cells using TRIzol, 
which was then cleaned up, reverse transcribed and the resulting cDNA used as a template for the 
JAK/STAT signalling arrays. Results are normalised to 5 housekeeping genes. Arrows indicate Jak2, 
Stat5b and Ghr. Values are the mean fold change in expression in B-13/H cells relative to B-13 cells from 
1 sample. 
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Figure 3.7: B-13/H cells are not responsive to hGH. A. Expression of CYP2C11 in B-13/H cells 
treated with different concentrations of hGH measured by qPCR. B-13/H cells (cultured normally or 
serum free for 1 day) were treated with the indicated concentrations of hGH for 24 hours following which 
RNA was extracted using TRIzol. The RNA was reverse transcribed and cDNA used as template for 
qPCR. Readings were normalised to 18S rRNA expression and fold change expressed relative to vehicle 
treated B-13/H cells (+FCS). Values are the mean and SD of 3 independent determinations from the same 
experiment, typical of 2 (SF) or 3 (+FCS) separate experiments. No statistical analysis was performed. B. 
Western blot for CYP2C11. Lysates were prepared from B-13/H cells treated as in A, and quantified by 
Lowry assay. 20μg of protein/well was separated by SDS-PAGE and transferred to a nitrocellulose 
membrane which was blocked and probed. Antibody binding was detected using ECL Western blot 
substrate. 
 
Based on the lack of CYP2C11 induction by GH in B-13/H cells (figure 3.7), it was 
postulated that the B-13/H cells were fully mature by 14 days and un-receptive to GH. 
To investigate if less mature B-13/H cells would be sensitive to the CYP450 modulating 
capacity of GH, B-13 cells were transdifferentiated in the presence or absence of GH. 
Measurement of sex-dependent CYP450 mRNA transcripts in these cells (figure 3.8) 
indicated that GH did not have a marked effect on CYP450 expression suggesting the 
cells are unresponsive to this pattern of GH at all stages of transdifferentiation under the 
conditions tested. 
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Figure 3.8: hGH does not affect the rate of sex-dependent CYP450 up-regulation during 
transdifferentiation. B-13 cells were treated with 10nM DEX with or without 50ng/ml hGH over 20 
days with medium changed daily. From each time point RNA was isolated using TRIzol and used as 
template for reverse transcription. The cDNA was used as template for qPCR to measure the expression 
of the indicated transcripts and results were normalised to 18S rRNA expression. Fold change is 
expressed relative to 14 day vehicle treated B-13/H cells. Results are the mean and SD of 3 independent 
determinations from a single experiment. No statistical analysis was performed. 
 
3.5 The AhR activator β-naphthoflavone (β-NF) induces CYP1A1 expression in B-
13 and B-13/H cells and sensitises cells to the genotoxic effects of benzo[α]pyrene.  
 
The CYP1A sub-family is of toxicological significance due to its metabolism of a range 
of carcinogens such as polyaromatic hydrocarbons and heterocyclic amines [33, 34]. 
These genes are inducible through their regulation by the AhR [32] as outlined in the 
introduction.  
 
To initially determine the potential of B-13 and B-13/H cells to induce CYP1A1, the 
expression of the AhR and ARNT, as well as the CYP1A family members CYP1A1, 
CYP1A2 and CYP1B1 was analysed by RT-PCR (figure 3.9A). This showed that both 
B-13 and B-13/H cells expressed AhR and ARNT mRNA similar to intact rat liver. 
They also both expressed CYP1A1 mRNA but not CYP1A2. Interestingly, the related 
CYP1B1 mRNA transcript, often expressed at high levels in tumour cells [197], was 
expressed in B-13 cells but down-regulated to near hepatocyte levels in B-13/H cells 
(figure 3.9A).  
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To quantitatively assess expression of CYP1A1 following induction, B-13 and B-13/H 
cells were treated with a range of prototypical CYP450 inducers including β-NF, a AhR 
ligand [198], and resulting CYP1A1 mRNA expression measured by qPCR. As shown 
in figure 3.9B, B-13/H cells expressed about 5 times more CYP1A1 mRNA than B-13 
cells. When treated with β-NF, both B-13 and B-13/H cells showed a significant 
induction of CYP1A1 mRNA to levels more than 100 fold greater than in vehicle 
treated cells. B-13/H cells, but not B-13s, also significantly induced CYP1A1 mRNA in 
response to 10μM DEX. Primary rat hepatocytes similarly treated also showed a 
significant induction of CYP1A1 mRNA expression in response to DEX and 
importantly β-NF (figure 3.9C), suggesting that B-13/H cells respond in an equivalent 
manner to AhR ligands to primary rat hepatocytes.  
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Figure 3.9: B-13 and B-13/H cells express inducible CYP1A1. A. RT-PCR for CYP1A associated 
transcripts. Total RNA was extracted from samples using TRIzol and cDNA produced which was used 
as the template for PCR. Following PCR, samples were separated by agarose gel electrophoresis and 
visualised by UV transillumination. B. qPCR for CYP1A1 in B-13 and B-13/H cells treated with 
prototypical CYP450 inducers. B-13 and B-13/H cells were treated for 3 days daily with vehicle (0.1% 
(v/v) DMSO) or inducer and harvested on the 4
th
 day. Total RNA was extracted from the cells using 
TRIzol and reverse transcribed. cDNA was used as template for qPCR measuring the expression of 
CYP1A1. Readings were normalised to 18S rRNA expression and fold change expressed relative to 
vehicle treated B-13/H cells. Bars are the mean and SD of 3 independent determinations from a single 
experiment, typical of at least 3 separate experiments. *significantly different to respective vehicle control 
at p<0.05. C. qPCR for CYP1A1 in primary rat hepatocytes treated with prototypical CYP450 
inducers. From primary rat hepatocytes treated as in B, RNA was extracted and reverse transcribed. The 
cDNA was used as a template for qPCR measuring the expression of CYP1A1 and results were 
normalised to 18S rRNA expression. Results are expressed as fold change relative to vehicle treated cells. 
Bars are the mean and SD of 3 independent determinations from a single experiment, typical of at least 3 
separate experiments. *significantly different to vehicle control at p<0.05. 
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To determine if the induction of CYP1A1 mRNA translated to an induction at the level 
of protein, Western blotting to detect CYP1A1 was performed on B-13 and B-13/H 
cells and primary rat hepatocytes treated with β-NF. This demonstrated (figure 3.10) 
that CYP1A1 protein was induced in all tested cell types.  
 
Based on the induction of CYP1A1 protein by β-NF, it was then investigated if 
CYP1A1 induction had functional consequences. Using 7-ethoxyresorufin (which as 
outlined in the methods is a substrate metabolised by CYP1A1 to fluorescent resorufin), 
CYP1A1 activity was assayed in B-13 and B-13/H cells and primary rat hepatocytes 
treated with a range of prototypical inducers. Lysates of β-NF and DEX treated B-13/H 
cells and primary rat hepatocytes showed significantly greater EROD activity than 
vehicle treated cells (figure 3.10B), suggesting that expressed CYP1A1 was functional. 
Although B-13 cells expressed a similar amount of CYP1A1 protein to B-13/H cells 
when induced with β-NF, their induced activity was markedly lower than B-13/H cells. 
This is likely because B-13 cells do not express CYP reductase which is required for 
CYP450 function [124]. Although DEX did lead to a significant increase in CYP1A1 
mRNA expression in B-13/H cells and primary rat hepatocytes (figure 3.9), the increase 
was smaller than that seen in response to β-NF. However, when measuring EROD 
activity, DEX induction led to similar EROD activity to β-NF induction. DEX can 
induce CYP2B and CYP3A expression through the PXR and it was hypothesised that 
DEX induced CYP2B and CYP3A may have non-specifically catalysed ethoxyresorufin 
deethylation. This would account for the significantly increased EROD activity in B-
13/H cells and primary rat hepatocytes induced with DEX.  
 
To test this hypothesis, EROD activity was measured in the presence or absence of α- 
naphthoflavone (α-NF), a CYP1A1 inhibitor [199], in B-13/H cells. Compared to 
lysates from vehicle induced B-13/H cells, only lysates from β-NF treated cells were 
significantly inhibited by α-NF (figure 3.10C). This result confirms the hypothesis as 
the lack of significant difference in lysates from DEX treated cells suggests that DEX 
was not increasing EROD activity through induction of CYP1A1. 
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Figure 3.10: B-13/H cells express inducible CYP1A1 protein which is functional and inducible. A. 
Western blot for CYP1A1 in normal and induced B-13 cells, B-13/H cells and primary rat 
hepatocytes. Cells were treated daily for 3 days with vehicle (0.1% (v/v) DMSO) or 20μM β-NF. On the 
4
th
 day, lysates were prepared from the treated cells and rat liver and quantified by Lowry assay. 20μg of 
protein/well was separated by SDS-PAGE and transferred to a nitrocellulose membrane which was 
blocked and probed. Antibody binding was detected using ECL Western blot substrate. Blot is 
representative of at least 3 separate experiments. B. EROD activity in induced B-13 and B-13/H cells, 
and primary rat hepatocytes. EROD activity was measured in lysates prepared from B-13 cells, B-13/H 
cells and primary rat hepatocytes treated as in A. Readings were normalised to lysate protein 
concentration. Results are the mean and SD of 3 determinations from a single experiment, typical of at 
least 3 separate experiments. *statistically significantly different to relevant vehicle treated control at 
p<0.05. C. Inhibition of EROD activity in induced B-13/H cells following α-NF treatment. EROD 
activity was determined in B-13/H lysates prepared as in B. with or without 5μM α-NF. Results are the 
mean and SD of 3 independent determinations from a single experiment, typical of at least 3 separate 
experiments.*statistically greater than vehicle treated cells at p<0.05. 
 
Finally, to determine the ability of CYP1A1 expressed in B-13 and B-13/H cells to bio-
activate pro-genotoxins to DNA damaging metabolites, vehicle and β-NF induced cells 
were treated with different concentrations of benzo[a]pyrene. Benzo[a]pyrene is 
primarily metabolised by CYP1A1 to produce DNA damaging metabolites [200]. As 
shown in figure 3.11, vehicle induced B-13 and B-13/H cells only showed significant 
DNA damage when treated with 100μM benzo[a]pyrene. However, B-13/H cells 
induced with β-NF were significantly more sensitive to benzo[a]pyrene induced DNA 
damage, as in these cells, DNA damage was detectable from 25μM. Furthermore, at 
100μM benzo[a]pyrene, the olive tail moment was approximately 13 whereas in vehicle 
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induced B-13/H cells it was only around 6. Benzo[a]pyrene induced DNA damage in B-
13 cells was unaffected by β-NF induction.  
 
 
Figure 3.11: Benzo[a]pyrene dose response in vehicle or β-NF induced B-13 and B-13/H cells 
measured by comet assay. B-13 and B-13/H cells were treated daily with vehicle (0.1% (v/v) DMSO) or 
20μM β-NF and on the 4th day treated additionally with vehicle (1% (v/v) DMSO) or different 
concentrations of benzo[a]pyrene for 16 hours. Following treatment, cells were subject to the alkaline 
comet assay and DNA stained with SYBR gold. Slides were viewed using a fluorescence microscope and 
DNA damage calculated using cometscore software. Data are the mean and SE of 50 cells from a single 
experiment, typical of at least 3 separate experiments. *significantly different, as calculated by ANOVA 
followed by the Bonferroni-Holm post-hoc test, to non-benzo[a]pyrene treated control at p<0.05. 
 
Initiation of apoptosis involves the activation of endonucleases which restrict cellular 
DNA. This could lead to a false positive in a comet assay where apoptotic cells 
typically have significant comets [201]. DNA replication involves single DNA strand 
breakage at replication forks, which although required for cell division, may also lead to 
increased tail length/DNA content and false positive findings [202]. To confirm that 
DNA damage resulting from treatments was not due to initiation of apoptosis or DNA 
replication, DNA diffusion and BrdU incorporation in treated cells was determined. 
Figure 3.12 shows that at the concentration range employed, comets were not associated 
with cytotoxicity or with a significant increase in DNA synthesis.  
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Figure 3.12: DNA damaging compounds did not induce significant cell death or division in treated 
cells. A. DNA diffusion assay of cells treated with inducers and pro-genotoxic compounds. B-13 and 
B-13/H cells were treated daily for 3 days with vehicle (0.1% (v/v) DMSO) or CYP450 inducer. On The 
4
th
 day, cells were treated additionally with positive controls (50μM etoposide or 400μM methapyrilene 
(MP)) or different pro-genotoxic compounds: (B[a]P (benzo[a]pyrene), 100μM; AFB1 (aflatoxin B1), 
400nM; CYCP (cyclophosphamide), 200μM). Following treatment cells were embedded in low melting 
point agarose, lysed and stained with SYBR gold. Slides were viewed using a fluorescence microscope 
and the percentage of cells with normal DNA diffusion (using the positive controls as a guide) calculated. 
Results are the mean and SD from 4 fields of view, with at least 100 individual cells counted in total, 
from a single experiment, typical of at least 3 separate experiments. B. Percentage of comet cells 
staining positive for BrdU following inducer and pro-genotoxin treatment. Cells treated as in A were 
incubated with 15μM BrdU for 2 hours then were subject to the alkaline comet assay and immunostained 
for BrdU. Following counterstaining with DAPI, slides were viewed using a fluorescence microscope and 
the percentage of comets staining positive for BrdU calculated. Data are the mean and SD calculated from 
4 fields of view, with at least 100 individual cells counted in total. Results are from a single experiment, 
typical of at least 3 separate experiments. For A and B, no statistical analysis was performed. 
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3.6 CAR activators induce CYP2B1 mRNA in B-13/H cells 
 
The CYP2B sub-family of CYP450s were some of the first CYP450s to be purified to 
homogeneity and shown to be markedly induced by PB pre-treatment. Although it has 
been established that CAR mediates this induction, PB does not bind directly to the 
CAR. The mechanism has recently been determined, as outlined in the introduction, to 
be associated with an interference in epidermal growth factor receptor signalling [50]. 
 
To determine the expression of CYP2B1 and associated transcripts in B-13/H cells, RT-
PCR was carried out. This showed (figure 3.13A) that B-13/H cells expressed CYP2B1 
mRNA but not CYP2B2 or CYP2B3. Importantly they also expressed the CAR similar 
to intact rat liver, suggesting that they would be able to induce CYP2B1. 
 
B-13 and B-13/H cells were therefore treated with a range of prototypical inducers and 
their CYP2B1 mRNA expression measured using qPCR. In B-13 cells, in agreement 
with the RT-PCR screening, CYP2B1 mRNA expression could not be detected. 
Conversely, in B-13/H cells, basal CYP2B1 expression could be detected and treatment 
with CAR agonists PB and TCPOBOP led to a significant increase in CYP2B1 mRNA 
expression to levels greater than in intact rat liver (figure 3.13B). Furthermore, 
treatment of B-13/H cells with the PXR agonist DEX also led to a significant increase in 
CYP2B1 mRNA expression; this would be expected as the PXR and CAR demonstrate 
some functional redundancy in that they have an overlapping affinity for consensus 
sequences in the promoter regions of numerous genes including CYP2B1 and CYP3A1 
[42]. In primary rat hepatocytes treated with the same range of inducers (figure 3.13C), 
all treatments significantly increased expression of CYP2B1 mRNA; bezafibrate 
induced the largest increase in expression but this was followed by DEX and PB.  
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Figure 3.13: B-13/H cells express inducible CYP2B1. A. RT-PCR for CYP2B associated transcripts. 
Total RNA was extracted from samples using TRIzol and cDNA produced which was used as the 
template for PCR. Following PCR, samples were separated by agarose gel electrophoresis and visualised 
by UV transillumination. B. qPCR for CYP2B1 in B-13/H cells treated with prototypical CYP450 
inducers. B-13/H cells were treated for 3 days daily with vehicle (0.1% (v/v) DMSO) or inducer and 
harvested on the 4
th
 day. Total RNA was extracted from the cells using TRIzol and reverse transcribed. 
cDNA was used as template for qPCR measuring the expression of CYP2B1. Readings were normalised 
to 18S rRNA expression and fold change expressed relative to vehicle treated cells. Bars are the mean and 
SD of 3 independent determinations from a single experiment, typical of at least 3 separate experiments. 
*significantly different to vehicle control at p<0.05. C. qPCR for CYP2B1 in primary rat hepatocytes 
treated with prototypical CYP450 inducers. From primary rat hepatocytes treated as in B, RNA was 
extracted and reverse transcribed. The cDNA was used as a template for qPCR measuring the expression 
of CYP2B1 and results were normalised to 18S rRNA expression. Results are expressed as fold change 
relative to vehicle treated cells. Bars are the mean and SD of 3 independent determinations from a single 
experiment, typical of at least 3 separate experiments. *significantly different to vehicle control at p<0.05. 
 
To assess if induction of CYP2B1 at the level of mRNA translated to an increase in 
CYP2B1 protein, Western blotting for CYP2B1 was performed on lysates from vehicle, 
TCPOBOP and PB treated B-13 and B-13/H cells, primary rat hepatocytes and rat liver. 
As illustrated in figure 3.14A, CYP2B1 protein could only be detected in vehicle and 
PB induced rat liver but not in any other samples. To test for CYP2B1 activity, a PROD 
assay was carried out on lysates from B-13 cells, B-13/H cells and primary rat 
hepatocytes treated with different prototypical inducers. Of all the cells tested, PROD 
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activity could only be detected in the lysates of B-13/H cells. Lysates from B-13/H cells 
treated with PB and DEX showed a small but significant increase in PROD activity 
compared to those from vehicle treated cells (figure 3.14B). These findings suggest that, 
although B-13/H cells express CYP2B1 mRNA, it is not efficiently translated to 
protein. This would account for the low basal and induced PROD activity. The 
induction in PROD activity may also have been a result of PB or DEX mediated 
induction of CYP3A1 through the CAR/PXR, which may have non-specifically 
metabolised the 7-pentoxyresorufin, thereby leading to an apparent induction of PROD 
activity. 
 
 
Figure 3.14: B-13/H cells express no detectable CYP2B1 protein. A. Western blot for CYP2B1 in 
induced B-13 and B-13/H cells and primary rat hepatocytes. Cells were treated daily for 3 days with 
vehicle (0.1% (v/v) DMSO), 1.5μM TCPOBOP or 1mM PB. On the 4th day, lysates were prepared from 
treated cells and rat liver and quantified by Lowry assay. 20μg of protein/well was separated by SDS-
PAGE and transferred to a nitrocellulose membrane which was blocked and probed. Antibody binding 
was detected using ECL Western blot substrate. Blot is representative of at least 3 separate experiments. 
B. PROD activity in induced B-13/H cells. PROD activity was measured in lysates prepared from B-
13/H cells treated as in A. Readings were normalised to lysate protein concentration. Readings are the 
mean and SD of 6 independent determinations from 2 separate experiments. *significantly different to 
vehicle treated control at p<0.05. 
  
Finally, B-13 and B-13/H cells were treated with cyclophosphamide, a CYP2B 
bioactivated pro-genotoxin, to determine if they were able to bioactivate it to produce 
DNA damaging metabolites. The results of this showed that B-13/H but not B-13 cells 
were susceptible to cyclophosphamide induced DNA damage at the highest tested dose 
(figure 3.15, 200μM). However, pre-treatment of either B-13 or B-13/H cells with PB, 
did not significantly change DNA damage resulting from cyclophosphamide treatment. 
The lack of change in response to PB is in agreement with the Western blot and PROD 
assay where PB treatment led to little to no change in CYP2B1 expression/function. 
Based on the low expression of CYP2B1 protein in B-13/H cells, it is likely that the 
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bioactivation of cyclophosphamide may be a result of non-specific metabolism by other 
CYP450s expressed more highly in B-13/H cells, rather than CYP2B1. At the 
concentration range employed, comets were not associated with cytotoxicity or with a 
significant increase in DNA synthesis (figure 3.12). 
 
 
Figure 3.15: Cyclophosphamide dose response in vehicle or PB induced B-13 and B-13/H cells 
measured by comet assay. B-13 and B-13/H cells were treated daily with vehicle (0.1% (v/v) DMSO) or 
1mM PB and on the 4
th
 day treated additionally with vehicle (0.1% (v/v) DMSO) or different 
concentrations of cyclophosphamide for 16 hours. Following treatment, cells were subject to the alkaline 
comet assay and DNA stained with SYBR gold. Slides were viewed using a fluorescence microscope and 
DNA damage calculated using cometscore software. Data are the mean and SE of 50 cells from a single 
experiment, typical of at least 3 separate experiments. *significantly different to non-cyclophosphamide 
treated control at p<0.05, calculated by ANOVA followed by the Bonferroni-Holm post-hoc test. 
 
3.7 PXR activators induce a quantitatively liver equivalent induction of CYP3A1 
in B-13/H cells 
 
The CYP3A sub-family is constitutively expressed and forms a major expressed sub-
family in adult rat liver. The orthologous sub-family in man includes the major 
expressed gene CYP3A4, which is responsible for the metabolism of approximately 
50% of drugs. Both CYP3A4 in man, and CYP3A1 (also referred to as CYP3A23) in 
the rat, are induced by activators of the PXR [203].  
 
To initially determine the expression of PXR and CYP3A associated transcripts, RT-
PCR was carried out on cDNA from B-13 and B-13/H cells, and intact male rat liver. 
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As shown in figure 3.16A, B-13/H cells, like rat liver, expressed the PXR as well as the 
transcription factors RXRα and RXRβ. These form heterodimers with activated PXR 
and are required for PXR regulated transactivation [42]. B-13/H cells also expressed 
CYP3A1, CYP3A2 and CYP3A19 mRNA which were not expressed by B-13 cells.  
 
As B-13/H cells expressed PXR, it was hypothesised that CYP3A1 could be induced in 
the cells using PXR agonists. To test this hypothesis, B-13 and B-13/H cells were 
treated with a range of prototypical inducers and CYP3A1 mRNA expression measured 
by qPCR. This demonstrated that B-13/H cells significantly induced CYP3A1 mRNA in 
response to the PXR ligands, DEX and PCN and this was to levels greater than that seen 
in male rat liver (figure 3.16B). The previously mentioned crosstalk between PXR and 
CAR means that CAR can initiate transcription of a range of PXR regulated genes 
including CYP3A1. Accordingly, B-13/H cells treated with the CAR activators PB and 
TCPOBOP also significantly increased expression of CYP3A1 mRNA. In B-13 cells, 
no CYP3A1 mRNA could be detected in either normal or inducer treated cells 
confirming the RT-PCR results. Primary rat hepatocytes treated in an equivalent manner 
showed a similar induction profile with DEX and PCN inducing CYP3A1 mRNA the 
most strongly, followed by PB (figure 3.16C).  
 
Western blotting for CYP3A1 in B-13 and B-13/H cells and primary rat hepatocytes 
treated with DEX and PCN (figure 3.17) showed that DEX and PCN both increased the 
amount of CYP3A1 protein in B-13/H cells and primary rat hepatocytes in a 
quantitatively similar manner. This demonstrates that the induction of CYP3A1 mRNA 
effectively translated to more CYP3A1 protein. 
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Figure 3.16: B-13/H cells express inducible CYP3A1. A. RT-PCR for CYP3A associated transcripts. 
Total RNA was extracted from samples using TRIzol and cDNA produced which was used as the 
template for PCR. Following PCR, samples were separated by agarose gel electrophoresis and visualised 
by UV transillumination. B. qPCR for CYP3A1 in B-13/H cells treated with prototypical CYP450 
inducers. B-13/H cells were treated for 3 days daily with vehicle (0.1% (v/v) DMSO) or inducer and 
harvested on the 4
th
 day. Total RNA was extracted from the cells using TRIzol and reverse transcribed. 
cDNA was used as template for qPCR measuring the expression of CYP3A1. Readings were normalised 
to 18S rRNA expression and fold change expressed relative to vehicle treated cells. Bars are the mean and 
SD of 3 independent determinations from a single experiment, typical of at least 3 separate experiments. 
*significantly different to vehicle control at p<0.05. C. qPCR for CYP3A1 in primary rat hepatocytes 
treated with prototypical CYP450 inducers. From primary rat hepatocytes treated as in B, RNA was 
extracted and reverse transcribed. The cDNA was used as a template for qPCR measuring the expression 
of CYP3A1 and results were normalised to 18S rRNA expression. Results are expressed as fold change 
relative to vehicle treated cells. Bars are the mean and SD of 3 independent determinations from a single 
experiment, typical of at least 3 separate experiments. *significantly different to vehicle control at p<0.05. 
 
 
Figure 3.17: Western blot for CYP3A1 in induced B-13 and B-13/H cells and primary rat 
hepatocytes. Cells were treated daily for 3 days with vehicle (0.1% (v/v) DMSO), 10μM DEX or 2μM 
PCN. On the 4
th
 day, lysates were prepared from treated cells and rat liver and quantified by Lowry assay. 
20μg of protein/well was separated by SDS-PAGE and transferred to a nitrocellulose membrane which 
was blocked and probed. Antibody binding was detected using ECL Western blot substrate. Blot is 
representative of at least 3 separate experiments. 
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Based on the induction of CYP3A1 protein, it was required to determine if induced 
CYP3A1 protein was functional. CYP3A1 and CYP3A4 catalyse the 6β-hydroxylation 
of testosterone and this forms the basis of the most common CYP3A1 activity assay. 
However, this assay requires high-performance liquid chromatography and is time 
consuming. As a high throughput alternative, the novel probe substrate luciferin-IPA 
was identified. This is advertised to be primarily metabolised by CYP3A1 in rats to 
luciferin, which can be detected photometrically through the addition of luciferase as 
outlined in the methods. To validate the assay, activity was determined in serially 
diluted rat liver microsomes. Fitting a line of best fit showed a correlation of 0.999 
indicating that there was a linear relationship between microsome concentration and 
relative light unit production (figure 3.18A). Treating rat liver microsomes with a range 
of inhibitors (figure 3.18B) showed that the specific CYP3A inhibitors troleandomycin 
and ketoconazole significantly reduced luciferin-IPA activity as did the general CYP450 
inhibitors metyrapone and SKF525A [204-207]. Testosterone did not reduce microsome 
luciferin-IPA metabolism and the flavin-containing monoxygenase inhibitor 
methimazole surprisingly significantly increased it [208]. These findings suggest that 
the metabolism of luciferin-IPA is primarily catalysed by CYP3A1 in a linear manner 
although flavin-containing monoxygenases may also play a role. 
 
With the assay validated, B-13 and B-13/H cells, and primary rat hepatocytes were 
treated with a range of prototypical inducers, lysates prepared and CYP3A1 activity 
determined. The results (figure 3.18C) showed that, in accordance with the mRNA and 
protein data, DEX and PCN induced a major and significant increase in CYP3A1 
activity followed by PB in both B-13/H cells and primary rat hepatocytes. This 
demonstrates that induced CYP3A1 in B-13/H cells is functional. 
  Chapter 3. Results 
 
104 
 
 
Figure 3.18: Induced CYP3A1 in B-13/H cells is functional. A. Measurement of luciferin-IPA 
metabolism in serially diluted microsomes. Rat liver microsomes were diluted 4 logs from 100μg/ml to 
0.01μg/ml and luciferin-IPA metabolism measured. Points are the mean of 3 different rat liver microsome 
preparations. B. Percentage change in luciferin-IPA metabolism in response to different CYP450 
modulators. Luciferin-IPA metabolism was measured in rat liver microsomes treated with vehicle (0.1% 
(v/v) DMSO) or the indicated compounds. Bars are the mean and SD or 3 different rat liver microsome 
preparations. *significantly different to vehicle treated microsomes at p<0.05. C. Luciferin-IPA 
metabolism in induced B-13 and B-13/H cells, and primary rat hepatocytes. Luciferin-IPA 
metabolism was measured in lysates prepared from B-13 cells, B-13/H cells and primary rat hepatocytes 
treated with vehicle (0.1% (v/v) DMSO) or the indicated CYP450 inducers daily for 3 days and harvested 
on the 4
th
 day. Readings were normalised to lysate protein concentration. Results are shown as the fold 
change relative to vehicle treated B-13/H cells. Results are the mean and SD of 3 independent 
determinations from a single experiment, typical of at least 3 separate experiments. *significantly 
different to relevant vehicle treated control at p<0.05. 
 
To establish if B-13/H cells could be used to test for CYP3A1 dependent pro-genotoxin 
bioactivation, normal and induced B-13 and B-13/H cells were treated with the pro-
carcinogen aflatoxin B1 (AFB1), which is metabolised to a genotoxic product by 
CYP3A enzymes [209, 210]. As illustrated in figure 3.19, it was seen that uninduced B-
13 cells were insensitive to AFB1 induced DNA damage whereas B-13/H cells showed 
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significant DNA damage at the highest tested dose (400nM). In both cell types, DEX 
induction significantly increased their sensitivity to AFB1 induced DNA damage in a 
dose dependent manner with B-13 cells showing significant damage at 200nM. This is 
likely due to a glucocorticoid receptor-dependent promotion of B-13/H phenotype and 
subsequent induction of CYP3A1 expression within the short period of induction. DEX 
induced B-13/H cells showed significant DNA damage from 100nM AFB1 treatment. 
Unexpectedly, induction with PCN in either cell type prior to AFB1 treatment had no 
effect on resulting DNA damage, in contrast to DEX induction. The lack of response 
with PCN in this experiment was likely because PCN induces a lesser fold increase in 
protein expression and activity compared to the potent effect of DEX (figure 3.17 and 
figure 3.18). At the concentration range employed, comets were not associated with 
cytotoxicity or with a significant increase in DNA synthesis (figure 3.12). 
 
 
Figure 3.19: Aflatoxin B1 dose response in vehicle, DEX or PCN induced B-13 and B-13/H cells 
measured by comet assay. B-13 and B-13/H cells were treated daily with vehicle (0.1% (v/v) DMSO), 
10μM DEX or 2μM PCN and on the 4th day treated additionally with vehicle (0.1% (v/v) DMSO) or 
different concentrations of AFB1 for 16 hours. Following treatment, cells were subject to the alkaline 
comet assay and DNA stained with SYBR gold. Slides were viewed using a fluorescence microscope and 
DNA damage calculated using cometscore software. Data are the mean and SE of 50 cells from a single 
experiment, typical of at least 3 separate experiments. *significant difference to non-AFB1 treated control 
at p<0.05 tested by ANOVA followed by Bonferroni-Holm post-hoc test. 
 
Cellular DNA damage, from endogenous or exogenous sources, causes the initiation of 
signalling cascades that result in DNA repair. A well documented signalling pathway is 
the phosphorylation of histone H2AX on serine 139 to ɤ-H2AX, at the site of double 
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stranded DNA (dsDNA) breaks, which in turn recruits DNA repair machinery [211, 
212]. The quantity of ɤ-H2AX within a cell can therefore be used as a measure of 
dsDNA breakage. The alkaline comet assay conversely measures both single and 
dsDNA breakage. 
 
To investigate the effect of AFB1 on dsDNA breakage, normal and DEX induced B-13 
and B-13/H cells were treated with 400nM AFB1 for different lengths of time following 
which ɤ-H2AX expression was measured by Western blot. This demonstrated that by 16 
hours, ɤ-H2AX was detectable in untreated B-13/H cells (figure 3.20A). DEX induction 
prior to AFB1 treatment clearly increased the rate of accumulation of ɤ-H2AX with 
saturation of ɤ-H2AX accumulation by 8 hours. This suggests that DEX induction 
increased the sensitivity of B-13/H cells to AFB1 induced dsDNA breakage. In B-13 
cells, ɤ-H2AX protein was detected, however its accumulation had no consistent 
relation to treatments. This variation may be because ɤ-H2AX accumulation has been 
shown to be dynamic and variable in proliferating cells such as B-13s [213]. 
Conversely, B-13/H cells do not proliferate (figure 3.1) and this may explain why they 
do not show the same variation.  
 
To confirm that increased DNA damage in DEX induced cells from AFB1 was due to 
enhanced CYP3A expression, vehicle and DEX induced B-13/H cells were treated with 
AFB1 in the presence or absence of ketoconzaole, a CYP3A specific inhibitor. As 
shown in figure 3.20B, both normal and DEX induced B-13/H cells treated with AFB1 
showed ɤ-H2AX accumulation which was attenuated by ketoconazole treatment. DEX 
induced AFB1 treated cells showed greater ɤ-H2AX accumulation than un-induced B-
13/H cells and the increased expression of CYP3A1 in DEX treated cells confirms that 
CYP3A1 was induced by DEX. Immunostaining of ɤ-H2AX in similarly treated B-13/H 
cells showed equivalent results with nuclear accumulation of ɤ-H2AX following AFB1 
treatment, which was enhanced by DEX induction (figure 3.21). Treatment with 
ketoconazole similarly attenuated AFB1 induced ɤ-H2AX nuclear accumulation. This 
result suggests that increased sensitivity of B-13/H cells treated with DEX to AFB1 
induced DNA damage is primarily due to increased expression of CYP3A1 rather than 
other CYP450s. 
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Figure 3.20: DEX induced B-13/H cells are significantly more sensitive to inhibitable AFB1 induced 
DNA damage. A. Western blot for ɤ-H2AX in B-13 and B-13/H cells treated with AFB1 for 
differing periods of time. B-13 and B-13/H cells were dosed daily for 3 days with vehicle (0.1% (v/v) 
DMSO) or 10μM DEX then on the 4th day with 400nM AFB1 for different periods of time. B. Western 
blot for ɤ-H2AX in treated B-13/H cells. B-13/H cells were treated with vehicle (0.1% (v/v) DMSO) or 
DEX daily for 3 days. On the 4
th
 day, cells were additionally incubated with vehicle or 10μM 
ketoconazole for 6 hours following which they were incubated additionally with vehicle or 400nM AFB1 
for 16 hours. For A and B, following treatment, lysates were prepared and quantified by Lowry assay. 
20μg of protein/well was separated by SDS-PAGE and transferred to a nitrocellulose membrane which 
was blocked and probed. Antibody binding was detected using ECL Western blot substrate. For B, blot is 
representative of at least 3 separate experiments. 
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Figure 3.21: DEX pretreatment of B-13/H cells causes nuclear accumulation of ɤ-H2AX in response to AFB1. B-13/H cells were treated with vehicle (0.1% (v/v) DMSO) or 
DEX daily for 3 days. On the 4
th
 day, cells were additionally incubated with vehicle or 10μM ketoconazole for 6 hours following which they were incubated additionally with vehicle 
or 400nM AFB1 for 16 hours. The cells were then fixed, blocked, immunostained for ɤ-H2AX and counterstained with DAPI. Cells were analysed using a Zeiss fluorescence 
microscope. Scale bar indicates 20μm. Images are representative of at least 3 separate experiments. 
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3.8 B-13/H cells express the PPARα and agonists induce peroxisome proliferation 
 
The CYP4A sub-family primarily catalyses the metabolism of endogenous substrates: 
mainly fatty acid and prostaglandin ω-hydroxylation. The expression of CYP4A is 
tightly regulated by the PPARα which is activated by a range of fatty acids and fibrates 
[63, 64]. Analysis of the B-13 genome indicated that Cyp4a2 contained a deletion 
within an exon and Cyp4a1, a deletion within an intron (figure 3.22) 
 
 
Figure 3.22: The coding region of rCyp4a2 is mutated in B-13 cells. Schematic diagram of B-13 
Cyp4a1, Cyp4a2 and Cyp4b1 genomic region indicating exon deletion of Cyp4a2. The sequence of the B-
13 cell line (including insertions and deletions) was aligned to Rattus novergicus reference sequence 4 
using Integrative Genomics Viewer software.  
 
Analysis of PPARα and CYP4A expression in B-13 and B-13/H cells by RT-PCR 
showed that, although they both expressed PPARα mRNA similar to male rat liver, no 
CYP4A mRNA could be detected in B-13 or B-13/H cells (figure 3.23A). To determine 
if B-13 and B-13/H cells could induce CYP4A1 in response to PPARα activation, they 
were treated with bezafibrate, a PPARα agonist. Compared to male rat liver, B-13/H 
cells expressed very low levels of CYP4A1 mRNA which was increased by treatment 
with bezafibrate, but only by around 4 fold (figure 3.23B). In B-13 cells, no CYP4A1 
mRNA could be routinely detected.  
 
The level of CYP4A1 mRNA expression in primary rat hepatocytes was around 1/10
th
 
of that seen in male rat liver and was significantly induced more than 200 fold in 
response to bezafibrate treatment (figure 3.23C). Probing for CYP4A1 protein in 
vehicle or bezafibrate induced B-13 and B-13/H cells, and primary rat hepatocytes 
showed that CYP4A1 protein was only detectable in primary rat hepatocytes and rat 
liver, not in B-13 or B-13/H cells (figure 3.23D). Treatment of primary rat hepatocytes 
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with bezafibrate caused a clear increase in CYP4A1 protein expression which suggests 
that the up-regulation of CYP4A1 mRNA in response to bezafibrate directly translated 
to an increase in CYP4A1 protein.  
 
 
Figure 3.23: B-13/H cells express PPARα but only weakly induce CYP4A1. A. RT-PCR for CYP4A 
associated transcripts. Total RNA was extracted from samples using TRIzol and cDNA produced which 
was used as the template for PCR. Following PCR, samples were separated by agarose gel electrophoresis 
and visualised by UV transillumination. B. qPCR for CYP4A1 in B-13/H cells treated with 
bezafibrate. B-13/H cells were treated for 3 days daily or over 14 days with vehicle (0.1% (v/v) DMSO) 
or 250μM bezafibrate. Total RNA was then extracted from the cells using TRIzol and reverse transcribed. 
The cDNA was used as template for qPCR measuring the expression of CYP4A1. Readings were 
normalised to 18S rRNA expression and fold change expressed relative to male rat liver. Bars are the 
mean and SD of 3 independent determinations from a single experiment, typical of at least 3 separate 
experiments. No statistical analysis was performed. C. qPCR for CYP4A1 in primary rat hepatocytes 
treated with bezafibrate. From primary rat hepatocytes treated as in B, RNA was extracted and reverse 
transcribed. The cDNA was used as a template for qPCR measuring the expression of CYP4A1 and 
results were normalised to 18S rRNA expression. Results are expressed as fold change relative to male rat 
liver. Bars are the mean and SD of 3 independent determinations from a single experiment, typical of at 
least 3 separate experiments. *significant difference to vehicle control at p<0.05. D. Western blot for 
CYP4A1. Cells were treated daily for 3 days with vehicle (0.1% (v/v) DMSO) or 250μM bezafibrate. On 
the 4
th
 day, lysates were prepared and quantified by Lowry assay. 20μg of protein/well was separated by 
SDS-PAGE and transferred to a nitrocellulose membrane which was blocked and probed. Antibody 
binding was detected using ECL Western blot substrate. Blot is representative of at least 3 separate 
experiments. 
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As outlined in the introduction, PPARα activation in the rat results in proliferation of 
peroxisomes in the liver [65]. This is a physiologically important response required for 
control of whole body energy homeostasis through the direct regulation of fatty acid β-
oxidation. To first identify if B-13/H cells contained peroxisomes (as has been 
previously shown [125]), they were imaged by transmission electron microscopy. As 
shown in figure 3.24A, cellular organelles with the appearance of peroxisome (arrowed) 
were identified in B-13/H cells. None could be found in B-13 cells. This suggests that 
the transdifferentiation of B-13 to B-13/H cells involves the initiation of peroxisome 
production.  
 
Based on the presence of peroxisomes in B-13/H cells, it was hypothesised that PPARα 
activation would induce peroxisomal proliferation. Previously, ciprofibrate has been 
shown to increase catalase activity in select B-13/H cells, but the change has not been 
quantified [125]. To test the hypothesis, B-13/H cells were treated for 3 or 14 days with 
vehicle or bezafibrate and the expression of PMP70, which is a major component of 
peroxisomes [214], measured. Results showed that treatment of B-13/H cells for 3 or 14 
days increased PMP70 expression, although the increase was marginal compared to 
primary rat hepatocytes similarly treated (figure 3.24B). To visualise the distribution of 
peroxisomes following induction, B-13/H cells were treated with bezafibrate for 14 
days and PMP70 then detected by immunostaining. Cells were treated for 14 days 
because PMP70 induction was more consistent than after only 3 days of treatment. 
Imaging showed that staining was punctate and cytoplasmic which suggests that PMP70 
was labelling peroxisomes in the cells (figure 3.24C). Treatment of B-13/H cells with 
bezafibrate for 14 days caused an apparent increase in PMP70 staining compared to 
vehicle treated cells. The mean number of peroxisomes per cell was quantified and this 
showed that bezafibrate significantly increased the number seen per cell compared to 
vehicle treated cells. 
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Figure 3.24: B-13/H cells are sensitive to peroxisome proliferators. A. Peroxisomes in B-13/H cells. 
Transmission electron photomicrograph at 34000x magnification of a B-13/H cell. Arrows indicate 
peroxisomes. B. Western blot for PMP70 in fibrate treated cells. Cells were treated daily for 3 days or 
over 2 weeks (as indicated) with vehicle (0.1% (v/v) DMSO), 250μM bezafibrate (bezafib) or 500μM 
clofibrate (clofib). Following treatment, lysates were prepared from treated cells and rat liver and 
quantified by Lowry assay. 20μg of protein/well was separated by SDS-PAGE and transferred to a 
nitrocellulose membrane which was blocked and probed. Antibody binding was detected using ECL 
Western blot substrate. Results are representative of at least 3 separate experiments. C. PMP70 
immunostaining in B-13/H cells. B-13/H cells were treated with vehicle (0.1% (v/v) DMSO) or 250μM 
bezafibrate for 14 days. Following treatment cells were fixed, blocked and immunostained for PMP70. 
The cells were then counterstained with DAPI. Cells were photographed using a Zeiss fluorescence 
microscope and staining quantified using ImageJ particle counter. Results were normalised to cell 
number. Results are the mean and SD of 5 fields of view from the same experiment, typical of at least 3 
separate experiments. Scale bar indicates 48μm. *significantly different to vehicle control at p<0.05. 
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3.9 Chapter discussion 
 
CYP450s are involved in the metabolism of the majority of drugs and it is therefore 
important that they are expressed in cell models being used for toxicity screening. Other 
hepatocyte-like cells commonly used for toxicity screening generally show limited 
expression of CYP450s, particularly HepG2 cells, restricting the extrapolation of results 
to an in-vivo setting. Based on their previously documented expression of several 
DMEs, it was hypothesised that B-13/H cells expressed a similar range of functional 
CYP450s to rat hepatocytes and had equivalent inductive capacity.  
 
As expected, treatment of B-13 cells with 10nM DEX caused the induction of hepatic 
markers, arrested proliferation and formation of haem-bound CYP450 and cytochrome 
b5. 
 
In numerous mammalian species including humans, sex effects numerous aspects of 
drug kinetics due to the differing levels of expression of different drug metabolising 
enzymes. Women for example show greater expression of CYP3A4 to men resulting in 
increased rates of metabolism of numerous drugs including erythromycin [215, 216]. It 
is therefore a clinically relevant phenomenon. Regulation of sexual dimorphic CYP450 
expression is complex and thought to involve epigenetic changes distinct in males and 
females [186] including the epigenetic patterning of the hypothalamus by gondal 
hormones during development [217]. Circulating GH activates the Ghr causing 
activation of Stat5b in hepatocytes. This promotes male specific gene expression whilst 
repressing the expression of female specific genes [218]. The Shapiro group have 
shown restoration of CYP2C11 expression in male rat hepatocytes, derived from 
hypophysectomized rats, treated with continuous or twice daily pulses of GH [195]. 
CYP2C13 and CYP3A2 were refractive to induction however and GH had no effect on 
male CYP450 expression in hepatocytes from female rats.  
 
Measurement of sex-dependent CYP450 mRNA expression in B-13/H cells showed that 
their pattern of expression was qualitatively similar to male liver, particularly in terms 
of the main sex-dependent CYP450s, CYP2C11 and CYP2C12. However, even though 
they expressed JAK/STAT signalling components, B-13/H cells appeared insensitive to 
GH induction of CYP2C11 at all stages of transdifferentiation. The male pattern of sex-
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dependent CYP450 expression in B-13/H cells but insensitivity to GH is surprising. It 
suggests that the cells retain sex-specific epigenetic patterning but due to defects in 
signalling pathways are unable to respond to GH. Potentially, recapitulation of an in-
vivo pattern of GH exposure (i.e. cyclical) could lead to the induction of CYP2C11 and 
up-regulation of male CYP450s. However, given the complete absence of response of 
the cells to a range of GH doses, it seems likely that the signalling pathway responsible 
for GH mediated regulation of sex-dependent CYP450 expression is non- or 
dysfunctional. 
 
Assessment of the function of the environmental toxin xenosensor AhR showed that it 
was expressed and, when activated by β-NF, was able to induce CYP1A1 in B-13 and 
B-13/H cells. Induced CYP1A1 was functional as shown using the probe-substrate 7-
ethoxyresorufin, with activity quantitatively similar to hepatocytes. Furthermore, B-
13/H cells showed dose responsive DNA damage in response to benzo[a]pyrene and β-
NF induced cells showed significantly more DNA damage compared to uninduced 
controls.  
 
In terms of CAR and CYP2B1, B-13/H but not B-13 cells expressed both CAR and 
CYP2B1 mRNA, similar to intact rat liver. CAR was also functional as CYP2B1 was 
inducible in response to CAR agonists. However, CYP2B1 protein was undetectable, 
basal PROD activity was low and not markedly increased by treatment with CAR 
agonists and DNA damage was only observed in B-13/H cells treated with a relatively 
high concentration of cyclophosphamide. This data suggests that although CYP2B1 
mRNA is effectively induced by CAR activation, it is not efficiently translated into 
protein. This may be due to limited haem availability, as the translation of CYP2B in 
rats is inhibited by low cell haem concentrations [219]. However, haem-bound CYP450 
was detectable in B-13/H cells suggesting that they are able to synthesise and 
incorporate haem. Currently therefore, based on the limited CYP2B1 metabolic activity 
in B-13/H cells, their utility for determination of toxicity of CYP2B bioactivated drugs 
is limited. However, the B-13 line could be used for study of transcriptional regulation 
of CYP2B1 and its translation to protein.  
 
B-13/H cells expressed the xenosensor PXR and a range of CYP3A transcripts. 
Treatment of B-13/H cells with PXR agonists led to significant induction of CYP3A1 
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mRNA which was efficiently translated into protein, as induction significantly increased 
probe substrate activity to levels greater than seen in equivalently treated primary rat 
hepatocytes. CYP3A1 induction also led to significantly increased sensitivity to AFB1 
induced DNA damage. Nuclear accumulation of γ-H2AX was seen in B-13/H cells 
treated with AFB1 and this was shown to be due to significant induction of CYP3A1 
(ketoconazole inhibitable). Similar staining was attempted with lysates from β-NF 
induced B-13/H cells treated with benzo[a]pyrene, however no γ-H2AX accumulation 
was seen. Previous work has shown contrasting results regarding benzo[a]pyrene 
induction of γ-H2AX in different cell types and it is postulated that the response is cell 
specific due to differential sensitivity and regulation of DNA damage and repair 
signalling pathways [220, 221].  
 
The lipid sensor and metabolic regulator PPARα was expressed by B-13 and B-13/H 
cells but no CYP4A transcripts were detectable. This is possibly attributable to the exon 
deletion of Cyp4a2 or intron deletion of Cyp4a1 which might inhibit effective binding 
of transcriptional activators including PPARα. Similarly, although CYP4A1 mRNA 
could be detected by qPCR and induced, the basal expression and induction were so low 
as to be irrelevant, particularly when compared to the >200 fold induction seen in 
bezafibrate induced primary rat hepatocytes. In contrast to the poor expression of 
CYP4A1, peroxisomes could be detected in B-13/H but not B-13 cells in agreement 
with a previous study by Tosh et al., (2002) [125]. Quantitative measurement of 
peroxisomes, using PMP70, showed that although induction by bezafibrate caused only 
a minor increase in PMP70 protein, immunostaining indicated that there was a 
significant increase in peroxisome number of around 2 fold. This suggests that B-13/H 
cells could be used to study peroxisomal proliferation.  
 
The data presented in this chapter demonstrates that B-13/H cells express a range of 
CYP450s similar to hepatocytes, which are inducible, confirming the initial hypothesis. 
In particular, expression and function of CYP1A1 and CYP3A1 was quantitatively 
equivalent to primary rat hepatocytes. This data indicates that B-13/H cells could be 
used for screening of CYP1A- and CYP3A-dependent hepatotoxins as well as the study 
of drug induced CYP450 induction. 
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Chapter 4. Generation of a humanised B-13 line and its suitability for 
genotoxicity screening of novel drugs and chemicals 
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4.1 Introduction 
 
The limited availability of primary human hepatocytes means that rodent hepatocytes 
are commonly used for drug and chemical toxicity screening. However, it is clear that 
there are significant differences in the metabolism of numerous drugs in humans 
compared to other species. These differences are due to variation in expression, 
substrate specificity and catalytic efficiency of DMEs including CYP450s between 
species [222]. A consequence of this is that some drugs are toxic to humans but not 
rodents and vice-versa. An example of this is OT-7100 (5-n-Butyl-7-(3,4,5-
trimethoxybenzoylamino)-pyrazolo[1,5-a]pyrimidine), which is metabolised by 
CYP1A2 in humans to produce a hydroxylated intermediate which is hepatotoxic [223]. 
Conversely, in rats it is metabolised via a different route which does not generate the 
toxic intermediate. 
 
In chapter 3, it was seen that B-13/H cells were capable of CYP450 induction and 
bioactivation of hepatotoxins. However, B-13 cells are rat cells and therefore they may 
not be a good model of human hepatocytes. The humanisation of cell lines, which have 
little to no drug metabolising capacity, with human DMEs, is actively used in order to 
study the metabolism of drugs and chemicals [224-226]. Based on this work, it was 
hypothesised that genes encoding human DMEs could be cloned into B-13 cells and the 
resulting proteins would be functional. This would increase the clinical relevance of the 
cells for toxicity screening of novel drugs and chemicals. To test the hypothesis, B-13 
cells were first stably transfected with hCYP1A2. Following this, the susceptibility of 
the humanised line to CYP1A2 bioactivated pro-carcinogens was assessed.  
 
4.2 The CYP1A2 gene is mutated in B-13 cells 
 
CYP1A2, similar to CYP1A1, is associated with the bioactivation of drugs, particularly 
pro-carcinogenic environmental toxins [33]. However, unlike CYP1A1, which shows 
significant extra-hepatic expression and which is not constitutively expressed in the 
liver, CYP1A2 is primarily expressed in the liver and is constitutively expressed [33]. It 
is therefore responsible for the majority of liver CYP1A activity in the absence of AhR 
activation.  
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Analysis of the B-13 cell genome showed that the rCyp1a2 gene was mutated in the 
form of a deletion between exon 1 (non coding) and exon 2 (coding), a region which 
includes the start codon (figure 4.1). The deletion of the start codon likely prevents 
transcription of the mRNA and therefore it was hypothesised that CYP1A2 would not 
be expressed by the cells, assuming all alleles were affected. 
 
 
 
Figure 4.1: The coding region of rCyp1a2 in B-13 cells is mutated. Schematic diagram of the Cyp1a2 
genomic region in the B-13 cell genome, indicating the deletion and the position of genomic primer 
hybridisation used in PCR amplification. The sequence of the B-13 cell line (including insertions and 
deletions) was aligned to Rattus novergicus reference sequence 4 using Integrative Genomics Viewer 
software.  
 
To determine if all alleles were affected, PCR was performed on DNA derived from B-
13 and B-13/H cells. Primers were designed with the forward sequence within the 
undeleted region of rCyp1a2 and the reverse sequence in the supposedly deleted intron 
region as shown in figure 4.1. If the deletion was present in all alleles, then only the 
forward primer would be able to bind as the reverse primer complementary sequence 
was deleted. If the appropriate size product was produced from B-13 DNA template by 
PCR therefore, it would suggest that B-13 cells did not contain the deletion in all alleles. 
Using wild type rat DNA as template, amplification should occur because they have no 
deletion and both the forward and reverse primers should be able to anneal to target 
DNA. Using these primers, amplification was only seen when rat liver DNA was used 
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as template but not B-13 or B-13/H cell DNA, apparently confirming the predicted 
deletion and suggesting all alleles are affected (figure 4.2A).  
 
Similar to CYP1A1, CYP1A2 can be induced at the transcriptional level by a range of 
environmental agents and dietary constituents under regulation of the AhR; β-NF, aside 
from inducing CYP1A1, can also significantly induce CYP1A2 [33]. As shown in 
figure 4.2B, treating B-13/H cells with β-NF did not cause an induction of CYP1A2 
mRNA, which was only detectable in rat liver. Quantitative measurement of CYP1A1 
and CYP1A2 mRNA expression (figure 4.2C), using primers which annealed around 
the deletion site (figure 4.2D), interestingly showed that alongside CYP1A1, CYP1A2 
expression could be detected in B-13 and B-13/H cells. However, compared to 
CYP1A1, which was expressed at greater levels in B-13/H cells than in rat liver, 
CYP1A2 was expressed at a significantly lower level.  
 
Evidence of CYP1A2 mRNA expression in B-13 and B-13/H cells may mean that, 
although the CYP1A2 gene is mutated on one chromosome, it is present on another. 
This is particularly likely considering that B-13 cells have an abnormal karyotype. They 
have double the normal rat chromosome complement (i.e. tetraploid (42 pairs) rather 
than diploid (21 pairs)) [184] and are likely therefore to have at least 4 copies of 
Cyp1a2. 
 
4.3 CYP1A1 but not CYP1A2 can be induced by β-NF 
 
To determine if CYP1A2 transcript detected in figure 4.2C was translated to protein and 
if it could be induced by the prototypical CYP1A inducer β-NF, B-13 and B-13/H cells 
and rat hepatocytes were treated with β-NF and CYP1A1 and CYP1A2 protein 
expression assessed by Western blot. As shown in figure 4.3, CYP1A1 could be 
induced by β-NF in all treated cells, but CYP1A2 could only be induced in primary rat 
hepatocytes induced with β-NF. This suggests that although CYP1A2 mRNA 
expression was detected, it may be a truncated version and/or not translated to protein. 
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Figure 4.2: Neither rCyp1a2 nor rCYP1A2 mRNA can be detected in B-13 cells. A. PCR for 
genomic CYP1A2. DNA samples were used as template for rCyp1a2 using gCyp1a2US and 
gCYP1A2DS as the forward and reverse primers respectively. Following PCR, samples were separated 
by agarose gel electrophoresis and visualised by UV transillumination. B. RT-PCR for rCYP1A2. B-
13/H cells were treated daily for 3 consecutive days with vehicle (0.1% (v/v) DMSO) or 20μM β-NF. On 
the 4
th
 day, total RNA was extracted using TRIzol and cDNA produced which was used as the template 
for PCR alongside cDNA produced from untreated rat liver. Following PCR, samples were separated by 
agarose gel electrophoresis and visualised by UV transillumination. C. qPCR for CYP1A1 and 
CYP1A2. Total RNA was extracted from B-13 cells, B-13/H cells and male rat liver using TRIzol and 
reverse transcribed. cDNA was used as template for qPCR measuring CYP1A1 and CYP1A2. Readings 
were normalised to 18S rRNA expression and fold change expressed relative to B-13/H cells. Bars are the 
mean and SD of 3 independent determinations from a single experiment, typical of at least 3 separate 
experiments. *statistically significant difference compared to B-13/H cells at p<0.05. D. Binding site of 
rCYP1A2 qPCR primers. Forward and reverse primers are in red italics and reported deleted region is 
in bold. 
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Figure 4.3: Western blot for CYP1A1 and CYP1A2. Rat hepatocytes, B-13 and B-13/H cells were 
treated daily for 3 consecutive days with vehicle (0.1% (v/v) DMSO) or 20μM β-NF. Lysates were 
prepared and quantified by Lowry assay. 20μg of protein/well was separated by SDS-PAGE and 
transferred to a nitrocellulose membrane which was blocked and probed. Antibody binding was detected 
using ECL Western blot substrate. Blot is representative of at least 3 separate experiments. 
 
EROD and MROD activities in B-13 and B-13/H cells (figure 4.4) induced with β-NF 
showed that only EROD, a marker of CYP1A1 activity, was significantly increased. 
MROD, which is a marker of CYP1A2 activity, was unaffected by induction. This 
supports the theory that CYP1A2 mRNA is not translated to protein. The MROD 
activity documented in the cells is likely from non-specific catalysis by CYP1A2 related 
proteins such as CYP1A1. 
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Figure 4.4: EROD but not MROD activity is inducible in B-13 and B-13/H cells. EROD and MROD 
activity in vehicle or β-NF induced B-13 and B-13/H cells. B-13 and B-13/H cells were treated daily for 3 
consecutive days with vehicle (0.1% (v/v) DMSO) or 20μM β-NF. Lysates were then prepared and 
EROD and MROD activity measured. Resorufin production was calculated using a standard curve and 
values were normalised to protein concentration calculated by Lowry assay. Bars are the mean and SD of 
3 independent determinations from the same experiment, typical of at least 3 separate experiments. 
*statistically significant difference compared to respective vehicle treated controls at p<0.05. 
 
 
4.4 Isolation and amplification of the hCYP1A2 coding sequence 
 
Due to the absence of functional CYP1A2 expression and the importance of CYP1A2 in 
the bioactivation of a range of clinically relevant compounds and dietary constituents, it 
was planned to knock hCYP1A2 into B-13 cells. The hypothesis was that the knocked 
in hCYP1A2 would produce functional protein with metabolic capacity in B-13/H, but 
not B-13 cells. Activity was not expected in B-13 cells because, as seen in chapter 3, 
unlike B-13/H cells they do not express CYP reductase or cytochrome b5 which are 
required for CYP450 activity. If the introduced hCYP1A2 was expressed and functional 
it could be used for analysis of drug and chemical toxicity. Additionally, it would stand 
as a proof of concept for the cloning of human genes into the B-13 cell line which has 
not been attempted before. 
 
hCYP1A2 would ultimately be cloned into the pT-REX-DEST30 vector, as illustrated 
in figure 4.5. When co-expressed with pcDNA6/TR, it in principle only allows 
expression of the cloned transgene in the presence of tetracycline. In the absence of 
  Chapter 4. Results 
  
123 
 
tetracycline, tetracycline repressor protein (TetR) binds to tetracycline operator sites in 
the transgene promoter; this inhibits binding of transcriptional machinery and therefore 
represses expression. 
 
 
 
Figure 4.5: Planned final vector for transformation. The human complete CYP1A2 coding sequence 
would be inserted by LR clonase from a gateway vector to this destination vector. Expression would be 
driven by the cyclomeglovirus promoter (CMV) in response to tetracycline. The neomycin resistance 
gene in the vector confers resistance to G418 in order to allow for selection in mammalian cells. 
 
CYP1A2 is highly polymorphic in humans with more than 15 identified polymorphisms. 
In order to isolate the prototypical allele of hCYP1A2 for cloning, hCYP1A2*1, RT-
PCR was carried out on RNA isolated from numerous human liver samples. Initially 
amplification of the entire coding region of hCYP1A2 (1548bp) was attempted in a 
single reaction, however most samples did not amplify. In order to isolate the coding 
sequence of hCYP1A2 from more donors to maximise the chance of identifying one 
donor expressing the prototypical allele, the two halves of the coding sequence were 
amplified separately (figure 4.6A). Interestingly, a huge range in the level of expression 
of hCYP1A2 mRNA was seen. The two fragments from different donors were gel 
extracted and fused by fusion PCR, as outlined in the methods section, to produce the 
single continuous hCYP1A2 coding sequence (figure 4.6B).  
 
This was then TOPO cloned into the gateway vector (pENTR/D-TOPO), transformed 
into bacteria and restriction analysis carried out to determine which bacterial colonies 
had been transformed with plasmid containing an insert (figure 4.7). Donor sample 4, 6 
and 11 had colonies with bands of approximately the correct size (2435bp, 1467bp and 
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280bp – uncut plasmid 4182bp). Sequencing of the plasmid insert in these colonies 
showed that one clone was transformed with the full coding sequence of hCYP1A2*1 
(figure 4.8). This was then transferred to the destination vector (pT-REX-DEST30) by a 
clonase reaction and transformed into bacteria once more. Colony PCR showed that all 
colonies transformed with the destination vector contained the cloned hCYP1A2*1 
coding sequence (figure 4.9). One colony was then expanded and plasmid DNA 
prepared. Finally, B-13 cells were co-transfected with pcDNA6/TR and pT-REX-
DEST30 (containing hCYP1A2*1) and stable transformants selected to create the B-13
-
TR/h1A2
 line. 
 
Figure 4.6: Construction of the hCYP1A2 coding sequence. A. PCR of the two fragments of 
hCYP1A2 from donor liver samples. Total RNA was extracted from donor liver samples using TRIzol 
then reverse transcribed. The cDNA was then used as a template for PCR using the primers indicated on 
the right. The PCR products were separated by agarose gel electrophoresis and visualised by UV 
transillumination. B. Fusion PCR of the two hCYP1A2 fragments. The two fragments of hCYP1A2 
amplified in A were gel extracted and fused by PCR. The human liver sample numbers correspond to 
those from A. The resulting PCR products were separated by agarose gel electrophoresis and visualised 
by UV transillumination. 
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Figure 4.7: Restriction digest of miniprep isolated plasmid DNA from transformants. TOP10 cells 
were transformed with the hCYP1A2 cloned into pENTR/D-TOPO from different donor samples (see 
Figure 4.6) then cultured overnight at 37°C on agar plates containing kanamycin. In the morning, colonies 
were picked into LB containing kanamycin and cultured overnight at 37°C shaking at 225rpm. In the 
morning, minipreps were used to isolate plasmid DNA which was restricted using NotI, EcoRV and 
BGl11. Following digestion, DNA loading dye was added to the reactions and they were separated by 
agarose gel electrophoresis and visualised by UV transillumination. 
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Figure 4.8: Clone 2.4 was cloned with the complete coding sequence of hCYP1A2*1. Sequence alignment of the insert in clone 2.4 with the complete coding sequence of 
hCYP1A2*1. Miniprepped plasmid DNA from clone 2.4 was sequenced twice forward and reverse and the resulting sequences averaged to one sequence. ClustalW2 was used to 
align the sequences (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
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Figure 4.9: The hCYP1A2 insert was successfully transferred from the gateway vector to the 
destination vector. PCR of colonies transformed with the product of the LR clonase reaction. Insert 
in pENTR/D-TOPO was transferred to pT-Rex-DEST30
 
using LR clonase then the reaction products 
transformed into TOP10 cells. The colonies were cultured overnight on agar containing ampicillin at 
37°C. In the morning, colony picks were used as template for PCR using primers for hCYP1A2. 
Following PCR, the products were separated by gel electrophoresis and visualised by UV 
transillumination. 
 
 
4.5 B-13
-TR/h1A2
 cells express hCYP1A2 independent of tetracycline 
 
To determine if B-13
-TR/h1A2
 cells expressed the introduced hCYP1A2 and if its 
expression was regulated by doxycycline (derivative of tetracycline), untransfected B-
13 cells and B-13
-TR/h1A2 
cells were treated with doxycycline for 24 hours and hCYP1A2 
expression assessed by RT-PCR and Western blotting. As can be seen in figure 4.10A, 
only B-13
-TR/h1A2 
cells expressed hCYP1A2 mRNA. However, repression of the 
transgene in the absence of doxycycline did not occur and therefore hCYP1A2 mRNA 
was constitutively expressed. To check for successful transfection of the pcDNA6/TR 
vector in B-13
-TR/h1A2
 cells, the expression of TetR, which is required for tetracycline 
inducible expression, was also assessed. Similar to hCYP1A2, TetR mRNA was only 
expressed by B-13
-TR/h1A2 
cells.  
 
Western blotting complemented the RT-PCR; it showed that B-13
-TR/h1A2
 cells, but not 
untransfected B-13 cells, expressed hCYP1A2 protein similar to human liver (figure 
4.10B). At the protein level, doxycycline treatment appeared to cause a small increase in 
expression of the cloned hCYP1A2. To confirm that B-13
-TR/h1A2
 cells could still 
transdifferentiate, hepatic markers were assessed by Western blotting before and after 
transdifferentiation. Figure 4.11 shows that B-13
-TR/h1A2
 cells could transdifferentiate to 
hepatocyte-like cells (B-13
-TR/h1A2
/H) as, following DEX induced transdifferentiation, 
they expressed the hepatic markers albumin, CYP2E1 and CPS-1. They also maintained 
expression of the hCYP1A2 transgene which showed a small induction of expression in 
response to doxycycline. 
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Figure 4.10: B-13
-TR/h1A2
 cells express hCYP1A2 independent of tetracycline. A. RT-PCR for 
hCYP1A2, TetR and GAPDH in the indicated samples. B-13 and B-13
-TR/h1A2
 cells were treated with 
vehicle (0.1% (v/v) PBS) or 2μg/ml doxycycline (DOX) for 24 hours then total RNA extracted using 
TRIzol. The RNA was reverse transcribed and used as template for PCR. PCR products were separated 
using agarose gel electrophoresis and visualised by UV transillumination. B. Western blot for 
CYP1A1/1A2 and β-actin in normal and doxycycline induced B-13 and B-13-TR/h1A2 cells. Lysates 
were prepared from samples treated as in A and quantified by Lowry assay. 20μg of protein/well was 
separated by SDS-PAGE and transferred to a nitrocellulose membrane which was blocked and probed. 
Antibody binding was detected using ECL Western blot substrate. Results are representative of at least 3 
separate experiments. 
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Figure 4.11: B-13
-TR/h1A2
 cells can transdifferentiate. Western blot for CYP1A1/1A2 and liver markers 
in indicated samples. B-13
-TR/h1A2 
and B-13
-TR/h1A2
/H cells were treated with vehicle (0.1% (v/v) PBS) or 
2μg/ml doxycycline (DOX) for 24 hours. Lysates were then prepared from treated cells, B-13 and B-13/H 
cells and rat and human liver samples and quantified by Lowry assay. 20μg of protein/well was separated 
by SDS-PAGE and transferred to a nitrocellulose membrane which was blocked and probed. Antibody 
binding was detected using ECL Western blot substrate. 
 
4.6 Cloned hCYP1A2 in B-13
-TR/h1A2
/H cells
 
is functional and inhibited by 
furafylline 
 
To determine if expressed hCYP1A2 in B-13
-TR/h1A2 
cells was functional, MROD 
activity was measured in vehicle and doxycycline induced B-13, B-13/H, B-13
-TR/h1A2
 
and B-13
-TR/h1A2
/H
 
cells. This showed that B-13
-TR/h1A2
/H cells had significantly higher 
MROD activity than B-13/H cells, suggesting the introduced hCYP1A2 was functional 
(figure 4.12A). Furthermore, treating lysates with furafylline, a specific inhibitor of 
hCYP1A2 [227], caused a significant reduction in MROD activity in B-13
-TR/h1A2
/H 
cells. Doxycycline induced cells showed essentially identical MROD activity to 
uninduced cells (not shown).  
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Figure 4.12: Transdifferentiated B-13
-TR/h1A2
/H cells express functional hCYP1A2. MROD activity in 
the indicated samples treated with or without the hCYP1A2 inhibitor furafylline. Lysates were prepared 
from the indicated samples which were then measured for MROD activity with or without 100μM 
furafylline. Human liver microsomes (HLM) were run alongside as a positive control. Resorufin 
production was calculated using a standard curve and readings were normalised to protein concentration 
measured using the Lowry assay. Results are the mean and SD of 3 independent determinations from the 
same experiment, typical of at least 3 separate experiments. *significantly different activity compared to 
extract without addition of furafylline, 
$
significantly different activity compared to respective B-13 
equivalent, 
†
significantly different activity compared to parent B-13 cells all at p<0.05. Abbreviations: 
HLM, human liver microsomes. 
 
4.7 hCYP1A2 expression significantly increases the susceptibility of B-13
-TR/h1A2
/H
 
cells to PhIP induced genotoxicity 
 
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) is a carcinogenic 
heterocyclic amine carcinogen derived from the prolonged cooking of meat at high 
temperatures, particularly by barbequing. It is ingested as a pro-genotoxin and 
metabolised to a genotoxic metabolite. Specifically, in the liver, PhIP is N-hydroxylated 
primarily by CYP1A2, and to a lesser extent CYP1A1 and CYP1B1 [228, 229]. N-
hydroxy-PhIP then undergoes O-esterification, catalysed by N-acetyltransferases or 
sulphotransferases (SULTs) as outlined in figure 4.13, to form reactive esters that bind 
and damage DNA [228, 229]. 
 
Due to the relative specificity of hCYP1A2 in bioactivation of PhIP, a dose response, 
using DNA damage as the endpoint, was performed on B-13 and B-13
-TR/h1A2
 cells and 
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their transdifferentiated forms. Measurement of DNA damage showed that B-13
-
TR/h1A2
/H cells were significantly more sensitive to DNA damage resulting from PhIP 
treatment than B-13/H cells (figure 4.14). Undifferentiated B-13 and B-13
-TR/h1A2
 cells 
did not show any marked genotoxicity in response to PhIP. Treatment of B-13
-TR/h1A2
/H 
cells with doxycycline, prior to PhIP treatment, had no effect on resulting DNA 
damage. 
 
To confirm that DNA damage resulting from PhIP treatment was not due to initiation of 
apoptosis or DNA replication, DNA diffusion and BrdU incorporation in PhIP treated 
cells was determined. Figure 4.15 shows that at the concentration range employed, 
comets were not associated with cytotoxicity or with a significant increase in DNA 
synthesis.  
 
 
 
 
Figure 4.13: Metabolism of PhIP. From Gu et al., (2010) [230]. 
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Figure 4.14: B-13
 -TR/h1A2
/H cells are susceptible to PhIP induced DNA damage. Dose response olive 
tail moment of indicated cells treated with different concentrations of PhIP. B-13, B-13/H. B-13
-TR/h1A2
 
and B-13
-TR/h1A2
/H cells were treated with (+) or without (-) 2μg/ml doxycycline for 24 hours then 
additionally with different concentrations of PhIP for 16 hours. Following treatment cells were subject to 
the alkaline comet assay and DNA stained with SYBR gold. Slides were viewed using a fluorescence 
microscope and DNA damage calculated using cometscore software. Data are the mean and SE of 100 
cells from 2 separate experiments, typical of at least 3 separate experiments. *indicates significant 
difference between indicated groups at p<0.05, calculated by ANOVA followed by the Bonferroni-Holm 
post-hoc test. 
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Figure 4.15: PhIP does not induce significant cell death or division. A. DNA diffusion assay of PhIP 
treated cells. B-13, B-13/H, B-13
-TR/h1A2
 and B-13
-TR/h1A2
/H cells were treated with (+) or without (-) 
2μg/ml doxycycline (DOX) for 24 hours then additionally with 200μM PhIP or positive controls (50μM 
etoposide or 400μM methapyrilene (MP)) for 16 hours. Following treatment, cells were embedded in low 
melting point agarose, lysed and stained with SYBR gold. Slides were viewed using a fluorescence 
microscope and the percentage of cells with normal DNA diffusion (using the positive controls as a 
guide) calculated. Results are the mean and SD from 4 fields of view, with at least 100 individual cells 
counted in total, from a single experiment, typical of at least 3 separate experiments. B. Percentage of 
comet cells staining positive for BrdU following PhIP treatment. Cells treated as in A were incubated 
with 15μM BrdU for 2 hours then were subject to the alkaline comet assay and immunostained for BrdU. 
After counterstaining with DAPI, slides were viewed using a fluorescence microscope and the percentage 
of comets staining positive for BrdU calculated. Data are the mean and SD calculated from 4 fields of 
view, with at least 100 individual cells counted in total. Results are from a single experiment, typical of at 
least 3 separate experiments. For A and B, no statistical analysis was performed.  
 
4.8 PhIP induced DNA damage is inhibited by furafylline in B-13
-TR/h1A2
/H cells 
 
To determine if the introduced hCYP1A2 in B-13
-TR/h1A2
/H cell was responsible for 
enhanced sensitivity of B-13
-TR/h1A2
/H
 
cells to PhIP compared to B-13/H cells, B-13/H 
and B-13
-TR/h1A2
/H cells were co-treated with PhIP as well as either the hCYP1A2 
inhibitor furafylline, the general CYP450 inhibitor metyrapone or CYP1A1 inhibitor α-
NF (figure 4.16). B-13/H cells showed significantly reduced DNA damage in response 
to α-NF and metyrapone but not furafylline. In B-13-TR/h1A2/H cells, furafylline but not 
metyrapone or α-NF, caused a significant reduction in DNA damage in response to 
PhIP. The almost complete inhibition of PhIP induced DNA damage in response to α-
NF in B-13/H cells suggests that CYP1A1 was primarily responsible for the 
bioactivation in these cells. The inhibition of DNA damage by furafylline in B-13
-
TR/h1A2
/H cells suggests that hCYP1A2 is responsible for the majority of PhIP 
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bioactivation in these cells and explains why they are more sensitive to PhIP induced 
DNA damage than B-13/H cells. 
 
 
 
Figure 4.16: PhIP genotoxicity is inhibited by furafylline in B-13
-TR/h1A2
/H
 
cells. DNA damage in B-
13/H and B-13
-TR/h1A2
/H
 
cells treated with PhIP and CYP450 inhibitors measured by comet assay. B-13/H 
and B-13
-TR/h1A2
/H cells were treated with vehicle (0.1% (v/v) DMSO), furafylline, metyrapone or α-NF 
for 6 hours then additionally with vehicle (1% (v/v) DMSO) or 50μM PhIP for 16 hours. Following 
treatment cells were subject to the alkaline comet assay and DNA stained with SYBR gold. Slides were 
viewed using a fluorescence microscope and DNA damage calculated using cometscore software. Data 
are the mean and SE of 50 cells from a single experiment, typical of 2 separate experiments. *indicates 
significant difference to cells treated with 50μM PhIP alone at p<0.05. 
 
4.9 PhIP bioactivation is dependent on SULT activity 
 
Sulphation reactions, in the context of drug metabolism, involve the transfer of the 
sulfonyl moiety from 3'-phosphoadenosine-5'-phosphosulphate (PAPS) to xenobiotics, 
catalysed by SULTs. Sulphation reactions are important in the liver for drug 
detoxification, but also for drug bioactivation. CYP1A proteins (including CYP1A2) are 
involved in the bioactivation of a range of pro-carcinogens which are subsequently 
sulphated to genotoxic forms, such as benzylic alcohols from polycyclic aromatic 
hydrocarbons and aromatic hydroxylamines (including hydroxylated PhIP and 
benzo[a]pyrene) [231]. If wild type or humanised B-13 cells, including B-13
-TR/h1A2
 
cells, were to be used for genotoxicity screening therefore, they would need to express 
functional SULTs.  
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Based on the sensitivity of B-13/H and B-13
-TR/h1A2
/H cells to PhIP, which requires 
sulphation for genotoxicity, cells were pretreated with 4-nitrophenol (PNP) or quercetin, 
prior to addition of PhIP. PNP is a substrate and quercetin an inhibitor of a range of 
SULTs, particularly SULT1A1. In humans, SULT1A1 and SULT1A2, and in rats 
SULT1A1, SULT1B1 and SULT1C1 have been shown to be able to sulphate 
hydroxylated PhIP [232-234]. 
 
The competitive inhibition of SULT activity by PNP significantly inhibited PhIP 
induced genotoxicity only in B-13/H cells whereas quercetin significantly reduced DNA 
damage in both B-13/H and B-13
-TR/h1A2
/H cells (figure 4.17). This result indicates that 
B-13/H cells express functional SULTs which are required for PhIP genotoxicity. 
 
 
Figure 4.17: PhIP genotoxicity is SULT dependent. DNA damage in B-13/H and B-13
-TR/h1A2
/H
 
cells 
treated with PhIP and SULT inhibitors measured by comet assay. B-13/H and B-13
-TR/h1A2
/H cells were 
treated with vehicle (0.1% (v/v) DMSO), PNP or quercetin for 6 hours then additionally with vehicle (1% 
(v/v) DMSO) or 20μM PhIP for 16 hours. Following treatment, cells were subject to the alkaline comet 
assay and DNA stained with SYBR gold. Slides were viewed using a fluorescence microscope and DNA 
damage calculated using cometscore software. Data are the mean and SE of 50 cells from a single 
experiment, typical of at least 3 separate experiments. *significantly different to vehicle treated cells at 
p<0.05. 
 
4.10 B-13/H cells express functional SULTs and are susceptible to 1-
hydroxyestragole induced DNA damage 
 
Based on the inhibition of PhIP induced DNA damage by SULT inhibitors, RT-PCR 
was carried out to determine which SULTs B-13 and B-13/H cells expressed. As shown 
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in figure 4.18A, RT-PCR showed that B-13 and B-13/H cells both expressed a number 
of SULT mRNA transcripts including SULT1A1 and SULT2B1. PAPS synthase 1 and 
2 (PAPSS1 & 2) catalyse the production of the SULT cofactor PAPS from ATP and 
sulphate and are required for SULT function. Analysis of the sequenced B-13 genome 
suggested that the Papss1 and Papss2 genes contained exon deletions. To verify the 
presence or absence of the deletions, primers were designed around the predicted sites 
of deletion. RT-PCR showed (figure 4.18B) that neither Papss1 nor Papss2 contained 
deletions in B-13 cells as PAPSS1 mRNA could be detected in B-13 and B-13/H cells 
and PAPSS2 mRNA in B-13/H cells.  
 
The dietary constituent estragole is an alkenylbenzene found in a range of herbs and 
spices, particularly in basil. As outlined in figure 4.19A, estragole can be bioactivated to 
a genotoxic metabolite. Specifically, it is primarily metabolised by CYP1A2 in humans 
to 1-hydroxyestragole which is then sulphated to the ultimate genotoxic metabolite, 1-
sulfoxyestragole [235]. Due to the primary role of CYP1A2 in the bioactivation of 
estragole, B-13, B-13/H, B-13
-TR/h1A2
 and B-13
-TR/h1A2
/H cells were treated with 
estragole, 1-hydroxestragole (the hydroxylated form of estragole) or PhIP and DNA 
damage measured using the comet assay to determine if B-13
-TR/h1A2
/H
 
cells were able 
to bioactivate estragole.  
 
Figure 4.19B shows that no cells showed significant DNA damage in response to 
estragole whereas 1-hydroxyestragole caused significant DNA damage in B-13/H and 
B-13
-TR/h1A2
/H cells. This suggests that B-13
-TR/h1A2
/H cells were unable to significantly 
hydroxylate estragole but were, like B-13/H cells, able to sulphate 1-hydroxyestragole. 
Interestingly, B-13 cells, which expressed a similar range of SULT transcripts to B-
13/H cells, were not sensitive to DNA damage resulting from 1-hydroxyestragole 
treatment. Treatment of B-13/H and B-13
-TR/h1A2
/H cells with a range of 1-
hydroxyestragole concentrations showed that DNA damage was induced in both cell 
types in a dose dependent manner (figure 4.20A), but B-13
-TR/h1A2
/H
 
cells were more 
sensitive. Importantly, DNA damage resulting from 1-hydroxyestragole treatment was 
not a consequence of cytotoxicity (figure 4.20B). 
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Figure 4.18: B-13 and B-13/H cells express a number of SULTs and PAPSS. A. RT-PCR for the 
indicated transcripts. B. RT-PCR for PAPSS1 and PAPSS2 using primers designed around the 
potential deletion site. For A and B, total RNA was extracted using TRIzol from B-13 and B-13/H cells 
and cDNA produced which was used as the template for PCR alongside cDNA produced from untreated 
rat liver. Following PCR, samples were separated by agarose gel electrophoresis and visualised by UV 
transillumination. Results shown are representative of at least 3 separate experiments. 
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Figure 4.19: B-13/H and B-13
-TR/h1A2
/H
 
cells are sensitive to 1-hydroxyestragole. A. Metabolism of 
estragole to a genotoxic metabolite. Adapted from Alhusainy et al., (2012) [235]. B. DNA damage in 
cells following estragole, 1-hydroxyestragole or PhIP treatment measured by comet assay. B-13, B-
13/H, B-13
-TR/h1A2
 and B-13
-TR/h1A2
/H cells were treated with vehicle (1% (v/v) DMSO), 1mM estragole, 
1mM 1-hydroxyestragole or 10μM PhIP for 16 hours. Following treatment, cells were subject to the 
alkaline comet assay and DNA stained with SYBR gold. Slides were viewed using a fluorescence 
microscope and DNA damage calculated using cometscore software. Data are the mean and SE of 50 
cells from a single experiment, typical of at least 3 separate experiments. *significant difference 
compared to respective vehicle control at p<0.05. 
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Figure 4.20: B-13
-TR/h1A2
/H cells are more sensitive to 1-hydroxyestragole than B-13/H cells. A. Dose 
response of B-13/H and B-13
-TR/h1A2
/H cells treated with 1-hydroxyestragole measured by comet 
assay. B-13/H and B-13
-TR/h1A2
/H cells were treated with vehicle (0.1% (v/v) DMSO) or different 
concentrations of 1-hydroxyestragole for 16 hours. Following treatment, cells were subject to the alkaline 
comet assay and DNA stained with SYBR gold. Data are the mean and SE of 50 cells from a single 
experiment, typical of at least 3 separate experiments. *indicates significant difference compared to 
respective vehicle control at p<0.05 calculated by ANOVA followed by the Bonferroni-Holm post-hoc 
test. B. DNA diffusion assay in cells following estragole or 1-hydroxyestragole treatment. B-13, B-
13/H, B-13
-TR/h1A2
 and B-13
-TR/h1A2
/H cells were treated with vehicle (0.1% (v/v) DMSO), 1mM estragole, 
1mM 1-hydroxyestragole or positive controls (50μM etoposide or 400μM methapyrilene (MP)) for 16 
hours. Following treatment, cells were embedded in low melting point agarose, lysed and stained with 
SYBR gold. Slides were viewed using a fluorescence microscope and the percentage of cells with normal 
DNA diffusion (using the positive controls as a guide) calculated. Results are the mean and SD from 4 
fields of view, with at least 100 individual cells counted in total, from a single experiment, typical of at 
least 3 separate experiments. No statistical analysis was performed. 
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4.11 1-hydroxyestragole induced damage is sulphation dependent  
 
To determine if DNA damage caused by 1-hydroxyestragole was dependent on SULT 
activity, B-13/H and B-13
-TR/h1A2
/H
 
cells were pre-treated with a range of inhibitors 
prior to treatment with 1-hydroxyestragole. Figure 4.21 shows that treatment of cells 
with SULT inhibitors (quercetin, PNP and pentachlorophenol (PCP)) significantly 
inhibited 1-hydroxyestragole induced DNA damage. These results suggest that, as 
expected, 1-hydroxyestragole induced DNA damage is SULT dependent in B-13/H and 
B-13
-TR/h1A2
/H cells 
 
 
Figure 4.21: 1-hydroxyestragole induced DNA damage is SULT dependent. DNA damage in B-13/H 
and B-13
-TR/h1A2
/H
 
cells treated with 1-hydroxyestragole and SULT inhibitors measured by comet assay. 
B-13/H and B-13
-TR/h1A2
/H cells were treated with vehicle (0.1% (v/v) DMSO), quercetin, PNP or PCP for 
6 hours then additionally with vehicle (0.1% (v/v) DMSO) or 1mM 1-hydroxyestragole for 16 hours. 
Following treatment cells were subject to the alkaline comet assay and DNA stained with SYBR gold. 
Slides were viewed using a fluorescence microscope and DNA damage calculated using cometscore 
software. Data are the mean and SE of 50 cells from a single experiment, typical of at least 3 separate 
experiments. *significant difference to cells treated with 1-hydroxyestragole alone at p<0.05. 
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4.12 Chapter discussion 
 
Although most toxicity data obtained from non-human species is relevant to humans at 
least in some form, in the case of some specific compounds this is not the case. This is 
why human hepatocytes, but not those derived from other species, are the gold standard 
for toxicity screening. Variation exists in the specificity, affinity and regulation of 
homologous enzymes between species which account for the differences in metabolism 
that have been documented. In this chapter, it was shown that B-13 and B-13/H cells do 
not express functional CYP1A2. hCYP1A2, derived from a donor sample, was therefore 
cloned into the cells to create the B-13
-TR/h1A2 
line. This line expressed hCYP1A2 and 
when transdifferentiated showed significantly increased and furafylline inhibitable 
MROD activity compared to wild type B-13/H cells. B-13
-TR/h1A2
/H
 
cells were also 
shown to be significantly more sensitive to PhIP induced DNA damage. 
Undifferentiated B-13
-TR/h1A2
 cells did not demonstrate any drug metabolising capacity 
and this is likely because undifferentiated B-13 cells do not express CYP reductase, 
which is required for CYP450 function [124].  
 
hCYP1A2 was cloned into the B-13 line using a doxycycline inducible system, however 
the introduced hCYP1A2 was not doxycycline regulated as originally planned, even 
though TetR mRNA was expressed. The expression of hCYP1A2 in the absence of 
doxycycline was likely therefore a consequence of incomplete repression of expression 
by TetR. An additional factor is that the B-13
-TR/h1A2
 line is a polyclonal population. 
Attempts were made to create a monoclonal line, selecting clones with low basal 
hCYP1A2 expression and high doxycycline inducible expression. However, when cells 
were sub-cultured as single cells/well they frequently died, likely due to lack of pro-
survival paracrine signalling, which prevented the creation of a monoclonal line. If 
inducible expression was required, then hCYP1A2 could be fused to a fluorescent 
protein (eg. green fluorescent protein) and fluorescent activated cell sorting used to 
create a monoclonal population regulated by doxycycline in a more straightforward 
manner. 
 
CYP450 hydroxylation of xenobiotics is often only the first step in the bioactivation 
process of a pro-drug. Conjugation reactions, particularly sulphation reactions, are 
frequently involved in the bioactivation of pro-carcinogenic xenobiotics following 
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CYP450 (often CYP1A) mediated hydroxylation [231]. If B-13/H cells (wild type or 
humanised versions) were to be used to screen genotoxins therefore, it was important 
that they expressed functional SULTs. A PCR array showed that B-13/H cells expressed 
6/14 SULT transcripts and PAPSS1 and PAPSS2 mRNA. Undifferentiated B-13 cells 
expressed only 3/14 SULT transcripts and not PAPSS2, suggesting that 
transdifferentiation is associated with the up-regulation of phase II, as well as phase I, 
DMEs. SULTs were shown to be functional in B-13/H, but not B-13 cells, as their 
inhibition in B-13/H cells significantly reduced the DNA damage resulting from 2 
SULT dependent pro-carcinogens, PhIP and 1-hydroxyestragole. Surprisingly, B-13
-
TR/h1A2
/H cells were more sensitive to 1-hydroxyestragole induced DNA damage than 
untransfected B-13/H cells. This may have been due to the presence of unhydroxylated 
estragole or other pro-carcinogenic impurities in the 1-hydroxyestragole we received 
which was metabolised by hCYP1A2 causing DNA damage. 
 
The insensitivity of B-13
-TR/h1A2
/H
 
cells to estragole induced DNA damage was 
unexpected, as estragole is primarily bioactivated by CYP1A2 [235]. When B-13
-
TR/h1A2
/H cells were treated with 1-hydroxyestragole, DNA damage was only seen at 
doses greater than 100μM, a relatively high dose. Considering that estragole and 1-
hydroxyestragole are substrates for numerous DMEs other than CYP1A2 and SULTs 
respectively, it is likely that a DNA damaging concentration of 1-sulfoxyestragole (the 
genotoxic metabolite) was unable to be produced, due to the rapid detoxification of 
estragole and 1-hydroxyestragole by competing DMEs.  
 
The lack of DNA damage in B-13 cells treated with 1-hydroxyestragole suggests that 
the sulphation of 1-hydroxyestragole is catalysed by a SULT expressed by B-13/H, but 
not B-13 cells (SULT1B1, SULT2A6 and SULT5A1). Alternatively, it may be related 
to the lack of PAPSS2 expression in B-13 cells as, although PAPSS 1 and 2 both 
produce the universal SULT substrate PAPS, evidence to date suggests that they are 
differentially regulated and localised. PAPSS1 accumulates in the nucleus and in 
humans shows greater expression in the brain and skin compared to PAPSS2 which is 
more cytoplasmic based and shows greater expression in the liver and cartilage [236, 
237]. Considering that SULTs are generally cytoplasmic and B-13 cells do not express 
PAPSS2, SULT mediated bioactivation of 1-hydroxyestragole could have been limited 
by a shortage of PAPS in B-13 cells.  
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The data presented in this chapter demonstrates that a human gene, stably introduced 
into the B-13 cell line, was expressed and functional following transdifferentiation, due 
to the expression of necessary coenzymes, thus proving the initial hypothesis. This work 
shows that, as a proof of concept, B-13 cells can be readily humanised with DMEs, 
which should be functional. It has also been shown that a humanised B-13 line could be 
used for genotoxicity screening, as B-13 cells, when transdifferentiated, express the 
enzymes required for complete bioactivation of pro-carcinogens. Commonly for 
genotoxicity screening, test compounds are bioactivated with exogenous metabolic 
activation systems (normally rat liver S9) before exposure to cells. However, these 
systems poorly recapitulate in-vivo metabolic activation where bioactivation is complex, 
requiring the activities of numerous enzymes, or where reactive intermediates are short 
lived and hence unable to reach target DNA. The use of B-13/H cells for genotoxicity 
screening could overcome these problems as they express a range of functional DMEs 
in proximity to the target DNA. The use of humanised B-13 cells (including B-13
-TR/h1A2
 
cells) would further improve their utility by enhancing the clinical relevance of any 
derived results. 
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Chapter 5. Expression and function of transporters in B-13/H cells  
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5.1 Introduction 
 
The expression of transporters, and their polarisation, is required for efficient 
hepatocyte function in-vivo. They facilitate the removal of potentially toxic compounds 
from systemic circulation through active uptake and the partitioning of metabolites into 
the bile. As outlined in the introduction, hepatocytes express a range of transporters 
which can be broadly categorised by which membrane they localise to, whether they are 
involved in the influx or efflux of compounds and if they are ATP dependent for 
function. Similar to CYP450s, the expression of hepatic transporters is in part regulated 
by nuclear receptors, particularly the PXR, CAR, PPARα and FXR [81]. Through these 
receptors, the rate and route of drug metabolism can be regulated from uptake through 
to modification/conjugation to efflux.  
 
Certain drugs can inhibit specific transporters, resulting in alterations in metabolism of a 
second co-administered drug. An example of this is statins, which are primarily influxed 
by OATPs. Cyclosporin A and gemfibrozil both inhibit OATPs and significantly 
increase the bioavailability of statins when co-administered. In some patients 
administered cerivastatin with cyclosporin A, skeletal muscle toxicity was documented 
and it has been hypothesised that this may, at least in part, be due to increased 
bioavailability of cerivastatin resulting from inhibition of OATP-mediated uptake [238-
240]. Due to the importance of BSEP in the export of bile acids, its inhibition can cause 
cholestasis and liver injury. Numerous drugs have been shown to inhibit BSEP function, 
including troglitazone and rifampicin, causing cholestatic liver injury [241, 242]. 
Inhibition of BSEP prevents sufficient bile acid export into the canaliculi, which leads 
to the intracellular accumulation of bile acids in hepatocytes. Through their detergent 
effect, this is thought to disrupt mitochondrial function, leading to necrosis and 
apoptosis [243, 244]. 
 
The assessment of the capacity of novel drugs and chemicals to inhibit transporter 
activity is therefore an important aspect of the characterisation of newly developed 
drugs and chemicals. Primary hepatocytes are the optimal model in which to evaluate 
drug-transporter interactions in-vitro as they, at least in the short term, express 
approximately physiological levels of transporters [245]. Additionally, metabolites of 
the parent compound, rather than the parent compound itself, may be inhibitors and 
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therefore testing in a metabolically competent cell is important to detect any effects. In 
hepatocytes in-vitro, apical transporter expression is generally relatively stable, however 
the expression of basal transporters including NTCP and OATP1 rapidly decreases over 
time [245-248]. Interestingly, the expression of transporters is more stable in human 
primary hepatocytes than rat primary hepatocytes in culture [245]. 3D culture of 
primary hepatocytes has been shown to help retain expression and polarisation of some 
hepatocyte transporters though it still only attenuates, rather than prevents, the loss of 
expression [245, 249]. 
 
As shown in chapter 3, B-13/H cells are metabolically competent in a manner 
quantitatively similar to primary hepatocytes. Based on this demonstrated similarity to 
primary hepatocytes, it was hypothesised that B-13/H cells express a physiologically 
relevant pattern of transporters, equivalent to that seen in the liver. Expression of 
hepatic transporters would improve the clinical relevance of B-13/H cells for the 
assessment of drug and chemical toxicity and allow them to be used in place of primary 
hepatocytes for the study of drug-transporter interactions.  
 
5.2 Transdifferentiation of B-13 cells is associated with up-regulation of drug 
transporter mRNA expression 
 
To test the hypothesis, drug transporter mRNA expression was assessed in B-13 and B-
13/H cells and rat liver using SABiosciences rat drug transporter qPCR arrays. Results 
for selected transporters (which were selected for all subsequent drug transporter 
arrays), chosen because of their known roles in xenobiotic and/or bile acid efflux/influx, 
are illustrated in figure 5.1. This shows that B-13 cells expressed detectable levels of 
drug transporter mRNA transcripts. Transdifferentiation of B-13 to B-13/H cells was 
associated with the up-regulation of almost all transcripts. Compared to intact rat liver, 
B-13 and B-13/H cells expressed approximately quantitatively equivalent mRNA levels 
of several important transporters including MDR1, MDR2, MRP1, MRP3-5, OCT2, 
OAT1 and OATP3 and 5. However, expression of the bile acid transporters BSEP and 
NTCP were low in comparison, as was expression of MRP2 amongst other important 
xenobiotic transporters. Comparing the average fold change in expression of all 
measured transcripts (table 5.1) showed that B-13/H cells expressed about 10 fold more 
transporter mRNA than B-13 cells, but around 100 fold less than rat liver.  
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Figure 5.1: B-13/H cells express several drug transporters at liver levels. Fold mRNA expression of 
indicated transcripts in B-13/H cells and intact rat liver shown relative to B-13 cells, quantified using a rat 
drug transporter array. Total RNA was produced from samples using TRIzol, which was then cleaned up, 
reverse transcribed and the resulting cDNA used as a template for the rat drug transporter arrays. Results 
are the mean of 3 independent determinations from the same experiment. No statistical analysis was 
performed. 
 
 B-13 B-13/H ♂ rat liver 
Mean 1 11.12 1158.85 
SD 0 43.28 4688.62 
Table 5.1: Average fold change in expression of all measured transcripts in B-13/H cells and rat 
liver relative to B-13 cells. 
 
5.3 3D culture does not markedly change B-13/H expression of drug transporters 
 
Due to the low transcript expression of several key transporters in B-13/H cells, they 
may not be a good model in which to test for transporter interactions with novel drugs 
and chemicals. Culture of hepatocytes in 3D culture systems has been shown to help 
restore hepatocyte polarity and retain expression of various transporters including 
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BSEP, NTCP and MRP2 [245]. This normally involves the sandwich culture of 
hepatocytes between rat tail collagen I and matrigel. It was therefore hypothesised that 
modification of culture substratum would induce transporter expression in B-13/H cells. 
Alvetex is a porous polystyrene matrix which, unlike other commercially available 
matrices, is characterised by an open but interconnected pore structure. Published 
studies using alvetex have shown that it enhances the hepatic phenotype of HepG2 cells 
and reduces the rate of primary hepatocyte dedifferentiation [250-253]. In order to 
determine the effect of 3D culture on transporter expression in B-13/H cells, B-13 cells 
were seeded onto alvetex as outlined in the methods and transdifferentiated as normal 
over 14 days. 
 
To assess if cells seeded onto the alvetex were viable, neutral red staining was carried 
out on cells. Figure 5.2A shows that cells seeded onto the alvetex accumulated neutral 
red, indicating that they were viable. To confirm the location of seeded cells on the 
scaffold, scaffolds containing B-13 and B-13/H cells were fixed, processed and 
embedded as outlined in the methods. They were then cut into 10μm sections and DAPI 
stained as shown in figure 5.2B. Both B-13 and B-13/H cells were localised to the top 
of the alvetex, the side they were originally seeded on, although B-13/H cells had 
invaded deeper into the scaffold. CYP2E1 immunostaining of B-13 and B-13/H cells on 
alvetex showed that B-13/H but not B-13 cells expressed CYP2E1, confirming that B-
13 cells treated with DEX on alvetex were still able to transdifferentiate (figure 5.2C). 
RT-PCR confirmed that B-13 cells were able to transdifferentiate on the scaffold as B-
13/H cells cultured on alvetex expressed the same markers as those grown as a 
monolayer (figure 5.3A).  
 
The expression of drug transporter mRNA was measured in monolayer and alvetex 
cultured B-13/H cells as illustrated in figure 5.3B. Alvetex culture caused some changes 
in transporter mRNA expression compared to B-13/H cells cultured as a monolayer, 
however the differences were small and whilst alvetex culture induced the mRNA 
expression of several transporters, it also inhibited the expression of a similar number. 
Indeed, the average fold change in expression of all measured transcripts between 
alvetex cultured B-13/H cells and those cultured as a monolayer was 1.18 ± 2.30, 
demonstrating that alvetex had essentially no net effect on transporter expression. 
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Figure 5.2: B-13 cells adhere to and transdifferentiate on alvetex. A. Neutral red stained alvetex 
seeded with or without B-13 cells. Scaffolds were incubated in 0.03% (w/v) neutral red in PBS for 1 
hour before a PBS wash. Staining was carried out 2 days after B-13 seeding. B. DAPI staining of B-13 
and B-13/H cells on alvetex. B-13 and B-13/H cells were cultured on alvetex for 3 and 14 days 
respectively before fixation. Scaffolds were fixed in 10% buffered formalin, embedded and cut into 10μm 
sections. Slides were dewaxed, rehydrated and stained with DAPI before imaging on a Zeiss fluorescence 
microscope. Scale bar indicates 50μm. C. CYP2E1 immunostaining of B-13 and B-13/H cells on 
alvetex. Scaffolds with cells cultured as in B, were fixed in 10% buffered formalin, embedded and cut 
into 10μm sections. Slides were then dewaxed, blocked and immunostained for CYP2E1 using DAB to 
detect bound antibody. Slides were then counterstained with haematoxylin. Slides were viewed using a 
Lecia upright microscope. Scale bar indicates 100μm. All images are representative of at least 3 separate 
experiments. 
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Figure 5.3: Alvetex does not enhance B-13/H expression of drug transporters. A. RT-PCR for 
indicated transcripts in B-13 and B-13/H cells cultured as a monolayer or on alvetex. B-13 cells and 
B-13/H cells were cultured for 3 and 14 days respectively as a monolayer or on alvetex. Total RNA was 
extracted from cells using TRIzol and cDNA produced which was used as the template for PCR. 
Following PCR, samples were separated by agarose gel electrophoresis and visualised by UV 
transillumination. B. Fold mRNA expression of indicated transcripts in monolayer and alvetex 
cultured B-13/H cells. Transporter mRNA expression in alvetex cultured B-13/H cells is shown relative 
to monolayer cultured B-13/H cells and was quantified using rat drug transporter array plates. Total RNA 
was produced from B-13/H cells cultured as a monolayer or on alvetex for 14 days using TRIzol, which 
was then cleaned up, reverse transcribed and the resulting cDNA used as a template for the rat drug 
transporter arrays. Results are the mean of 3 independent determinations from the same experiment. No 
statistical analysis was performed. 
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5.4 Culture on PU134 does not up-regulate B-13/H expression of drug transporters 
 
Recent interesting work has shown that hepatocyte-like cells derived from hESCs and 
cultured on PU134 show an improved hepatocyte phenotype compared to those cultured 
on plastic [254]. This use of PU134 was identified through a screen of 380 different 
polymers; hepatocyte-like cells were cultured on different polyurethane or polyacrylate 
polymers and then immunostained for albumin. The 6 polymers which induced the 
greatest increase in albumin expression were then tested for their ability to induce 
hepatocyte export proteins in the same cells. PU134 was identified as best at promoting 
a hepatocyte phenotype in these studies and was shown to improve CYP1A2 and 
CYP3A4 activity and CYP3A4 induction. It has been used in subsequent work to 
improve the predictive capacity of hESC and iPSC derived hepatocyte-like cells for 
toxicity screening [255]. Based on these findings, it was anticipated that culture of B-
13/H cells on the polymer would improve their hepatic phenotype and up-regulate 
transporter expression. B-13 cells were therefore seeded onto PU134 coated slides in 24 
well plates and either cultured as normal or transdifferentiated over 2 weeks. Figure 5.4 
shows that B-13 and B-13/H cells cultured on PU134 had the same morphology as those 
cultured on plastic and transdifferentiated B-13 cells expressed CYP2E1 when 
transdifferentiated on plastic as normal, or on PU134. 
 
RT-PCR and Western blotting confirmed that culture on PU134 did not have a marked 
effect on the expression of hepatic markers and did not lead to an up-regulation of 
MRP2, BSEP or NTCP mRNA expression (figure 5.5A & B). Drug transporter mRNA 
expression was analysed by qPCR as shown in figure 5.5C. B-13 and B-13/H cells on 
PU134 showed similar expression of transporters to those cultured on plastic as 
illustrated by the average fold change in expression of all measured transcripts (table 
5.2). Several of the transcripts were poorly detected using the qPCR plates including 
BSEP and MRP2, presumably due to their low expression, which explains why the liver 
fold change in this experiment was relatively low in comparison to that seen previously.  
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Figure 5.4: Culture on PU134 does not affect B-13 transdifferentiation. CYP2E1 fluorescence 
immunostaining of B-13 and B-13/H cells cultured on plastic as normal or on PU134 coated inserts for 14 
days. Cells were fixed, blocked and immunostained for CYP2E1 and counterstained with DAPI. Cells 
were photographed using a Zeiss fluorescence microscope. Scale bar indicates 50μm. Results are typical 
of 2 separate experiments. 
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Figure 5.5: Culture on PU134 does not cause up-regulation of transporter expression. A. RT-PCR 
for the indicated mRNA transcripts in B-13 and B-13/H cells cultured on plastic or PU134. B-13 
cells and B-13/H cells were cultured for 14 days on plastic or PU134. After culture, total RNA was 
extracted from samples using TRIzol and cDNA produced which was used as the template for PCR. 
Following PCR, samples were separated by agarose gel electrophoresis and visualised by UV 
transillumination. B. Western blot for liver markers in samples cultured as in A. Lysates were 
prepared from rat liver and samples treated as in A, and quantified by Lowry assay. 20μg of protein/well 
was separated by SDS-PAGE and transferred to a nitrocellulose membrane which was blocked and 
probed. Antibody binding was detected using ECL Western blot substrate. C. Fold mRNA expression of 
indicated transcripts in plastic and PU134 cultured B-13 and B-13/H cells. Expression is shown 
relative to plastic cultured B-13/H cells and was quantified using rat drug transporter array plates. From 
cells treated as in B, total RNA was produced using TRIzol which was cleaned up, reverse transcribed 
and the resulting cDNA used as a template for the rat drug transporter arrays. For A and B, results are 
typical of 2 separate experiments. For C, results are the fold change of single samples from the same 
experiment. 
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 B-13 plastic B-13/H 
plastic 
B-13 PU134 B-13/H 
PU134 
♂ rat liver 
Mean 0.58 1 0.67 1.03 39.32 
SD 1 0 0.97 1.25 125.91 
Table 5.2: Average fold change in expression of all measured transcripts in rat liver and B-13 and 
B-13/H cells cultured on plastic or PU134 relative to B-13/H cells cultured on plastic. 
 
 
5.5 Introduction of liver enriched transcription factor HNF4α increases expression 
of drug transporters 
 
Liver transporter expression, and hepatocyte specification and phenotype more 
generally, is regulated by a complex network of liver enriched transcription factors 
(LETFs). The main LETFs are part of the HNF-1, -3, -4, -6 and C/EBP families [256]. 
To assess if overexpression of different LETFs could lead to up-regulation of hepatic 
transporters in B-13/H cells, B-13/H cells were infected with adenoviral constructs 
encoding C/EBPα (Ad-C/EBPα), HNF1α (Ad-HNF1α), HNF4α (Ad-HNF4α), C/EBPβ-
liver enriched activator protein (LAP, Ad-LAP) or C/EBPβ-liver enriched inhibitory 
protein (LIP, Ad-LIP). HNF1α and 4α are part of the HNF family of transcription 
factors. They regulate a broad range of hepatocyte-specific functions including energy 
and xenobiotic metabolism, but are also required for liver development and hepatocyte 
differentiation [256, 257]. C/EBPα and C/EBPβ are members of the C/EBP family of 
transcription factors, which, like HNF1α and HNF4α, regulate expression of liver 
specific genes including several CYP450s but also enzymes involved in 
gluconeogenesis [258]. C/EBPβ is also required for B-13 transdifferentiation, a 
physiologically conserved response in-vivo, which also shows that it has a role in 
specifying between pancreatic or hepatic differentiation [123, 126]. The C/EBPα and 
C/EBPβ genes are transcribed to full length mRNA which, due to the presence of 
downstream in-frame start sites, is translated to give several different N-truncated 
isoforms. C/EBPβ-LAP contains the activation domains and can therefore be activated 
and in turn promote gene transcription. Conversely, C/EBPβ-LIP lacks the activation 
domains and is therefore a dominant negative form of LAP and represses transcription 
[259, 260]. 
 
Prior to cell adenoviral infection, the MOI of B-13/H cells was established. This was 
determined as outlined in figure 5.6, as described in the methods. B-13/H cells were 
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infected with a serially diluted adenovirus encoding GFP and infection efficiency 
calculated (figure 5.6A & B). As the number of B-13/H cells that were infected was 
known, the MOI could be calculated, which for an infection efficiency of ~88%, was 
2.37 pfu/cell (figure 5.6C).  
 
 
 
Figure 5.6: Calculation of B-13/H MOI. A. Brightfield and fluorescence photomicrographs of B-
13/H cells infected with 100μl of Ad-GFP crude supernatant. Images were taken at 100x 
magnification on a Leica fluorescence microscope 24 hours after infection. B. Plot of infection efficiency 
of B-13/H cells against volume of Ad-GFP crude supernatant used for infection. C. Plot of infection 
efficiency against MOI. For B and C, points are the mean and SD of 3 independent determinations from 
the same experiment. 
 
B-13/H cells were subsequently infected with the different adenoviruses. Some B-13/H 
cells were infected with an adenovirus carrying an empty construct (Ad-null) as a 
control. Infection was carried out using an MOI of 2.37 pfu/cell. Following adenoviral 
infection, B-13/H cells were cultured, in DEX free medium, for 5 days then harvested. 
Ad-HNF4α infected B-13/H cells showed a slight morphological change, flattening, 
forming more cell-cell contacts and appearing more hepatocyte-like (figure 5.7A). RT-
PCR and Western blotting showed that adenoviral infection of B-13/H cells did not 
markedly affect expression of hepatocyte markers (figure 5.7B & C). RT-PCR for the 
transporters BSEP, MRP2 and NTCP demonstrated that Ad-HNF4α infected B-13/H 
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cells showed detectable expression of BSEP and increased expression of MRP2 mRNA 
compared to the no virus and other adenoviral infected B-13/H cells. Adenoviral 
C/EBPα, HNF1α and HNF4α were detected by RT-PCR, indicating that B-13/H cells 
were expressing the relevant mRNA transcripts after adenoviral infection (figure 5.7B). 
C/EBPβ mRNA expression could not be detected by RT-PCR in either Ad-LAP or Ad-
LIP infected B-13/H cells or human liver using species specific primers, preventing 
confirmation of adenoviral C/EBPβ expression in Ad-C/EBPβ infected B-13/H cells. 
 
Figure 5.7: Adenoviral infection with HNF4α causes a phenotype change and induction of BSEP 
and MRP2 expression. A. Photomicrograph of B-13/H cells 5 days after adenoviral infection. 
Images are at 100x magnification. B. RT-PCR for the indicated transcripts in adenoviral infected B-
13/H cells. Total RNA was extracted from samples 5 days after infection using TRIzol and cDNA 
produced which was used as the template for PCR. Following PCR, samples were separated by agarose 
gel electrophoresis and visualised by UV transillumination. C. Western blotting for liver markers in B-
13 cells, adenoviral infected B-13/H cells and rat liver. Lysates from rat liver, B-13 cells and B-13/H 
cells treated as in A and B, were prepared and quantified by Lowry assay. 20μg of protein/well was 
separated by SDS-PAGE and transferred to a nitrocellulose membrane which was blocked and probed. 
Antibody binding was detected using ECL Western blot substrate. All results are typical of at least 3 
separate experiments. 
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Drug transporter mRNA expression was determined using drug transporter qPCR arrays 
as shown in figure 5.8. In agreement with the semi-quantitative RT-PCR data, it was 
confirmed that Ad-HNF4α infection of B-13/H cells led to up-regulation of MRP2 and 
BSEP mRNA (by 96 and 73 fold respectively) compared to Ad-null infected cells. 
Several other transcripts, which could not be detected in Ad-null infected cells, were 
also measureable in Ad-HNF4α infected cells such as OCT2 and OAT5. Although Ad-
HNF4α caused the up-regulation of several transporters, down-regulation was seen in 
other transcripts including all MRPs, excluding MRP2, and MDRs. Considering that 
these are expressed at greater levels in B-13/H cells in comparison to rat liver 
(excluding MRP6 and MDR2), the effect of their down-regulation brings their 
expression level more in line with that seen in-vivo. Compared to Ad-HNF4α infected 
B-13/H cells, infection with other adenoviral constructs had little effect on the mRNA 
expression of transporters overall. The average fold change in expression of all 
measured transcripts is shown in table 5.3 and demonstrates that only HNF4α 
overexpression markedly increased average drug transporter expression. This was in 
comparison to the other adenoviral constructs which had no net effect on expression. 
 
 
Figure 5.8: Adenoviral overexpression of HNF4α induces expression of transporters including 
MRP2 and BSEP. Fold mRNA expression of indicated transcripts in adenoviral infected B-13/H cells 
quantified using rat drug transporter array plates. Expression is shown relative to Ad-null infected B-13/H 
cells. Total RNA was produced from B-13/H cells 5 days after infection using TRIzol, which was then 
cleaned up, reverse transcribed and the resulting cDNA used as a template for the rat drug transporter 
arrays. Legend corresponds to which adenovirus construct B-13/H cells were infected with. Results are 
the fold change of single samples from the same experiment. 
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 Ad-null Ad-C/EBPα Ad-HNF1α Ad-HNF4α Ad-LIP ♂ rat liver 
Mean 1.00 2.27 1.50 17.67 1.50 449.22 
SD 0.00 5.55 0.95 108.24 1.37 1641.18 
Table 5.3: Average fold change in expression of all measured transcripts in rat liver or B-13/H cells 
following adenoviral infection relative to Ad-null infected B-13/H cells. 
 
5.6 Co-expression of HNF4α with SGK1F or FOXA2 does not improve drug 
transporter expression 
 
Based on the net increase in drug transporter mRNA expression induced by HNF4α, it 
was hypothesised that co-expression of HNF4α with another transcription factor may 
have a cumulative effect on transporter expression. As C/EBPα, C/EBPβ and HNF1α 
did not induce a net fold increase in the expression of transporter mRNA, the 
transcription factor FOXA2, and kinase SGK1F would be co-overexpressed with 
HNF4α. Forkhead box A2 (FOXA2/ HNF3β) is a transcription factor involved in liver 
specification during development [261]. It is considered a “pioneer” factor in that it 
facilitates access of LETFs to liver specific genes, which would otherwise be 
inaccessible due to significant DNA compaction and lack of co-activator binding [261, 
262]. SGK1F is a human SGK1 isoform, similar to rat SGK1C, whose overexpression 
in B-13 cells is sufficient to initiate transdifferentiation [130].  
 
B-13/H cells were therefore infected with either Ad-null, Ad-HNF4α, Ad-SGK1F 
(encoding SGK1F) or Ad-FOXA2 (encoding FOXA2). Ad-SGK1F and Ad-FOXA2 
were also separately infected in combination with Ad-HNF4α. As previously, infection 
was at an MOI of 2.37 pfu/cell and over 5 days. B-13/H cells infected with Ad-SGK1F 
or Ad-FOXA2 in combination with Ad-HNF4α appeared morphologically the same as 
those infected with Ad-HNF4α alone, which appeared flatter with more cell-cell 
contacts (figure 5.9A). Infection with the adenoviral constructs did not affect hepatocyte 
phenotype as determined by mRNA and protein expression of hepatocyte markers 
(figure 5.9B & C). RT-PCR showed that, as expected, HNF4α overexpression led to 
increased mRNA expression of BSEP and MRP2. Co-overexpression of HNF4α with 
either FOXA2 or SGK1F did not appear to increase the expression of MRP2 or BSEP 
transcripts (figure 5.9B) in comparison with those infected with Ad-HNF4α alone. 
Blotting for HNF4α and SGK1 protein confirmed that adenoviral infection with Ad-
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HNF4α and Ad-SGK1F led to an up-regulation of the respective protein. No specific 
FOXA2 antibody could be identified and therefore expression of transduced hFOXA2 
in Ad-FOXA2 infected B-13/H cells was confirmed by RT-PCR (figure 5.10).  
 
 
Figure 5.9: Adenoviral overexpression of SGK1F or FOXA2 does not enhance transporter 
expression in B-13/H cells. A. Photomicrograph of B-13/H cells 5 days after adenoviral infection. 
Images are at 100x magnification. B. RT-PCR for the indicated transcripts in adenoviral infected B-
13/H cells. Total RNA was extracted from samples 5 days after infection using TRIzol and cDNA 
produced which was used as the template for PCR. Following PCR, samples were separated by agarose 
gel electrophoresis and visualised by UV transillumination. C. Western blotting for liver markers in B-
13 cells, adenoviral infected B-13/H cells and rat liver. Lysates from rat liver, B-13 cells and B-13/H 
cells treated as in A and B, were prepared and quantified by Lowry assay. 20μg of protein/well was 
separated by SDS-PAGE and transferred to a nitrocellulose membrane which was blocked and probed. 
Antibody binding was detected using ECL Western blot substrate. All results are typical of at least 3 
separate experiments. 
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Figure 5.10: RT-PCR for hSGK1F, hFOXA2 and HNF4α in indicated cell samples. Total RNA was 
extracted from samples 5 days after infection using TRIzol and cDNA produced which was used as the 
template for PCR. Following PCR, samples were separated by agarose gel electrophoresis and visualised 
by UV transillumination. 
 
Quantitative measurement of transporter expression showed that, compared to Ad-null 
infected B-13/H cells, cells infected with Ad-HNF4α expressed 691 and 385 fold more 
BSEP and MRP2 mRNA respectively. Cells infected with Ad-HNF4α and Ad-SGK1F 
expressed 796 and 295 fold more BSEP and MRP2 mRNA respectively and those 
infected with Ad-HNF4α and Ad-FOXA2 only 75 and 27 fold more BSEP and MRP2 
mRNA respectively (figure 5.11). Indeed, B-13/H cells infected with Ad-HNF4α and 
Ad-SGK1F had an essentially identical transporter expression profile compared to those 
infected with Ad-HNF4α alone. In comparison, those infected with Ad-HNF4α in 
combination with Ad-FOXA2 showed an intermediate up-regulation of transporters 
when compared with B-13/H cells infected with Ad-HNF4α alone. The average fold 
change in expression of all measured transcripts supports this (table 5.4), as B-13/H 
cells infected with Ad-HNF4α alone, or in combination with Ad-SGK1F, had 
essentially identical average fold changes. In contrast, B-13/H cells infected with Ad-
HNF4α in combination with Ad-FOXA2 had an average fold change of more than 3.5 
fold less. 
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Figure 5.11: Adenoviral overexpression of SGK1F or FOXA2 does not increase drug transporter 
expression. Fold mRNA expression of indicated transcripts in adenoviral infected B-13/H cells quantified 
using rat drug transporter array plates. Expression is shown relative to Ad-null infected B-13/H cells. 
Total RNA was produced from B-13/H cells 5 days after infection using TRIzol, which was then cleaned 
up, reverse transcribed and the resulting cDNA used as a template for the rat drug transporter arrays. 
Legend corresponds to which adenovirus construct(s) B-13/H cells were infected with. Results are the 
fold change of single samples from the same experiment. 
 
 
Ad-
null 
Ad-
HNF4α 
Ad-
SGK1F 
Ad-
FOXA2 
Ad-HNF4α 
+ Ad-
SGK1F 
Ad-
HNF4α + 
Ad-
FOXA2 
♂ rat 
liver 
Mean 1.00 25.42 1.58 1.65 25.33 6.79 1409.15 
SD 0 105.19 1.37 2.98 105.85 22.39 5918.45 
Table 5.4: Average fold change in expression of all measured transcripts in B-13/H cells infected 
with different adenovirus constructs alone or in combination relative to Ad-null infected cells 
 
To determine if increased mRNA expression of transporters led to increased protein 
expression, Western blotting for MRP2 and NTCP was carried out (figure 5.12). MRP2 
protein was detectable in Ad-HNF4α, and Ad-HNF4α and Ad-SKG1F infected B-13/H 
cells, but not in any other samples. This corresponded well to the matching increases in 
MRP2 mRNA expression seen in these 2 samples. As expected, no change in NTCP 
protein expression was seen following adenoviral infection of B-13/H cells as it was 
undetectable in all samples. Attempts were made to measure BSEP protein but the 2 
different primary antibodies tried were found to be too non-specific for reliable 
measurement. 
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Figure 5.12: Western blot for MRP2 and NTCP in B-13 cells, adenoviral infected B-13/H cells and 
rat liver. Lysates from B-13/H cells infected for 5 days with the indicated adenovirus, B-13 cells and rat 
liver were prepared and quantified by Lowry assay. 20μg of protein/well was separated by SDS-PAGE 
and transferred to a nitrocellulose membrane which was blocked and probed. Antibody binding was 
detected using ECL Western blot substrate. MRP2 blot is typical of 4 separate experiments. 
 
5.7 Ad-HNF4α infected B-13/H cells show significantly increased MDR and BCRP 
activity. 
 
To determine the effect of Ad-HNF4α infection on B-13/H transporter activity, the 
activity of MDR, BCRP, MRP and BSEP was analysed using dye retention assays as 
outlined in the methods. The assays were carried out using the dyes H33342, CMFDA 
and H2FDA.  
 
H33342 is a fluorescent dye which, like DAPI, fluoresces when bound to double 
stranded DNA and is effluxed from cells by MDR and BCRP. Cyclosporin A (CsA), at 
low concentrations (<10μM), inhibits MDR but not BCRP, allowing it to be used in 
combination with H33342 to determine MDR activity [263, 264]. Ko143 is a specific 
BCRP inhibitor meaning it can be used to determine the role of BCRP on H33342 
efflux [265]. CMFDA is a non-fluorescent compound which, once it diffuses into cells, 
is conjugated to glutathione and cleaved by intracellular esterase to 5-
chloromethylfluorescein, which is fluorescent and a substrate of MRP transporters 
[266]. The conjugation of CMFDA prevents its passive diffusion from the cell. Use of 
MK571, a specific MRP inhibitor [267], allows the relative activity of MRP transporters 
to be determined when used in conjugation with CMFDA. H2FDA is, like CMFDA, a 
non-fluorescent compound, which is cleaved by intracellular esterases to a fluorescent 
product. The fluorescent product is a substrate of BSEP [268]. No specific cell 
permeable BSEP inhibitors are commercially available. To measure BSEP activity 
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therefore, cells were treated with H2FDA in tandem with compounds which are known 
to inhibit BSEP, which were glibenclamide and troglitazone [269]. 
 
The results of the dye retention assays are shown in figure 5.13. Ad-null infected B-
13/H cells showed significant retention of H33342 in response to CsA, indicative of 
MDR activity (figure 5.13A). This retention was significantly greater in Ad-HNF4α 
infected cells. Similar findings were seen in terms of BCRP activity. Ad-null infected 
B-13/H cells showed significant retention of H33342 following treatment with the 
BCRP inhibitor Ko143 (figure 5.13B). B-13/H cells infected with Ad-HNF4α however 
showed significantly greater retention when incubated with Ko143 compared to B-13/H 
cells infected with Ad-null. There was no difference in CMFDA retention in the 
presence or absence of the MRP inhibitor MK571, between B-13/H cells infected with 
Ad-null or those infected with Ad-HNF4α (figure 5.13C), suggesting that there was no 
difference in MRP activity. However, both Ad-null and Ad-HNF4α infected cells 
showed significantly increased fluorescence when treated with CMFDA and MK571 
compared to those treated with CMFDA alone, indicating that B-13/H cells express 
functional MRP transporters.  
 
Retention of H2FDA was significantly increased in B-13/H cells infected with Ad-null 
or Ad-HNF4α in response to BSEP inhibitors glibenclamide or troglitazone (figure 
5.13D). The degree of retention was equivalent between Ad-null and Ad-HNF4α 
infected cells suggesting that HNF4α overexpression had no effect on BSEP activity. 
Reaction of reactive oxygen species (ROS) with H2FDA causes fluorescence, meaning 
H2FDA is often used for measuring ROS production in cells [270]. To confirm that the 
increased fluorescence in troglitazone and glibenclamide treated B-13/H cells was from 
retention of H2FDA fluorescent metabolites and not from ROS production, B-13/H cells 
were treated with menadione, which causes ROS production through redox cycling 
[271], alongside the BSEP inhibitors. Treatment with 50μM menadione had no effect on 
fluorescence. This suggests that in these experiments, under the conditions used, that 
increased fluorescence following troglitazone and glibenclamide treatment was from 
inhibition of H2FDA metabolite efflux, not ROS production. 
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Figure 5.13: HNF4α overexpression significantly increases MDR and BCRP, but not MRP or BSEP 
activity. A. MDR activity in Ad-null and Ad-HNF4α infected B-13/H cells. Dye retention assay using 
H33342 as the dye and CsA as the inhibitor. B. BCRP activity in Ad-null and Ad-HNF4α infected B-
13/H cells. Dye retention assay using H33342 as the dye and Ko143 as the inhibitor. C. MRP activity in 
Ad-null and Ad-HNF4α infected B-13/H cells. Dye retention assay using CMFDA as the dye and 
MK571 as the inhibitor. D. BSEP activity in Ad-null and Ad-HNF4α infected B-13/H cells. Dye 
retention assay using H2FDA as the dye and indicated compounds as the inhibitors. For A-D, vales are 
expressed as the mean difference in fluorescence relative to vehicle controls (set at 100%) and SD. 
Retention assays were carried out on B-13/H cells infected for 5 days with either Ad-null or Ad-HNF4α. 
For A and C, results are the mean and SD of 15 independent determinations from 5 separate experiments. 
For B and D, results are the mean and SD of 9 independent determinations from 3 separate experiments. 
For A-C, *significant difference between the indicated groups at p<0.05. In D, *significant difference 
compared to respective vehicle control at p<0.05. 
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5.8 Chapter discussion 
 
The interaction of drugs and their metabolites with hepatic transporters has historically 
been the cause of drug attrition during the late stages of clinical testing or after release, 
such as in the case of troglitazone [241], with significant financial consequences. These 
interactions are difficult to determine in-vitro due to the substrate promiscuity of 
transporters and the complex interactions between hepatic drug uptake/export and drug 
modifying enzymes [81]. Due to the difficulties of maintaining hepatocyte DME 
expression, including transporters, in culture, the potential of B-13/H cells as a model 
for assessment of hepatic transporter-drug interactions was investigated. 
 
Measurement of drug transporter expression in B-13 and B-13/H cells showed that, 
although the expression of several transporters such as MDRs and some MRPs was 
similar or greater in B-13/H cells at the level of mRNA compared to rat liver, the 
mRNA expression of many others including BSEP and MRP2 was more than 10,000 
fold lower. Consequently, it was hypothesised that modification of culture conditions 
would cause an up-regulation of transporter expression. However, culture of B-13/H 
cells on different substrata (alvetex or PU134) had no marked effect on transporter 
mRNA expression. 
 
Hepatocyte transporter expression is regulated by a number of LETFs. Adenoviral 
based overexpression of B-13/H cells with selected LETFs showed that hepatocyte 
phenotype was broadly unchanged by LETF overexpression in terms of albumin, CPS-1 
and CYP2E1 expression. However, B-13/H cells infected with Ad-HNF4α showed an 
up-regulation in the mRNA expression of several transporters including BSEP and 
MRP2, not seen when any of the other LETFs were overexpressed. No evidence 
suggests that HNF4α directly regulates the expression of BSEP and MRP2 and 
knockout of HNF4α has no effect on BSEP or MRP2 expression [272]. However, the 
PXR and CAR do regulate transcription of a number of transporters including BSEP 
and MRP2, and HNF4α has been documented to potentiate PXR and CAR mediated-
transactivation [61, 273-275]. This may explain the documented up-regulation of PXR 
and CAR regulated transporters including BSEP and MRP2 in Ad-HNF4α infected B-
13/H cells. In terms of other up-regulated transporters, HNF4α knockout represses 
expression of several transporters including BCRP and OCT1 [272], which were up-
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regulated in Ad-HNF4α infected B-13/H cells. This suggests that HNF4α positively 
regulates the expression of a number of transporters including BCRP and OCT1 and 
explains the documented up-regulation in Ad-HNF4α infected B-13/H cells. 
 
Co-overexpression of HNF4α with either SGK1F or FOXA2 did not enhance 
transporter mRNA expression. In fact, FOXA2 co-overexpression with HNF4α 
attenuated the induction in transporter expression seen when HNF4α was overexpressed 
alone. Although it has homeostatic regulatory roles in the adult liver, arguably the most 
important biological role of FOXA2 is in the hepatic specification of foregut endoderm 
during development, as targeted deletion of FOXA2 and FOXA1 in murine embryonic 
endoderm tissue is embryonic lethal due to the failure of liver development [261, 276]. 
This response is not seen in mice with deletion of FOXA1 or FOXA2 alone, presumably 
due to functional redundancy owing to the overlapping sequence affinity between 
FOXA family members. The overexpression of FOXA2, in Ad-FOXA2 infected B-
13/H cells, may therefore promote a more plastic phenotype and an associated reduction 
in the expression of specific adult hepatocyte associated markers such as transporters. 
Alternatively, as the expression of adult hepatocyte markers albumin, CPS-1 and 
CYP2E1 were unaffected by FOXA2 overexpression in B-13/H cells, the antagonistic 
effect of FOXA2 on HNF4α overexpression may be due to direct interaction inhibiting 
HNF4α mediated transactivation. This is plausible considering that 
immunoprecipitation studies confirm that FOXA2 does interact with HNF4α [277].  
 
Dye retention assays to determine MDR, BCRP, MRP and BSEP activity in Ad-null and 
Ad-HNF4α infected B-13/H cells showed that only MDR and BCRP activity were 
significantly increased by HNF4α overexpression. The increase in BCRP activity was 
consistent with the BCRP qPCR results, which showed that Ad-HNF4α infection was 
associated with an increase in BCRP mRNA expression. MDR mRNA expression was 
conversely not consistently increased so the difference documented may be due to 
inhibition of transporters, which also efflux H33342, other than MDR by CsA. The lack 
of difference in MRP activity between Ad-null and Ad-HNF4α infected B-13/H cells 
may be because B-13/H cells overexpressing HNF4α showed an up-regulation of MRP2 
mRNA and protein, but reduced mRNA expression of MRP1 and MRP4-5. Considering 
that other MRP proteins may transport CMFDA, reduced transport by MRP1 and 
MRP4-5 may mask increased MRP2 activity. An MRP2 specific inhibitor would allow 
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for the activity of MRP2 alone to be determined, however no specific inhibitor is 
currently commercially available. 
 
The H2FDA retention assays suggested that there was no difference in BSEP activity 
between Ad-null and Ad-HNF4α infected B-13/H cells. The cause for the lack of effect 
may be that, although BSEP mRNA expression was strongly induced in Ad-HNF4α 
infected B-13/H cells relative to Ad-null infected B-13/H cells, its relative expression 
was still more than 10-100 fold less than that expressed in the liver. The induction 
therefore may not have been sufficient to see a difference. Alternatively, no difference 
between Ad-null or Ad-HNF4α infected cells may have been observed because HNF4α 
induced BSEP mRNA was not translated and/or de-novo BSEP protein was not targeted 
to the plasma membrane. BSEP, like many other membrane localised proteins, cycles 
between the plasma membrane and endosomes in the cell [278]. Tauroursodeoxycholic 
has been shown to enhance targeting of BSEP to the plasma membrane and could, in 
combination with HNF4α overexpression, improve BSEP activity and therefore H2FDA 
retention [279].  
 
The data in this chapter demonstrates that B-13/H cells express a number of drug 
transporters but only a selection are expressed at mRNA levels equivalent to that seen in 
intact liver. Several physiologically important transporters were barely expressed, 
including bile acid transporters NTCP and BSEP. Of all approaches undertaken, only 
adenoviral mediated overexpression of HNF4α resulted in a major change in transporter 
expression. However, although the activity of BCRP and MDR proteins was 
significantly increased following adenoviral infection, the activity of MRP proteins and 
BSEP under the conditions tested was not affected. The data overall suggests that, 
although B-13/H cells do not express a liver equivalent pattern of transporters as 
originally hypothesised, they could still be used as a model for particular transporters 
including BCRP, MDR, BSEP and MRP, with a phenotype improved by HNF4α 
overexpression. Study of MRP2 specific function requires the identification of an 
MRP2 specific inhibitor and improved study of BSEP function may require further 
investigation to improve BSEP transcription and/or targeting to the plasma membrane.  
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Chapter 6. Chronic administration of MP causes reversible and 
modulatable periportal fibrosis comparable to BDL 
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6.1 Introduction 
 
Chronic liver damage results in hepatic fibrosis that restricts liver regeneration and 
facilitates the development of cirrhosis, hepatocellular carcinoma and ultimately liver 
failure [16]. Hepatic fibrosis cannot be pharmacologically treated and it is largely 
responsible for the significant morbidity and mortality caused by liver disease 
worldwide [138]. There is therefore an ongoing utilisation of animal models of liver 
fibrosis to aid in the development of novel anti-fibrogenic drugs. Due to the differences 
in fibrogenesis in different regions of the liver lobule, as discussed in the introduction, 
prior to toxicity screening and initiation of clinical trials, the efficacy of novel anti-
fibrogenic drugs should be determined in a periportal and centrilobular model of 
fibrosis [5, 16].  
 
BDL is a surgical procedure involving the double ligation of the common bile duct as 
outlined in the introduction. It is the most frequently used model of periportal fibrosis 
and gives rise to cholestatic liver injury, causing robust activation of portal tract 
fibroblasts, hepatic stellate cells and a ductular reaction, all leading to development of 
portal-portal bridging fibrosis [161, 280, 281]. The procedure however has associated 
animal welfare issues. The ligation operation requires a degree of expertise and the 
surgery, together with the severity of the procedure, frequently results in a significant 
level of mortality [280, 282]. This restricts the long term use of BDL animals (generally 
no longer than 4 weeks [283]). The procedure can be reversed; however this requires 
further surgery and due to the associated risks and costs, including to animal welfare, is 
unlikely to occur. Under the Animals (Scientific Procedures) Act 1986 it is therefore 
classified as a “substantial” procedure due to its severity. 
 
The H1 receptor antagonist methapyrilene (MP) [N,N-dimethyl-N’-Pyridyl-N’(2-
thienylmethyl)-1,2-ethanediamine] was used clinically as a sedative and antihistamine 
in the late 1970s. It was withdrawn from use when rats chronically administered MP 
showed development of hepatocellular carcinomas [284]. Subsequent work has 
demonstrated that its carcinogenic effect appears not to be due to genotoxicity. Rather, 
studies have shown that MP is a periportal hepatotoxin in rats and its administration 
leads to hepatic damage [196, 285-292]. Specifically, MP is bioactived in the liver by 
CYP450 activity leading to the production of a reactive intermediate (potentially a 
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thioether of MP S-oxide, figure 6.1) [196, 293]. The intermediate(s) are thought to 
disrupt mitochondria through opening of mitochondrial pores leading to mitochondrial 
depolarisation and Ca
2+ 
loss. This causes hepatocyte apoptosis and necrosis and 
consequently hepatic inflammation [196, 291, 294]. 
 
 
Figure 6.1: Main MP metabolites produced in-vitro by male primary rat hepatocytes. The indicated 
CYP450s have been shown to catalyse the designated reactions in enzymatic incubations in-vitro. Starred 
is the S-oxide thioether implicated in MP cytotoxicity. The glutathione adduct of MP is M8. Adapted 
from Graham et al., (2008) [293] 
 
Based on the observation that MP causes periportal hepatic damage, it was hypothesised 
that the chronic dosing of MP to rats would provide a more controllable reversible 
periportal fibrosis. The fibrosis generated in rats by MP treatment and BDL was 
therefore compared. Fibrosis in male Sprague-Dawley rats was generated by the chronic 
administration of MP, as outlined in table 6.1, at a dose of 150mg/kg 3 times per week 
for 3 or 6 weeks. In order to investigate the reversal of fibrosis, one group of rats was 
dosed with MP for 3 weeks followed by vehicle for 3 weeks. The dose of MP used was 
chosen based on pilot work [3]. 
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Group Treatment 
T0 
(Control) 
Culled at initiation of study 
3 week MP  
(3wk MP) 
Dosed with 150mg/kg MP 3 times per week for 3 weeks 
6 week MP 
(6wk MP) 
Dosed with 150mg/kg MP 3 times per week for 6 weeks 
3 week MP/ 3 week 
vehicle 
(3wk MP/ 3wk veh.) 
Dosed with 150mg/kg MP 3 times per week for 3 weeks then with vehicle (PBS) 
3 times per week for 3 weeks 
MP was made up 1 x PBS (150mg MP/1ml) and dosed by oral gavage (1ml/kg) 
Table 6.1: MP dosing regime 
 
6.2 Chronic administration of MP significantly inhibits weight gain 
 
All rats chronically dosed with MP gained weight over the course of the study. At 3 
weeks, rats that began to receive vehicle began gaining weight at an accelerated rate 
compared to rats that continued to receive MP (figure 6.2). At termination (day 42), 
vehicle treated rats were significantly heavier than their MP treated counterparts 
indicating that MP inhibited weight gain. All MP treated rats also showed a 
significantly higher liver to body weight ratio than controls, indicating that MP 
significantly increased liver weight in treated animals. Importantly, the chronic dosing 
of MP caused no mortalities and treated rats did not appear to be in any distress. 
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Figure 6.2: MP treatment inhibits weight gain and increases relative liver size. A. Effect of MP 
treatment on body weight. Arrow indicates half way point of study. B. Liver weight as percentage 
body mass at harvest. For A, *indicates significant difference in weight between the indicated groups 
and for B, *indicates significant difference compared to T0 control both at p<0.05. For A and B, data are 
the mean and SD of the following animal numbers- for control, n=3; for 3wk MP and 3wk MP/3 wk 
vehicle, n=5 and for 6 wk MP, n=6. 
 
6.3 Administration of MP causes significant and reversible portal tract 
inflammation 
 
Liver sections from MP treated and control animals were stained with H&E and 
compared to liver sections from rats culled 14 days after BDL surgery (BDL liver tissue 
donated by Jelena Mann). Control animals showed occasional infiltrating leukocytes in 
the periportal region whereas both MP and BDL treated rats showed a marked 
significant increase in the number of periportal inflammatory cells (figure 6.3). The 
inflammation seen after 3 weeks of MP treatment was equivalent and not significantly 
different to that seen after 6 weeks of MP treatment or BDL. In the livers of animals 
that received MP for 3 weeks followed by vehicle for 3 weeks, portal tract inflammation 
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was no longer significant indicating that ceasing MP dosing led to a reversal of hepatic 
inflammation.  
 
MP becomes toxic through its bioactivation by CYP450s [196]. Although the liver is 
the major organ of xenobiotic clearance, the kidney also has some xenobiotic 
metabolising activity, due to expression of some CYP450s [295]. Kidney sections were 
therefore also H&E stained to determine if MP induced toxicity was localised to the 
liver (figure 6.3). The staining and subsequent analysis of kidney sections showed that 6 
weeks of MP treatment caused no discernible changes to kidney pathology, indicating 
that MP toxicity was likely restricted to the liver.  
 
To further establish the specificity of MP to the liver, the lungs and spleen were also 
stained with H&E (figure 6.4) and this indicated that they too were unaffected, at least 
at the microscopic level, by chronic MP treatment. 
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Figure 6.3: MP treatment and 14 day BDL cause periportal inflammation. A. H&E stained sections 
of rat liver and kidney tissue after the indicated treatment. Liver and kidney fixed in 10% formalin 
and paraffin embedded was cut into 5μm sections. Sections were dewaxed and rehydrated and stained 
with H&E prior to dehydration, mounting and analysis using a Leica upright microscope. Images are 
representative of groups and scale bar indicates 100μm. Note, control is from the T0 control group, which 
had an identical histopathological appearance to sections from sham BDL operated rats, hence only one 
view is shown and referred to as control. Abbreviations: pt, portal tract; cv, central vein. B. Quantified 
mean number of periportal inflammatory cells. The mean number of inflammatory cells in and around 
5 random portal tracts was determined by an examiner blinded to the treatment groups, per section per 
animal. Data are the mean and SD of the following animal numbers - for control, n=3; for 3wk MP, 3wk 
MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL, n=8. *significant difference compared 
to the respective control group, 
$
significant difference compared to the 3 week MP/3 week vehicle group 
both at p<0.05. 
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Figure 6.4: MP causes liver specific injury. H&E stained lung and spleen from control or 6 week MP 
treated rats. Lung and spleen fixed in 10% formalin and paraffin embedded were cut into 5μm sections. 
Sections were dewaxed and rehydrated and stained with H&E prior to dehydration, mounting and analysis 
using a Leica upright microscope. Scale bar indicates 100μm. 
 
6.4 MP treatment causes activation of hepatic regeneration pathways  
 
The liver has significant regenerative capacity after injury and is able to fully regenerate 
mass and function when as much as 70% is irreversibly lost [16, 296]. The sources of 
parenchymal cells during regeneration are hepatic bipotent progenitor cells and 
undamaged hepatocytes that are induced to divide to replace damaged cells. 
 
To determine the effect of the different MP dosing regimens on hepatic regeneration, 
proliferating cell nuclear antigen (PCNA) was immunostained in the liver sections. 
PCNA forms part of the DNA replication machinery required for DNA replication in S-
phase. It can therefore be used as a marker of cellular proliferation [297]. The staining 
and subsequent quantification (figure 6.5) showed that the administration of MP for 3 
weeks caused a significant increase in cholangiocyte PCNA expression. Conversely, 
rats that received MP for 6 weeks showed a significant increase in both periportal 
hepatocyte and cholangiocyte PCNA expression as seen in rats that had undergone 
BDL. The induction of cholangiocyte and hepatocyte division suggests that in MP 
treated and BDL rats, the liver was sufficiently damaged to induce cholangiocytes and 
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hepatocytes to divide to replace damaged cells. The animals that received MP for 3 
weeks followed by vehicle for 3 weeks showed neither significant periportal hepatocyte 
nor cholangiocyte PCNA expression, suggesting that liver regeneration was complete. 
 
6.5 MP administration causes expansion of hepatic pro-fibrogenic cell populations 
 
Hepatic fibrogenesis is dependent upon the deposition of ECM by (myo)fibroblasts, 
several different populations of which are involved in fibrogenesis with varying 
contributions [16]. Portal tract fibroblasts, although their contribution to fibrogenesis is 
currently controversial, proliferate and activate in response to periportal injury and are 
an identifying characteristic of periportal fibrosis [6, 161].  
 
To determine the effect of MP on hepatic portal tract fibroblast populations, liver 
sections were examined for vimentin expression, which is expressed by portal tract 
fibroblasts [298]. The expression of vimentin, as illustrated in figure 6.6, appeared to be 
evenly spread throughout the lobule in control animals. In those animals treated with 
MP or subject to BDL however, vimentin staining of periportal regions was 
significantly increased. This implies that MP treatment, like BDL, caused an expansion 
of portal tract fibroblasts as has been documented during periportal fibrogenesis [161]. 
Rats that received MP for 6 weeks showed significantly more periportal vimentin 
staining than rats that received MP for only 3 weeks and rats that were treated with MP 
for 3 weeks followed by vehicle for 3 weeks did not show significant periportal 
vimentin staining.  
 
Myofibroblasts express α-SMA and are responsible for the majority of ECM deposition 
during fibrogenesis [5, 147]. α-SMA is therefore a commonly used biomarker of hepatic 
fibrosis. In control rat liver sections, only smooth muscle cells surrounding portal 
arterioles stained positive for α-SMA (figure 6.7). In MP treated and BDL rat liver 
sections, a significant increase in periportal α-SMA staining was observed. Liver 
sections of rats treated with MP for 6 weeks showed significantly more periportal α-
SMA staining than rats treated for only 3 weeks. Similar to periportal vimentin staining, 
the significant increase in periportal α-SMA staining seen in rats after 3 weeks of MP 
treatment was reversible after 3 weeks of vehicle treatment. 
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Figure 6.5: 6 weeks chronic MP treatment and 14 day BDL cause hepatocyte and cholangiocyte 
proliferation. A. Rat liver sections immunostained for PCNA after the indicated treatment. Liver 
fixed in 10% formalin and paraffin embedded was cut into 5μm sections. Sections were dewaxed, 
rehydrated and endogenous peroxidases blocked. Sections were then subject to trypsin-based antigen 
retrieval and serum blocking then immunostained for PCNA using DAB to detect bound antibody. 
Sections were then stained with haematoxylin prior to dehydration, mounting and analysis using a Leica 
upright microscope. Images are representative of groups and scale bar indicates 100μm. Note, control is 
from the T0 control group, which had an identical histopathological appearance to sections from sham 
BDL operated rats, hence only one view is shown and referred to as control. B. Quantification of 
periportal PCNA positive hepatocytes and cholangiocytes. The mean number of PCNA positive 
hepatocytes and cholangiocytes in and around 5 random portal tracts was determined by an examiner 
blinded to the treatment groups, per section per animal. Data are mean and SD of the following animal 
numbers - for control, n=3; for sham, n=4; for 3wk MP, 3wk MP/3 wk vehicle, n=5; for 6wk MP, n=6; 
and for BDL, n=8. *significant difference compared to the respective control group at p<0.05.  
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Figure 6.6. Chronic MP treatment and 14 day BDL cause a significant increase in periportal 
vimentin staining. A. Rat liver sections immunostained for vimentin after the indicated treatment. 
Liver fixed in 10% formalin and paraffin embedded was cut into 5μm sections. Sections were dewaxed, 
rehydrated and endogenous peroxidases blocked. Sections were then subject to sodium citrate antigen 
retrieval and serum blocking then immunostained for vimentin using DAB to detect bound antibody. 
Sections were then stained with haematoxylin prior to dehydration, mounting and analysis using a Leica 
upright microscope. Images are representative of groups and scale bar indicates 100μm. Note, control is 
from the T0 control group, which had an identical histopathological appearance to sections from sham 
BDL operated rats, hence only one view is shown and referred to as control. B. Quantified vimentin 
labelling of periportal regions. Vimentin staining was quantified using Qwin software: the percentage of 
periportal regions staining positive for vimentin was calculated around 10 random portal tracts per section 
per animal by an examiner blinded to the treatment groups. Values are expressed relative to respective 
controls. Data are the mean and SD of the following animal numbers - for control, n=3; for 3wk MP, 3wk 
MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL n=8. *significant difference compared 
to the respective control group, 
$
significant difference compared to the 3 week MP/3 week vehicle group 
and 
£
significant difference compared to the 3 week MP group all at p<0.05. 
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Figure 6.7. Chronic MP treatment and 14 day BDL cause a significant increase in periportal α-
SMA staining. A. Rat liver sections immunostained for α-SMA after the indicated treatment. Liver 
fixed in 10% formalin and paraffin embedded was cut into 5μm sections. Sections were dewaxed, 
rehydrated and endogenous peroxidases blocked. Sections were then subject to sodium citrate antigen 
retrieval and serum blocking then immunostained for α-SMA using DAB to used to detect bound 
antibody. Sections were then stained with haematoxylin prior to dehydration, mounting and analysis 
using a Leica upright microscope. Images are representative of groups and scale bar indicates 100μm. 
Note, control is from the T0 control group, which had an identical histopathological appearance to 
sections from sham BDL operated rats, hence only one view is shown and referred to as control. B. 
Quantified α-SMA labelling of periportal regions. α-SMA staining was quantified using Qwin 
software: the percentage of periportal regions staining positive for α-SMA was calculated around 10 
random portal tracts per section per animal by an examiner blinded to the treatment groups. Values are 
expressed relative to respective controls. Data are the mean and SD of the following animal numbers - for 
control, n=3; for 3wk MP, 3wk MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL, n=8. 
*significant difference compared to the respective control group, 
$
significant difference compared to the 3 
week MP/3 week vehicle group and 
£
significant difference compared to the 3 week MP group all at 
p<0.05.  
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6.6 MP administration causes significant and reversible periportal fibrosis 
 
To determine the severity of fibrosis in rats chronically dosed with MP, sirius red 
staining (which stains for collagen) was carried out on liver sections. This showed that 
both MP treatment and BDL induced significant periportal fibrosis compared to controls 
(figure 6.8). Prolonged treatment with MP (6 weeks) led to a significant increase in 
periportal fibrosis compared to that seen after 3 weeks of MP treatment or 14 day BDL. 
The increase in periportal fibrosis after 3 weeks of MP treatment was reversible because 
the rats treated with MP for 3 weeks followed by vehicle for 3 weeks no longer showed 
significant periportal collagen deposition. Central veins appeared similar in MP treated 
and control animals indicating that MP primarily caused periportal damage and fibrosis. 
 
Assessment of whole liver fibrosis showed that administration of MP, like BDL, caused 
a significant increase in whole lobule collagen deposition (figure 6.9A). Administration 
of MP for 6 weeks did increase collagen deposition compared to only 3 weeks but the 
difference was not significant. Similar to when collagen deposition was measured 
around periportal regions, 3 weeks of MP treatment followed by 3 weeks of vehicle 
treatment did not lead to a significant increase in whole liver collagen deposition. As 
shown in figure 6.9B, assessment of hepatic hydroxyproline content, which is a 
quantitative measure of fibrosis severity [183], gave similar results to the whole liver 
sirius red measurement. Specifically, 3 and 6 weeks of MP administration caused a 
significant increase in liver hydroxyproline content whereas the group that received MP 
for 3 weeks followed by vehicle for 3 weeks did not show a significant difference in 
hepatic hydroxyproline content. Unfortunately the effect of 14 day BDL on liver 
hydroxyproline content could not be measured for comparison due to a shortage of liver 
tissue.  
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Figure 6.8. Chronic MP treatment and 14 day BDL cause significant periportal fibrosis. A. Rat 
liver sections stained with sirius red after the indicated treatment. Liver fixed in 10% formalin and 
paraffin embedded was cut into 5μm sections. Sections were dewaxed and rehydrated and stained with 
picrosirius red prior to dehydration, mounting and analysis using a Leica upright microscope. Images are 
representative of groups and scale bar indicates 400μm. Note, control is from the T0 control group, which 
had an identical histopathological appearance to sections from sham BDL operated rats, hence only one 
view is shown and referred to as control. B. Quantified sirius red staining of periportal fibrosis. Sirius 
red staining was quantified using Qwin software: the percentage of periportal regions staining positive for 
sirius red was calculated around 10 random portal tracts per section per animal by an examiner blinded to 
the treatment groups. All individual readings are shown, lower lines are the means and the upper lines are 
the SD. Values are expressed relative to respective controls. *significant difference compared to the 
respective control group, 
£
significant difference compared to the 3 week MP group (all p<0.05) and 
†
significant difference compared to the 14d BDL group. Animal numbers - for control, n=3; for 3wk MP, 
3wk MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL, n=8. 
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Figure 6.9: Chronic MP treatment and BDL cause significant hepatic fibrosis. A. Quantification of 
sirius red staining. Sirius red stained liver sections were scanned using a Leica SCN400 slide scanner 
and once scanned the liver masked to exclude large vessels. Analysis of whole liver staining was then 
carried out using optimised settings. B. Liver hydroxyproline content following the indicated 
treatments. Frozen liver tissue was weighed and acid hydrolysed before calculation of hydroxyproline 
content. Results were normalised to protein concentration calculated by Lowry assay. For A, data are 
expressed relative to respective controls and for A and B, data are the mean and SD of the following 
animal numbers - for control, n=3; for 3wk MP, 3wk MP/3 wk vehicle and sham (A only), n=5; for 6wk 
MP, n=6; and for BDL (A only), n=8. *significant difference compared to respective control group at 
p<0.05. 
 
6.7 MP treatment causes a ductular reaction 
 
Ductular reaction is a regenerative response involving the proliferation of a hepatic 
bipotent progenitor population (“oval cells” in rats) which can differentiate into 
cholangiocytes or hepatocytes. It is also thought to play an important role in 
fibrogenesis [4]. Oval cells have a cholangiocyte phenotype and express CK-19. MP 
treatment and BDL significantly increased periportal CK-19 staining (figure 6.10) 
indicating that they both caused a ductular reaction. The reaction was significantly more 
severe after 6 weeks than 3 weeks of MP treatment and the significant increase seen 
after 3 weeks of MP treatment was reversible after 3 weeks of vehicle treatment. 
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Figure 6.10: Chronic MP treatment and 14 day BDL cause activation of a ductular reaction. A. Rat 
liver sections stained with CK-19 after the indicated treatment. Liver fixed in 10% formalin and 
paraffin embedded was cut into 5μm sections. Sections were dewaxed, rehydrated and endogenous 
peroxidases blocked. Sections were then subject to sodium citrate antigen retrieval and serum blocking 
then immunostained for CK-19 using DAB to detect bound antibody. Sections were then stained with 
haematoxylin prior to dehydration, mounting and analysis using a Leica upright microscope. Images are 
representative of groups and scale bar indicates 100μm. Note, control is from the T0 control group, which 
had an identical histopathological appearance to sections from sham BDL operated rats, hence only one 
view is shown and referred to as control. B. Quantified CK-19 labelling of liver sections. CK-19 
staining was quantified using Qwin software: the percentage of periportal regions staining positive for 
CK-19 was calculated around 10 random portal tracts per section per animal by an examiner blinded to 
the treatment groups. Values are expressed relative to respective controls. Data are the mean and SD of 
the following animal numbers - for control, n=3; for 3wk MP, 3wk MP/3 wk vehicle and sham, n=5; for 
6wk MP, n=6; and for BDL, n=8. *significant difference compared to the respective control group, 
$
significant difference compared to the 3 week MP/3 week vehicle group and 
£
significant difference 
compared to the 3 week MP group all at p<0.05. 
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6.8 MP treatment significantly up-regulates expression of fibrosis-associated 
markers 
 
To further characterise how chronic MP treatment and its withdrawal affects the liver, 
the expression of fibrogenesis associated genes was measured using qPCR (table 6.2). 
In support of the histology, administration of MP for 3 and 6 weeks was associated with 
the significant up-regulation of α-SMA, COL1A1 and vimentin mRNA expression 
similar to that seen after BDL. TGF-β1 is a key pro-fibrogenic growth factor produced 
by inflammatory leukocytes during fibrogenesis that promotes ECM deposition by 
myofibroblasts [5]. Chronic dosing of MP led to the significant up-regulation of TGF-
β1 mRNA expression to similar levels to that seen after BDL. Similarly, the hepatic 
mRNA expression of TGF-β2, another TGF isoform also implicated in promotion of 
fibrosis, was significantly increased after 6 weeks of chronic MP treatment. 
 
Fibrosis occurs due to an imbalance in deposition of ECM versus its degradation. 
However, enhanced breakdown of ECM can be pro-fibrogenic by releasing pro-
fibrogenic ECM bound growth factors and by enhancing motility of pro-fibrogenic cell 
types (eg. myofibroblasts and leukocytes). Matrix metalloproteinase-2 (MMP-2) is a 
myofibroblast derived matrix metalloproteinase that is generally considered pro-
fibrogenic [5, 299] and its mRNA expression was significantly up-regulated following 6 
weeks of MP treatment, but not 3 weeks of MP treatment or BDL. Tissue inhibitor of 
metalloproteinase-1 (TIMP-1) is part of the tissue inhibitor of metalloproteinase family 
which competitively inhibit the matrix metalloproteinases; they promote fibrogenesis 
through inhibition of ECM remodelling and inhibition of apoptosis of activated hepatic 
stellate cells [5]. The expression of TIMP-1 mRNA was significantly increased 
following MP treatment and BDL. Importantly, in terms of reversal of MP induced 
hepatic fibrosis, for all the markers of fibrogenesis measured, the rats treated with MP 
for 3 weeks followed by vehicle for 3 weeks showed reversion of mRNA expression to 
control levels. This is in agreement with the histology and suggests that after 3 weeks of 
vehicle treatment the hepatic injury caused by 3 weeks of MP treatment was essentially 
repaired. 
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Group mRNA transcript (fold control levels)  
 α-SMA COL1A1 MMP-2 TGF-β1 TGF-β2 TIMP-1 Vimentin  
        
Control 1 ± 0.24 1 ± 0.24 1 ± 0.89 1 ± 0.23 1 ± 0.47 1 ± 0.85 1 ± 0.33  
3wk MP 2.19 ± 0.47* 3.26 ± 2.1* 1.87 ± 1.22 2.82 ± 0.56* 2.05 ± 1.79 3.46 ± 2.34* 2.18 ± 1.21*  
6wk MP 4.84 ± 6.63* 4.03 ± 6.43* 4.62 ± 6.41* 3.97 ± 3.7* 3.82 ± 3.89* 7.8 ± 15.56* 3.42 ± 2.62*  
3wk MP/3 wk veh. 1.01 ± 0.26 1.39 ± 0.78 2.12 ± 1.05 1.28 ± 0.38 0.88 ± 0.3 1.14 ± 0.33 0.68 ± 0.27  
14d BDL 3.88 ± 1.83* 25.06 ± 13.74* 1.43 ± 5.09 2.71 ± 0.44* 5.78 ± 8.31* 2.83 ± 9.77 8.83 ± 2.95*  
         
Table 6.2: Whole liver changes in gene expression after MP treatment or 14 day BDL as measured 
by qPCR. Total RNA was extracted from liver samples using TRIzol and then subject to reverse 
transcription to produce cDNA. The cDNA was used as template for real-time PCR and relative 
expression calculated using 18S rRNA as the endogenous control and fold change expressed relative to 
control liver. Values are the mean and SD of the following animal numbers - for control liver, 3wk MP 
and 3wk MP/3wk vehicle, n=5; for 6wk MP, n=6 and for 14d BDL, n=8.
 
*Significant difference 
compared to control, all at p<0.05. 
 
6.9 Chapter discussion 
 
Models of periportal fibrosis are important for research into anti-fibrogenics; prior to 
clinical testing, it is recommended that anti-fibrogenic drugs are tested in both a 
centrilobular model as well as a periportal model of fibrosis due to their different 
pathologies [5, 6, 16]. Due to the limitations associated with the BDL model of 
periportal fibrosis, chronic MP dosing was investigated as an alternative. 
 
Assessment of pathology following BDL and MP treatment showed that the 2 models 
induced a similar pattern of liver injury. Chronic inflammation is a key driver of 
fibrogenesis in chronically injured liver [16]. H&E staining of liver from MP treated 
and BDL rats showed that both treatments caused significant periportal inflammation. 
MP induced inflammation was also shown to be reversible. PCNA immunostaining 
showed that 6 weeks of MP treatment and BDL both significantly increased hepatocyte 
and cholangiocyte proliferation, demonstrating that both treatments lead to hepatic 
damage and activation of hepatic regenerative pathways.  
 
In terms of fibrogenic cells, the numbers of myofibroblasts and portal tract fibroblasts in 
the periportal region positively correlated with the length of MP administration and 
numbers significantly decreased following the cessation of MP treatment. Sirius red 
staining showed that MP treatment and BDL were both associated with significant 
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periportal collagen deposition, in a manner that mirrored the changes in fibrogenic cell 
populations. Specifically, MP induced periportal fibrosis that significantly increased in 
severity with treatment time and reversed when treatment was ceased. 
 
Spontaneous reversal of fibrosis is recognised to occur in some patients where the 
underlying cause of hepatic insult is successfully treated, however the processes that 
underlie this reversal are poorly understood [16]. The severity of periportal fibrosis in 
MP treated rats correlated with the number of pro-fibrogenic cells. The resolution of 
fibrosis seen in rats treated with MP for 3 weeks followed by vehicle for 3 weeks is 
therefore likely to be the result of apoptosis or reversal of the pro-fibrogenic phenotype 
of these populations. This may result from a decline in inflammation and associated 
pro-fibrogenic growth factors released from inflammatory cells. That the mRNA 
expression of hepatic TGF-β1 and TGF-β2 returned to control levels in rats treated with 
MP for 3 weeks followed by vehicle for 3 weeks (table 6.2) supports this hypothesis. 
The ease of reversal in this model facilitates its use as a method to study the reversal of 
periportal fibrosis.  
 
Increasing evidence suggests that reactive ductules, arising from ductular reaction 
activation, are important mediators of fibrogenesis through secretion of pro-fibrogenic 
and inflammatory factors [4]. CK-19 staining demonstrated that both MP treatment and 
BDL were associated with the activation of a ductular reaction. The reaction induced by 
MP treatment was also shown to be reversible. 
 
Similar to periportal fibrosis, ductular reaction is commonly studied in BDL rats. 
However the severity of hepatic damage caused by BDL means that it is currently 
difficult to model the initiation and progression of ductular reactions in this model. This 
is because within a very short period of time after ligation surgery, a significant ductular 
reaction develops [300]. Chronic MP treatment causes liver damage and activation of a 
ductular reaction less rapidly than BDL. The use of a MP model for the study of this 
phenomenon would give a longer time frame for the investigation into the early stages 
of a ductular reaction. Additionally, the examination of ductular reaction reversal would 
also be simplified compared to the use of BDL for the reasons previously mentioned. 
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In terms of potential drug interactions, MP administration has been shown to reduce 
CYP2C11 and CYP3A activity in rats in-vivo whilst CYP1A and CYP2B activity were 
unaffected [196]. Although MP is a H1 receptor antagonist, knockout of the H1 receptor 
has been demonstrated to have no effect on hepatic injury in a murine model of liver 
damage [301]. The antagonistic action of MP on the H1 receptor is therefore not 
predicted to have a significant effect on MP induced hepatic injury. Although MP drug 
interactions may need to be taken into account when analysing results, MP is not unique 
in having “off-target” effects. Most compounds used to generate liver fibrosis have 
similar “off-target” activity. For example, CCl4, the commonly used centrilobular 
hepatotoxin, is also a relatively potent inhibitor of protein kinase C activity [302]. 
 
The data presented in this chapter demonstrates that, in agreement with the initial 
hypothesis, chronic MP treatment of male rats causes periportal fibrosis with 
characteristics qualitatively equivalent to that seen following BDL, but without the 
requirement for surgery, distress and high mortality rates. The severity of fibrosis could 
be easily modulated and generated fibrosis was reversible on cessation of treatment. 
Chronic MP treatment is therefore, compared to BDL, a refined and alternative model 
for the generation of reversible periportal fibrosis in the rat. 
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Chapter 7. The PXR is anti-fibrogenic in an α-
naphthylisothiocyanate-induced model of periportal fibrosis in 
the mouse 
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7.1 Introduction 
 
Mice are the most commonly used mammalian species in biomedical research due to 
their ease of care and the huge range of genetically engineered mouse strains that have 
been created. Mice subject to BDL are a frequently used model of periportal fibrosis 
[16, 163, 283]. However, similar to its use in rats, the use of BDL in mice is associated 
with animal welfare and methodology problems. These include, but are not limited to, 
high rates of mortality, practical irreversibility of the procedure and inability to 
modulate the intensity of the hepatic injury.  
 
Non-surgical models of periportal and biliary fibrosis in mice are limited. Previous 
work in this lab has shown that MP, although hepatotoxic in rats, does not cause 
significant liver injury in mice [3]. This appears to be because its metabolism differs 
between the two species. Evidence to date shows that mouse hepatocytes do not 
produce the S-oxide thioether of MP that is postulated to be the cause of MP toxicity in 
rat hepatocytes [293]. 
 
α-naphthylisothiocyanate (ANIT) is a hepatotoxic compound which is known to cause 
portal and periportal liver injury in rats and mice [303, 304]. Rather than causing liver 
injury through hepatocyte toxicity directly, ANIT is thought to accumulate in bile where 
it causes necrosis in surrounding biliary epithelia through modification of cellular 
proteins [305, 306]. Hepatocyte damage may come secondarily to cholangiocyte death, 
recruitment of neutrophils and initiation of inflammation.  
 
Several studies have demonstrated that the chronic administration of ANIT also causes 
ductular reaction as well as portal fibrosis leading to cirrhosis when given chronically 
[307-310]. The pattern of fibrosis seen however has not been thoroughly explored, 
particularly in respect to its potential as an alternative to BDL in mice. It was therefore 
hypothesised that the chronic administration of mice with ANIT would cause periportal 
fibrosis qualitatively similar to that seen after BDL.  
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7.2 ANIT treatment causes hepatic injury 
 
Before the hypothesis was tested, pilot work was carried out to confirm and examine the 
distribution and dynamics of ANIT induced liver injury. To confirm the distribution of 
injury and identify an appropriate dose for treatment, a small pilot study was carried out 
as outlined in table 7.1.  
 
Number of animals Treatment Notes 
2 male C57BL/6 Vehicle (olive oil) 
Animals were dosed twice per 
week for 4 weeks. Dosing was 
by oral gavage.  
1 male C57BL/6 10mg/kg ANIT 
1 male C57BL/6 25mg/kg ANIT 
1 male C57BL/6 50mg/kg ANIT 
Table 7.1: Pilot animal dosing groups 
 
Figure 7.1A shows that the administration of ANIT at the doses tested had no effect on 
weight gain in the treated mice over the course of the study. At harvest, measurement of 
liver weight to body mass ratios showed that ANIT treatment increased this ratio in a 
dose dependent manner (figure 7.1B). In terms of serum markers of liver injury, ALT 
activity was not increased by ANIT treatment and appeared to decrease in mice treated 
with 10 or 25mg/kg ANIT. ALP activity was almost twice as high in the mouse treated 
with 50mg/kg ANIT compared to all other treatment groups (figure 7.1C). 
 
Assessment of liver pathology and fibrosis showed that 50mg/kg ANIT treatment 
caused marked portal tract inflammation and collagen deposition around portal tracts 
which was not apparent in other treatment groups (figure 7.2A). The severity of 
periportal fibrosis increased in a dose responsive manner (figure 7.2B).  
 
Following this pilot study, it was realised that ANIT was incompletely dissolved in the 
olive oil vehicle during preparation. A consequence of this is that mice in the pilot study 
may have received less than the dose planned. Constant agitation was found to be 
required for more complete dissolution of ANIT into the vehicle. This method was used 
for all subsequent ANIT work.  
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Figure 7.1: ANIT treatment does not give rise to weight loss but does increase serum ALP activity. 
A. Weights of treated mice over the study. B. Liver weight as percentage body mass at harvest. C. 
Serum ALT and ALP values of treated mice. Values are expressed relative to the vehicle treated mice. 
Results are the mean of the following animal numbers - for vehicle, n=2; for ANIT treated animals, n=1. 
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Figure 7.2: ANIT treatment causes portal tract inflammation and fibrosis. A. H&E and sirius red 
stained livers of vehicle and ANIT treated mice. Liver fixed in 10% formalin and paraffin embedded 
was cut into 5μm sections. Sections were dewaxed, rehydrated and stained with H&E or sirius red prior to 
dehydration and mounting and analysis using a Leica upright microscope. Scale bar indicates 100μm. B. 
Quantified sirius red staining of periportal fibrosis. Sirius red staining was quantified using Qwin 
software: the percentage of periportal regions staining positive for collagen was determined by an 
examiner blinded to the treatment groups, from 10 random portal tracts per section per animal. Results are 
the mean of the following animal numbers - for vehicle, n=2; for ANIT treated animals, n=1. 
 
7.3 Acute ANIT administration induces hepatic NF-κB signalling in-vivo 
 
The development of in-vivo imaging systems, in combination with fluorescent or 
luminescent reporters, allows for live imaging of animals. 3x-κB-luc C57BL/6 mice 
(NF-κB –luc mice) express luciferase under control of a NF-κB response element [164, 
311]. In cells with active NF-κB signalling, luciferase is therefore expressed. Through 
administration of luciferin, which is metabolised by luciferase to produce light, the 
localisation of NF-κB transcriptional activity can be determined. NF-κB signalling is 
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activated by a range of stimuli, including tissue damage, and initiates and regulates 
inflammation, tissue regeneration and immune responses [312, 313]. It is consequently 
active in all chronic liver diseases and is generally considered pro-fibrogenic. Amongst 
other effects, NF-κB inhibits apoptosis of myofibroblasts and drives inflammation 
through promotion of the release of pro-fibrogenic/inflammatory cytokines from various 
cell types, particularly TGFβ1 release from Kupffer cells/macrophages [314-317]. 
Monitoring its expression in NF-κB-luc mice therefore permits the extent of hepatic 
injury and inflammation caused by a given treatment to be determined.  
 
To assess if ANIT treatment would cause hepatic NF-κB activation and inflammation 
measurable in-vivo, and to determine the dynamics of ANIT induced liver injury more 
generally, NF-κB-luc mice were treated with a single dose of vehicle, or a low 
(30mg/kg) or high dose (50mg/kg) of ANIT (outlined in table 7.2). CCl4 was used as a 
positive control as it is known to cause hepatic damage and activation of NF-κB 
signalling [318]. Luminescence was measured over 7 days. 
 
Number of animals Treatment Notes 
2 female NF-κB –luc Vehicle (olive oil) 
Animals were given a single 
dose of vehicle, ANIT or CCl4 at 
T0 and luminescence measured 
periodically over 7 days 
1 female NF-κB –luc 50mg/kg ANIT 
1 female NF-κB –luc 30mg/kg ANIT 
1 female NF-κB –luc  0.6g/kg CCl4 
Table 7.2: Pilot NF-κB-luc mouse study groups 
 
Results showed that CCl4 treatment led to peak signal in the upper abdominal region of 
the mouse (location of the liver) at 24 hours (figure 7.3). The 50mg/kg ANIT treated 
mouse showed peak signal at 48 hours. 30mg/kg ANIT treatment conversely had little 
effect on luminescence. The increase in luminescence induced by CCl4 treatment 
rapidly dropped back to control levels by day 7 whereas luminescence induced by 
50mg/kg ANIT remained elevated at the end of the study. 
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Figure 7.3: Acute dosing of 50mg/kg but not 30mg/kg ANIT causes long term hepatic inflammation. 
A-C: IVIS images of treated mice at 0, 24 and 48 hours respectively. Mice were treated with the 
indicated compounds and imaged at different time points. For imaging, mice were anesthetised with 
isofluorane and injected i.p. with 200μl of D-luciferin at 15mg/ml. Images are from scans 10 minutes 
after injection. D. Quantified abdominal luminescence of treated mice. 
 
In order to be able to carry out statistical tests, the study was repeated using more mice 
treated, as previously, with a single dose of either vehicle, ANIT (50mg/kg) or CCl4. 
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Luminesence was measured over 39 days and following the end of the study organs 
were excised, ex-vivo scans performed and tissue histology assessed.  
 
As shown in figure 7.4 and figure 7.5A, luminescent signal was again apparent in the 
upper abdominal region of ANIT treated mice by 36 hours and which peaked at 60 
hours (2.33 x 10
7
 ± 7.49 x 10
6 
p/s (photons/second)). CCl4 treatment caused upper 
abdominal luminescence which peaked at 24 hours with a total flux of 3.23 x 10
6 
± 9.58 
x 10
5
 p/s and the difference was not significantly different to mice at time point zero. 
Measurement of luminescence over time indicated that the increase in upper abdominal 
luminescence caused by ANIT remained elevated and was significantly different 
compared to time point zero till day 10 following treatment. At the end of the study, 
total flux was still 1.57 x 10
6
 ± 3.87 x 10
5
 p/s (3 fold higher than control mouse values), 
compared to CCl4 treated mice in which luminescence had dropped to control levels by 
day 6. To confirm the source of luminescence in the treated mice, organs were excised 
following the termination of the study and immediately imaged (figure 7.5B). This 
showed that significantly more luminescence could be detected in the livers of ANIT 
treated mice compared to those of control animals. This suggests that the upper 
abdominal signal detected during the in-vivo imaging was from liver luminescence. 
Livers from CCl4 treated mice showed no difference in luminescence. ALP serum 
activity of treated mice showed no difference regardless of treatment (figure 7.5C). 
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Figure 7.4: Acute dosing of 50mg/kg ANIT causes long term hepatic inflammation. IVIS images of 
treated mice at 0 and 60 hours after dosing. Mice were treated with the indicated compounds and 
imaged at different timepoints. For imaging, mice were anesthetised with isofluorane and injected i.p. 
with 200μl of D-luciferin at 15mg/ml. Images are from scans 10 minutes after injection. 
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Figure 7.5: Acute treatment of 50mg/kg ANIT causes long term significant hepatic inflammation. 
A. Quantified abdominal luminescence of treated mice. B. Quantified ex-vivo luminescence of 
harvested organs. C. Serum ALP measurements of treated mice. Serum was taken at harvest. For A 
and B, points and bars respectively are the mean and SD of the following animal numbers - vehicle, n=3; 
CCl4
 
and ANIT, n=4. For C, bars are the mean and SD of the following animal numbers - vehicle, n=3; 
CCl4
 
and ANIT, n=4. In A, *indicates significant difference compared to respective time point zeros at 
p<0.05; statistical significance was determined by a repeated measures ANOVA followed by a Dunnett’s 
multiple comparisons test using Graphpad prism 6. For B, *indicates significantly different total organ 
flux compared to those from control mice determined by 2-tailed Student’s t-test at p<0.05. Pilot animal 
readings, culled on day 46 following treatment, were included in mean and SD values. 
 
 
To assess for an inflammatory response in the livers of the treated mice, the livers were 
fixed, embedded and stained with H&E. Histologically, portal tract inflammation and 
bile duct hyperplasia were only apparent in the livers of ANIT treated mice (figure 
7.6A). Quantification of portal tract inflammation confirmed that ANIT caused 
significant periportal inflammation (figure 7.6B). These data suggest that the NF-κB 
activity measured in this study is a measure of hepatic inflammation. In support of this, 
figure 7.6C depicts the result of plotting the mean number of periportal inflammatory 
cells against total liver flux, indicating a correlation between the two parameters.  
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Figure 7.6: Abdominal luminescence was proportional to hepatic inflammation following acute 
50mg/kg ANIT treatment. Liver fixed in 10% formalin and paraffin embedded was cut into 5μm 
sections. Sections were dewaxed, rehydrated and stained with H&E prior to dehydration, mounting and 
analysis using a Leica upright microscope. Images are representative of groups and scale bar indicates 
100μm. B. Quantified periportal inflammation. The mean number of inflammatory cells around 6 
random portal tracts, per section per animal, was determined by an examiner blinded to the treatment 
groups. Data are the mean and SD of the following animal numbers - for vehicle, n=3; CCl4
 
and ANIT, 
n=4 *significant difference compared to vehicle treated mice at p<0.05. C. Correlation between total 
flux and periportal inflammation. Flux values are from the ex-vivo liver scan. 
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7.4 ANIT treatment causes portal tract inflammation in WT and PXR KO mice 
 
Based on the pilot work, which suggested that ANIT caused liver injury localised to and 
around portal tracts in agreement with the literature, the initial hypothesis (that chronic 
administration of mice with ANIT would cause periportal fibrosis qualitatively similar 
to that seen after BDL) was still appropriate and would therefore be tested. 
  
ANIT treatment causes intrahepatic cholestasis through biliary epithelial cell damage 
[319]. Human cholestatic liver disease may result from a wide range of diseases with a 
number of different aetiologies. These disorders cause a reduction of bile flow and an 
associated retention of substances that are secreted into the bile leading to biliary tree 
obstruction and intrahepatic accumulation of bile acids and hepatotoxicity. Chronic 
hepatic cholestasis is generally associated with the development of biliary and periportal 
fibrosis within the liver [58, 320]. Evidence to date indicates that activation of the PXR, 
the nuclear receptor xenosensor, is hepatoprotective in experimental animal models of 
liver injury [56, 60, 61, 311]. It has also been shown to be anti-fibrogenic in a CCl4 
model of fibrosis [321]. To date, however, a role for the PXR in modulating the severity 
of fibrosis in a periportal model has not been established. Therefore, to further test the 
hypothesised ANIT model of periportal fibrosis, ANIT was dosed in wild type (WT) 
mice and mice lacking expression of a functional PXR (PXR KO). The hypothesis was 
that the expression of a functional PXR protects against liver fibrosis. 
 
ANIT was dosed as outlined in table 7.3, 3 times per week for 8 weeks. ANIT was 
dosed at 30mg/kg as administration of 50mg/kg led to weight loss in treated mice 
following a single dose. The mice were culled the day following the final treatment. 
 
Group Treatment Number of mice Notes 
Vehicle 3ml/kg olive oil by oral gavage 4 WT & 3 PXR KO 
Mice used were 
all male ANIT 
30mg/kg ANIT (by oral 
gavage) 
5 WT & 4 PXR KO 
Table 7.3: Animal dosing groups for ANIT and PCN study 
 
In terms of serum markers of liver injury, treatment of mice with ANIT led to a 
significant increase in serum ALP activity in both WT and PXR KO animals compared 
to vehicle controls (figure 7.7A). Figure 7.7B shows that WT mice, but not PXR KO 
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mice, also had significantly increased ALT serum activity in response to ANIT 
treatment. The liver to body mass ratio however was unaffected by treatment (figure 
7.7C). Importantly, the chronic dosing of ANIT caused no mortalities and treated mice 
did not appear to be in any distress. 
 
 
Figure 7.7: Chronic ANIT treatment significantly increases serum ALP and ALT activity. A. ALP 
serum values of treated mice. B. ALT serum values of treated mice. C. Liver weight as percentage 
body mass at harvest. Data are the mean and SD of the following animal numbers – for PXR KO 
vehicle, n=3; for WT vehicle, and PXR KO ANIT, n=4; for WT ANIT, n=5. *significantly different to 
respective control at p<0.05. 
 
At harvest, livers were dissected from treated mice, fixed and processed. Sections were 
then stained with H&E in order to assess changes in liver histology following treatment. 
Archived tissue from a 21 day BDL study was similarly stained (donated by Fiona 
Oakley). Figure 7.8A shows that ANIT administration was associated with increased 
numbers of infiltrating leukocytes in and around the portal tracts in both WT and PXR 
KO mice similar to that seen after BDL. Aside from inflammation, no major 
histological abnormalities were seen and central veins appeared unaffected by ANIT 
treatment. Figure 7.8B shows that periportal inflammation was significantly increased 
by treatment with ANIT, the severity of which was unaffected by the lack of a 
functional PXR. 
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Figure 7.8: Chronic ANIT treatment causes significant portal tract inflammation. A. H&E stained 
liver tissue. Liver fixed in 10% formalin and paraffin embedded was cut into 5μm sections. Sections were 
dewaxed and rehydrated and stained with H&E prior to dehydration, mounting and analysis using a Leica 
upright microscope. Images are representative of groups and scale bar indicates 100μm. Note, control is 
from the vehicle control group, which had an identical histopathological appearance to sections from 
sham BDL operated mice, hence only one view is shown. B. Quantified mean number of periportal 
inflammatory cells per portal tract. The mean number of inflammatory cells around 5 random 
periportal regions, per section per animal, was determined by an examiner blinded to the treatment 
groups. Data are the mean and SD of the following animal numbers – for PXR KO vehicle, n=3; for WT 
vehicle, sham and BDL, and PXR KO ANIT, n=4; for WT ANIT, n=5. *significant difference compared 
to the respective control group at p<0.05. 
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7.5 Hepatic pro-fibrogenic cell populations expand in response to ANIT treatment 
 
As in rats, hepatic fibrogenesis is a consequence of ECM deposition by different 
populations of fibroblasts and portal tract fibroblasts are an identifying characteristic of 
periportal fibrogenesis [6, 161]. To assess the effect of ANIT treatment upon portal tract 
fibroblasts, the expression of vimentin, which is expressed by portal tract fibroblasts 
[298], was examined by immunostaining. Figure 7.9A shows that ANIT treatment, 
similar to BDL, caused an increase in periportal vimentin staining compared to controls. 
Quantification of the staining (figure 7.9B) showed that ANIT treatment significantly 
increased periportal vimentin staining in both WT and PXR KO animals by around 2 
fold. BDL significantly increased periportal vimentin staining by approximately 3 fold 
compared to sham operated animals. 
 
To determine if ANIT caused activation of fibroblasts to myofibroblasts, α-SMA was 
immunolabelled. Figure 7.10A shows that following ANIT treatment in WT and PXR 
KO animals, there was an apparent increase in the number of α-SMA positive cells 
around portal tracts, particularly surrounding bile ducts. The increase however was less 
pronounced than that seen after BDL in which more α-SMA staining was evident both 
in and around the portal tracts. The results of quantification of the staining is shown in 
figure 7.10B. Treatment with ANIT in both WT and PXR KO mice caused a small but 
significant increase in the number of periportal α-SMA positive cells, qualitatively 
similar to that seen after BDL. 
 
7.6 The PXR protects against ANIT-induced periportal fibrosis 
 
Fibrosis severity following treatment was assessed by sirius red staining (figure 7.11A). 
Treatment of mice with ANIT caused increased periportal collagen deposition in both 
WT and PXR KO mice, with central veins appearing unaffected by treatment. However, 
the degree of deposition appeared more severe in the PXR KO animals. Quantification 
of staining (figure 7.11B) indicated that ANIT treatment significantly increased 
periportal fibrosis in both WT and PXR KO mice similar to that seen after BDL. In the 
PXR KO mice, periportal fibrosis was significantly more severe than that seen in ANIT 
treated WT mice. This suggests that the PXR inhibits ANIT induced periportal 
fibrogenesis.  
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Figure 7.9: Chronic ANIT treatment causes a significant increase in periportal vimentin staining. 
A. Vimentin immunostained liver sections. Liver fixed in 10% formalin and paraffin embedded was cut 
into 5μm sections. Sections were dewaxed, rehydrated and endogenous peroxidases blocked. Sections 
were then subject to sodium citrate antigen retrieval and serum blocking then immunostained for vimentin 
using DAB to detect bound antibody. Sections were then stained with haematoxylin prior to dehydration, 
mounting and analysis using a Leica upright microscope. Images are representative of groups and scale 
bar indicates 100μm. Note, control is from the vehicle control group, which had an identical 
histopathological appearance to sections from sham BDL operated mice, hence only one view is shown. 
B. Quantified periportal vimentin staining. Vimentin staining was quantified using Qwin software: the 
percentage of periportal regions staining positive for vimentin was calculated around 10 random portal 
tracts per section per animal by an examiner blinded to the treatment groups. Values are expressed 
relative to WT vehicle treated mice (or sham for sham and BDL measurements). Data are the mean and 
SD of the following. Animal numbers – for PXR KO vehicle, n=3; for WT vehicle and BDL, and PXR 
KO ANIT, n=4; for WT ANIT and sham, n=5. *significant difference compared to the respective control 
group at p<0.05. 
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Figure 7.10: Chronic ANIT treatment causes a significant increase in periportal myofibroblast 
recruitment/activation. A. α-SMA immunostained liver sections. Liver fixed in 10% formalin and 
paraffin embedded was cut into 5μm sections. Sections were dewaxed, rehydrated and endogenous 
peroxidases blocked. Sections were then subject to sodium citrate antigen retrieval and serum blocking 
then immunostained for α-SMA using DAB to detect bound antibody. Sections were then stained with 
haematoxylin prior to dehydration, mounting and analysis using a Leica upright microscope. Images are 
representative of groups and scale bar indicates 100μm. Note, control is from the vehicle control group, 
which had an identical histopathological appearance to sections from sham BDL operated mice, hence 
only one view is shown. B. Quantified number of α-SMA positive cells per periportal region. The 
mean number of α-SMA positive cells around 6 random portal tracts was calculated per section per 
animal by an examiner blinded to the treatment groups. Data are the mean and SD of the following animal 
numbers – for PXR KO vehicle, n=3; for WT vehicle, sham and BDL, and PXR KO ANIT, n=4; for WT 
ANIT, n=5. *significant difference compared to the respective control group at p<0.05. 
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Figure 7.11: Chronic ANIT treatment causes periportal fibrosis significantly more severe in PXR 
KO mice. A. Sirius red stained liver sections. Liver fixed in 10% formalin and paraffin embedded was 
cut into 5μm sections. Sections were dewaxed and rehydrated and stained with sirius red prior to 
dehydration, mounting and analysis using a Leica upright microscope. Images are representative of 
groups and scale bar indicates 100μm. Note, control is from the vehicle control group, which had an 
identical histopathological appearance to sections from sham BDL operated mice, hence only one view is 
shown. B. Quantification of sirius red staining. Sirius red staining was quantified using Qwin software: 
the percentage of periportal regions staining positive for collagen was calculated around 10 random portal 
tracts per section per animal by an examiner blinded to the treatment groups. Values are expressed 
relative to WT vehicle treated mice (or sham for sham and BDL measurements). Data are the mean and 
SD of the following animal numbers – for PXR KO vehicle, n=3; for WT vehicle, and PXR KO ANIT, 
n=4; for WT ANIT, sham and BDL, n=5. *significant difference compared to the respective control group 
and 
$
significantly more severe fibrosis compared to WT ANIT treated mice at p<0.05. 
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7.7 ANIT administration causes a ductular reaction and induces NTCP expression 
 
To determine if a ductular reaction was initiated by chronic ANIT treatment, liver 
sections were stained for CK-19. Figure 7.12A shows that in response to ANIT 
administration, there was an increase in CK-19 staining around portal tracts in WT and 
PXR KO mice as seen after BDL. Quantification of the staining (figure 7.12B) 
confirmed this as ANIT treatment significantly increased periportal CK-19 staining in 
both WT and PXR KO mice. This confirms that chronic ANIT administration, like 
BDL, causes initiation of a ductular reaction. 
 
In response to cholestatic disease, the expression of proteins involved in bile acid 
metabolism are modulated to minimise hepatic damage caused by bile acid 
accumulation and reduce the synthesis of bile acids from cholesterol [84]. The PXR has 
been shown to play a role in this homeostatic response and is thought to function to 
protect against cholestatic injury through regulation of bile acid metabolism [56-59]. It 
was hypothesised that ANIT treatment would lead to a similar pattern of CYP450 and 
transporter expression to that seen after BDL. 
 
To test the hypothesis, the expression of the hepatic CYP450s that regulate bile acid 
synthesis was analysed by qPCR (figure 7.13A). In mice lacking expression of a 
functional PXR, greater basal levels of CYP7A1 and CYP8B1 mRNA expression were 
seen compared to WT mice, although the increase was not significant. The chronic 
administration of ANIT, to WT or PXR KO mice, was not associated with a significant 
change in the expression of any of the CYP450 mRNAs tested. BDL conversely led to a 
significant increase in the expression of CYP7A1 mRNA and decreased expression of 
CYP8B1 mRNA as has been reported previously [61].  
 
The expression of transporters has been shown to change in response to cholestatic 
disease in the liver in order to ameliorate cellular injury resulting from the intracellular 
accumulation of bile acids [61, 273]. Analysis of the expression of sinusoidal 
transporters involved in hepatocyte bile acid influx in this study (figure 7.13B), showed 
that the mRNA expression of NTCP was significantly higher in ANIT treated WT but 
not PXR KO mice compared to vehicle treated controls.  
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In terms of canalicular transporters (figure 7.13C), in BDL mice, the expression of 
MRP2, MDR1A and MDR2 mRNA, but not BSEP, was significantly increased. No 
significant changes were seen in WT or PXR KO mice treated with ANIT. 
 
Figure 7.12: Chronic ANIT treatment causes activation of a ductular reaction. A. CK-19 
immunostained liver sections. Sections were dewaxed, rehydrated and endogenous peroxidases blocked. 
Sections were then subject to sodium citrate antigen retrieval and serum blocking then immunostained for 
CK-19 using DAB to detect bound antibody. Sections were then stained with haematoxylin prior to 
dehydration, mounting and analysis using a Leica upright microscope. Images are representative of 
groups and scale bar indicates 100μm. Note, control is from the vehicle control group, which had an 
identical histopathological appearance to sections from sham BDL operated mice, hence only one view is 
shown. B. Quantified liver periportal CK-19 staining. CK-19 staining was quantified using Qwin 
software: the percentage of periportal regions staining positive for CK-19 was calculated around 10 portal 
tracts per section per animal by an examiner blinded to the treatment groups. Values are expressed 
relative to WT vehicle treated mice (or sham for sham and BDL measurements). Data are the mean and 
SD of the following animal numbers – for WT sham and BDL, and PXR KO vehicle, n=3; for WT 
vehicle, and PXR KO ANIT, n=4; for WT ANIT, n=5. *significant difference compared to the respective 
control group at p<0.05. 
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Figure 7.13: Chronic ANIT treatment significantly increases NTCP expression. A. Relative mRNA 
expression of CYP450s involved in bile metabolism. B. Relative mRNA expression of the sinusoisdal 
transporter NTCP. C. Relative mRNA expression of the canalicular transporters BSEP, MDR1A, 
MDR2 and MRP2. RNA was isolated from liver samples using TRIzol, reverse transcribed and the 
cDNA used as template for qPCR. Results were normalised to 18S rRNA expression. Data are expressed 
relative to vehicle treated WT mice and are the mean and SD of the following animal numbers – for PXR 
KO vehicle, n=3; for WT vehicle and sham, and PXR KO ANIT, n=4; for WT ANIT, n=5; for BDL, 
n=10. *indicates significant difference compared to respective control at p<0.05. 
 
 
7.8 Chapter discussion 
 
Mice subjected to BDL are a frequently used model for the study of liver disease and 
periportal fibrosis. Due to severity and practical issues associated with the use of BDL, 
liver injury resulting from ANIT treatment was investigated and compared to that seen 
after BDL. The data in this chapter shows that ANIT treatment gives rise to periportal 
fibrosis qualitatively similar to that seen following BDL. Furthermore, through 
administration of ANIT in mice lacking expression of a functional PXR, it was seen that 
the PXR plays an anti-fibrogenic role in this model. 
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As part of the pilot work, the effect of ANIT on hepatic inflammation was investigated. 
This showed that a single dose of 50mg/kg ANIT gave rise to long term hepatic 
inflammation still detectable 39 days after dosing. This was in contrast to CCl4, which 
caused inflammation that peaked around 24 hours before dropping to control levels by 
day 6. ANIT is detoxified by glutathione conjugation in hepatocytes and effluxed into 
the bile by MRP2 [306, 322, 323]. Cannulation of the bile duct to prevent enterohepatic 
recirculation is known to prevent ANIT induced cholestasis and therefore it is expected 
that a significant proportion of metabolised ANIT is re-absorbed in the gut [324]. In the 
bile, glutathione conjugated ANIT is documented to be unstable, potentially limiting the 
efficient clearance of ANIT [322]. The enterohepatic cycling of ANIT would prolong its 
associated toxicity which could explain the long term inflammation observed. However, 
the systemic half-life of orally administered ANIT in rats has been shown to be 6 hours 
and it is likely that the majority of dosed ANIT would be cleared by 48 hours, including 
from the bile [325, 326]. The long term inflammation observed after a single dose of 
ANIT could alternatively be due to initiation of a self-sustaining leukocyte-mediated 
inflammatory response, similar to that seen in human autoimmune liver disorders such 
as primary biliary cirrhosis. This response may be targeted to/maintained by 
cholangiocytes, as it is in primary biliary cirrhosis [327], which is plausible considering 
that they are the primary target of ANIT-mediated toxicity in the liver and ANIT 
induces cholangiocytes to release leukocyte chemo-attractants [328]. It is clear however 
that further study is required to ascertain the cause of the prolonged inflammatory 
response induced by ANIT. 
 
The ability of an acute dose of ANIT to cause significant hepatic inflammation, which 
can be detected in real time, means that this could be a valuable model in which to test 
anti-inflammatory compounds. Compared to other in-vivo models, this model would 
allow relatively rapid screening of compounds and reduced group sizes, due to the 
ability to repeatedly measure an inflammation endpoint in the same animals. 
 
The pattern of hepatic injury seen following chronic ANIT administration was 
qualitatively similar to that seen after BDL in terms of all measured markers of liver 
injury. However, for all tested markers, the magnitude of injury was greater in BDL 
mice compared to ANIT treated mice. This likely reflects that BDL causes constant and 
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uncontrollable hepatic injury in contrast to the periodic dosing regimen of ANIT. The 
severity of liver injury resulting from ANIT treatment could possibly be increased by 
dosing ANIT more regularly or at a higher dose.  
 
Administration of ANIT in both WT mice and mice lacking a functional PXR allowed 
the role of the PXR in ANIT-induced periportal fibrogenesis to be examined. At the 
level of inflammation, equivalent severity of portal tract inflammation was observed 
between WT and PXR KO mice treated with ANIT. Previously published work suggests 
that activation of the PXR suppresses portal tract inflammation in SJL/J mice, which 
show chronic hepatic portal tract inflammation [311]. No difference was seen in the 
severity of portal tract inflammation between SJL/J mice expressing functional PXR 
and those that did not express functional PXR (SJL-PXR
−/−
 mice). This indicates that 
activation of the PXR is required for its anti-inflammatory role which, considering that 
the PXR was not activated in this work, is consistent with the similar severity of portal 
tract inflammation seen in ANIT treated WT and PXR KO mice in this study. 
 
In terms of fibrogenic cell populations, vimentin immunostaining, corresponding to 
portal tract fibroblasts, was significantly increased by ANIT treatment but unaffected by 
genotype (no difference between WT or PXR KO mice). The number of α-SMA 
positive cells was similarly significantly increased by ANIT treatment although not to a 
marked extent in comparison with BDL. Using a CCl4 model of hepatic fibrosis, Marek 
et al., (2005) showed that, unlike WT mice in which CCl4 treatment significantly 
increased both the numbers of α-SMA positive and negative (myo)fibroblasts, in mice 
lacking a functional PXR, only the number of α-SMA negative cells was increased by 
CCl4 treatment [321]. These results are in contrast to this study in which ANIT treated 
WT and PXR KO mice both showed equivalent increases in the numbers of periportal 
vimentin and α-SMA positive cells. These differences may be due to the different 
pattern and localisation of hepatic injury induced by ANIT and CCl4 treatment. 
 
Interestingly, although the relative increase in the number of (myo)fibroblasts was 
equivalent between WT and PXR KO mice following ANIT treatment, the severity of 
periportal fibrosis was significantly greater in the PXR KO mice compared to the mice 
expressing intact PXR. This finding suggests that the PXR, in WT mice, attenuates 
fibrogenesis resulting from chronic ANIT treatment. In a CCl4 induced model of hepatic 
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fibrosis in contrast, the severity of fibrosis caused by chronic CCl4 treatment was not 
markedly changed between WT mice and those lacking expression of a functional PXR 
[321]. An anti-fibrogenic PXR-dependent effect was only seen, in WT mice, when the 
PXR was activated by PCN treatment and this effect was lost in mice with a PXR 
knockout. The role of the PXR, in respect to modulation of fibrogenesis, therefore 
appears to vary depending on the location of fibrosis development. 
 
Activation of a ductular reaction following ANIT treatment was determined by CK-19 
staining. This showed that chronic ANIT administration, similar to BDL, causes 
activation of a ductular reaction the severity of which was not affected by the absence of 
a functional PXR. 
 
Evidence suggests that the PXR regulates bile acid synthesis through repression of 
CYP7A1, which catalyses the rate limiting step in the synthesis of bile acids from 
cholesterol, but also of CYP8B1, which is required for cholic acid synthesis [60, 329]. 
The increased basal, though not significant, expression of CYP7A1 and CYP8B1 
mRNA in PXR KO mice compared to WT mice is therefore likely due to a loss of 
transcriptional repression by the PXR.  
 
NTCP is the main hepatocyte transporter involved in influx of bile acids [72]. During 
cholestasis, the expression of NTCP is repressed by the FXR, as a hepatoprotective 
mechanism to prevent the intracellular accumulation of bile acids to cytotoxic 
concentrations [83, 330]. ANIT treatment was shown in this study to significantly 
increase the expression of NTCP mRNA in WT mice compared to those treated with 
vehicle alone [321]. The reason and mechanism for the observed induction of NTCP 
mRNA expression is unclear. Potentially, it may be due to ANIT, or a metabolite, 
binding and activating the glucocorticoid receptor leading to up-regulation of NTCP 
expression. DEX treatment has been shown to induce NTCP expression in-vivo, acting 
through the glucocorticoid receptor. The effect was not seen with specific PXR or CAR 
activators (PCN and TCPOBOP respectively) and was lost in DEX treated mice lacking 
a functional PXR [331]. However, although functional PXR expression appears to be 
required for the response, the NTCP promoter lacks a PXR consensus sequence, 
suggesting that PXR dependency is likely a consequence of cross-talk between the 
glucocorticoid receptor and PXR signalling pathways such as occurs during CAR and 
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PXR-mediated DME induction [332]. That the induction of NTCP mRNA was seen in 
WT mice alone, not in those lacking functional PXR expression, indicates that ANIT or 
its metabolites may induce NTCP in an equivalent manner to DEX, through the 
glucocorticoid receptor or downstream.  
 
Up-regulation of canalicular transporter expression is hepatoprotective in order to 
reduce intracellular accumulation of bile acids and bilirubin. Several canalicular 
transporters have been shown to be regulated by the PXR including MDR1 and MRP2, 
but not MDR2 [61, 273, 274]. In this study, BDL, but not ANIT, caused a significant 
up-regulation of MDR1A, MDR2 and MRP2 mRNA expression, as has been previously 
shown [61, 273]. Analysis of mRNA expression of enzymes and hepatic transporters 
involved in bile acid and xenobiotic metabolism indicated that the chronic 
administration of ANIT was not associated with changes to bile acid synthesis. The 
expression analysis of CYP450s and transporters involved in hepatobiliary homeostasis 
are in contrast to previously published studies demonstrating that a single high dose of 
ANIT (75mg/kg) caused a significant reduction in the mRNA expression of CYP450s 
CYP7A1, CYP27A1 and CYP8B1 when measured 48 hours after dosing [326, 330]. 
The mRNA expression of apical transporters MRP2, BSEP and MDR2 were also shown 
to significantly increase and NTCP expression to decrease in the same study. The 
markedly different patterns of ANIT administration (75mg/kg ANIT over 48 hours 
compared to 30mg/kg ANIT dosed over 8 weeks) between this study and those 
aforementioned are likely the reason for the contrasting results seen. 
 
The data presented in this chapter has shown that chronic administration of ANIT gives 
rise to significant periportal fibrosis which is qualitatively equivalent to that induced by 
BDL in mice, thus successfully proving the initial hypothesis. Furthermore, in this 
model the PXR was shown to play an anti-fibrogenic role in periportal fibrogenesis 
although the mechanism by which it exerts this effect requires further elucidation. The 
uncovering of the mechanism is likely complicated by the functional redundancy 
between nuclear receptors, such as between the PXR and CAR, acting to mask the effect 
of the PXR knockout [203]. 
  
The use of the ANIT model of periportal fibrosis as an alternative to BDL would 
improve animal welfare and reduce mortality rates whilst likely allowing the severity of 
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fibrosis generated to be modulated similar to the MP model of periportal fibrosis in the 
rat. Mice lacking the expression of a functional PXR showed significantly more severe 
periportal fibrosis in response to chronic ANIT treatment. This result, together with 
findings from this lab demonstrating reduced severity of CCl4 induced fibrosis in 
rodents when treated with the PXR activator PCN [321], suggests that PXR activators 
could be used for treatment of hepatic fibrosis. The PXR agonists ursodeoxycholic acid 
and rifampicin are currently used for the treatment of chronic cholestasis and its 
complications. Unfortunately, rifampicin is associated with hepatotoxicity if 
administered chronically and the efficacy of ursodeoxycholic acid for the treatment of 
cholestatic liver disease remains controversial [333-335]. However these compounds are 
also agonists for targets other than the PXR [335, 336] and there is no evidence that 
PXR activation alone is toxic [337]. Non-hepatotoxic but potent PXR activators could 
therefore be a superior approach to treat hepatic fibrosis in a wide range of chronic liver 
diseases. 
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Liver disease and the associated fibrosis is prevalent worldwide, the 14
th
 leading cause 
of mortality [138]. Due to the unique architecture and resident cell populations of the 
liver, liver disease is complex, involving the contributions of, and interactions between, 
numerous different cell types. Furthermore, the defining cell of the liver, the hepatocyte, 
is not amenable to tissue culture, rapidly dedifferentiating within a few days to lose all 
liver specific functions. The complexity of liver disease pathogenesis limits the use of 
in-vitro models in this field of research and necessitates the use of animal models. 
However many of these models are in need of refinement, including the BDL model of 
periportal fibrosis. Hepatocytes are responsible for the drug metabolising activity of the 
liver and human hepatocytes are the gold standard for drug and chemical toxicity 
screening. However, the limited availability of quality human hepatocytes means that 
animals are culled to derive hepatocytes and the number of animals required to source 
hepatocytes is exacerbated by the rapid dedifferentiation and lack of proliferation of 
hepatocytes in culture. The primary aims of this thesis were to address these issues 
through the refinement of the BDL model of rodent periportal fibrosis and 
characterisation of the B-13/H cell as an alternative to primary hepatocytes for drug and 
chemical toxicity screening.  
 
Investigation of the drug metabolising properties of B-13/H cells demonstrated that they 
are metabolically competent as the 3 main families of rat CYP450s could be induced (at 
the mRNA level) and in the case of CYP1A1 and CYP3A1, induced mRNA was 
translated into functional protein. Furthermore, although CYP4A could not be reliably 
induced to any marked extent, peroxisome proliferation could be. As B-13 cells are 
derived from rats, potentially species differences could limit extrapolation of derived 
results to humans. The stable B-13
-TR/h1A2
 line was therefore created which stably 
expressed human CYP1A2. The expressed hCYP1A2 was shown to be functional, as 
were SULT enzymes required for the bioactivation of the pro-genotoxins PhIP and 1-
hydroxyestragole. This work showed the potential in humanising the B-13 line with 
human genes in order to improve the clinical relevance of the line. Assessment of the 
drug transporter expression profile of B-13/H cells indicated that they expressed a range 
of transporters, at least at the level of mRNA, at levels similar to that seen in liver. 
However, several important hepatic transporters were poorly expressed including MRP2 
and BSEP and therefore different strategies were investigated to enhance transporter 
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expression. HNF4α overexpression was uniquely shown to induce transporter 
expression, although no change in MRP or BSEP activity was seen, even with the 
strong induction of MRP2 protein and BSEP mRNA.  
 
The data presented in this thesis in regard to B-13/H cells suggests that they could be 
used as an alternative to primary hepatocytes for the study of drug metabolism and drug 
and chemical toxicity screening. In respect to screening, the suitability for genotoxicity 
screening in the form of comet assays using B-13/H cells has been validated, however 
sensitivity to other hepatotoxins such as paracetamol, flutamide and troglitazone has 
also been recorded although it is not presented in this thesis. In comparison to the most 
commonly used model of hepatocytes, HepG2 cells, B-13/H cells are a superior model; 
HepG2 cells show only limited CYP450 activity when compared to primary hepatocytes 
whereas B-13/H cells show a quantitatively similar pattern of expression, including 
inducibility in response to prototypical inducers of the primary CYP450 isoforms. 
Consequently, HepG2 cells are relatively insensitive to hepatotoxins requiring 
bioactivation by CYP450s other than CYP1A1, which they express [89]. The expression 
of phase II and III enzymes in HepG2 cells is similar to that of B-13/H cells, with many 
genes expressed at liver equivalent levels. Although, similar to B-13/H cells, HepG2 
cells show low expression of several important transporters including BSEP and NTCP 
[338].  
 
The use of B-13/H cells as an alternative to primary hepatocytes could solve the issues 
associated with primary hepatocyte sourcing and culture. An unlimited number of B-
13/H cells can be quickly and cheaply generated from B-13 cells, which don’t require 
culling of rats to generate, therefore significantly reducing the number of animals culled 
to derive hepatocytes. In culture, B-13/H cells have a stable phenotype and unlike 
primary hepatocytes, B-13 cells can be stably transfected. This allows human genes to 
be introduced into B-13 cells to increase the clinical predictivity of B-13/H cells. Based 
on their drug metabolising capacity, further elucidation of the mechanism of B-13 
transdifferentiation could allow for the isolation of a human equivalent, which would 
express human DMEs. This human equivalent would have significant utility for drug 
and chemical toxicity screening and also for use in bioartificial liver devices.  
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Investigation of alternatives to BDL in rodents demonstrated that the chronic 
administration of MP in rats and ANIT in mice gave rise to periportal fibrosis 
qualitatively equivalent to that seen following BDL. The similarity was seen in terms of 
significant portal tract inflammation, proliferation of pro-fibrogenic cell populations and 
development of periportal fibrosis. The MP model of periportal fibrosis in the rat was 
also reversible when dosing was ceased. This work shows the potential in the chronic 
administration of MP and ANIT, as alternatives to BDL, for the generation of periportal 
fibrosis in rats and mice respectively. Compared to BDL, they are not associated with 
significant mortality or surgical associated complications. In the case of MP, it was also 
shown that unlike BDL, which causes uncontrollable hepatic injury, MP caused 
periportal fibrosis of which the severity could be modulated be increasing the dose. 
Although not tested, this is also likely the case for ANIT induced periportal fibrosis.  
 
Pilot work with ANIT showed that a single dose could cause long term liver portal tract 
inflammation. Although the mechanism responsible for the long term effect documented 
was not clear, this model may provide a useful system with which to study hepatic 
inflammation and therapeutics. Chronic administration of ANIT to PXR KO mice 
caused significantly more severe periportal fibrosis than that seen in WT mice. This, 
together with the previously published work showing the hepatoprotective action of the 
PXR [56, 60, 61, 311], suggests that PXR specific activators could be used as a therapy 
for patients with liver damage and fibrosis. 
 
The use of chronic administration of hepatotoxins to generate fibrosis is a common 
method in the study of liver fibrosis, for example the commonly used model of 
centrilobular fibrosis in rodents involves the chronic administration of CCl4 over 4-8 
weeks [153]. The use of ANIT or MP to generate periportal fibrosis may also therefore 
help standardise models of liver fibrosis, due to the similar method of fibrosis 
generation to the CCl4 model. CCl4 induced fibrosis for example, will spontaneously 
reverse when dosing is ceased [163], similar to MP induced fibrosis. Considering the 
recommendation that novel anti-fibrogenic drugs are tested in a centrilobular and 
periportal model of fibrosis [16], the similar method of generation of fibrosis between 
the CCl4, MP and ANIT models may help with the comparison of results. 
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The data presented in this thesis demonstrates the application of the “3Rs” 
(replacement, refinement and reduction) to liver research. Through the use of B-13/H 
cells and chronic hepatotoxin administration models of periportal fibrosis, fewer 
animals would be required for less severe procedures. Further validation of the 
described models and consideration of the “3Rs” in existing animal based models would 
ultimately improve research outcomes whilst reducing the number of animals used in 
scientific procedures. 
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Appendix A. List of primers used for PCR 
 
Oligo ID Primer sequence (5'-3') Comments 
18S rRNA US CCCGAAGCGTTTACTTTGAA Will amplify 136bp fragment of rat, mouse and human 18S rRNA 
  DS CCCTCTTAATCATGGCCTCA   
rα-collagen US TGTGTTGCTGAAAGACTACCTCGT Will amplify 53bp fragment of rat collagen 1A1 (NM_053304) 
  DS AGTTGCCCCGGTGACACACAA   
rα-SMA US TGCCATGTATGTGGCTATTCA Will amplify 55bp fragment of rat α-SMA (NM_031004) 
  DS ACCAGTTGTACGTCCAGAAGC   
rAhR US TGGCTGTGATGCCAAAGGGCAG Will amplify 100bp fragment of rat AhR (NM_013149.2) 
  DS AAGCATGTCAGCGGCGTGGA   
rAlbumin US TGGTCGCAGCTGTCCGTCAGA Will amplify 182bp fragment of rat albumin (NM_134326.2) 
  DS CAGGTCGCCGTGACAGCACTC   
rAmylase US CAAAATGGTTCTCCCAAGGA Will amplify 224bp fragment of rat pancreatic amylase 2 (NM_031502.1 ) 
  DS AAGGGCTCTGTCAGTAGGCA   
rARNT US GGTTTGCCAGGTCGGATGAT Will amplify 219bp fragment of rat ARNT (NM_012780.1 ) 
  DS CCGTTCCCCTCAAGGACTTC   
mBSEP US TGGCCGTGCTCATCGCCTTC  Will amplify 200bp fragment of mouse BSEP (NM_021022.3) 
  DS TCCAATTCCAGCCACGGTGCG    
rBSEP US GCCAGGGGAAACGACGGCTC Will amplify 113bp fragment of rat BSEP (NM_031760.1) 
  DS GGCCGTCCAGAGTCACCATGC   
rCAR  US CTCTCCTGACAGGCCTGGGGT Will amplify 156bp fragment of rat CAR (NM_022941.3) 
  DS CGAAGCTCAGCTAGCAGGCCC   
hC/EBPα US CCATGCCGGGAGAACTCTAA Will amplify 218bp fragment of human C/EBPα (NM_004364.4) 
  DS ATGTCGATGGACGTCTCGTG   
rCPS-1 US ATACAACGGCACGTGATGAA  Will amplify 390bp fragment of rat CPS-1 (NM_017072.1) 
  DS GCTTAACTAGCAGGCGGATG    
rCYP1A1 US TCCCTGGGGTCCTAGAGAACACTCT Will amplify 109bp fragment of rat CYP1A1 (NM_012540.2) 
  DS TGTGGCTGATGTGAAGGCTGGG   
hCYP1A2 US CACACCAGCCATTACAACCCTGCC Will amplify 1608bp coding sequence of human CYP1A2 (NM_000761.3) 
  DS TCAGTTGATGGAGAAGCGCAGCC   
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gCYP1A2 US GTGGTCACTGGCATCCACACCA Will amplify 460bp fragment of genomic rat CYP1A2 (NC_005107.3) 
  DS AAGGGCAAGCCCCAGGGTCC   
rCYP1A2 US CGCATTGGCTCCACACCCGT Will amplify 412bp fragment of rat CYP1A2 (NM_012541.3) 
  DS TCTCCTCGCTCTTCCTGGGGA   
rCYP1A2 US CTACAACTCTGCCAGTCTCCAG Will amplify 130bp fragment of rat CYP1A2 (NM_012541.3 ) - used for qPCR 
  DS CCTCTCAACACCCAGAACACT   
rCYP1B1 US CAGCTTTTTGCCTGTCACCC Will amplify 180bp fragment of rat CYP1B1 (NM_012940.2) 
  DS ATGAAGCCGTCCTTGTCCAG   
rCYP2A1 US ATGCTGCTTTCCTCCCTTTC Will amplify 64bp fragment of rat CYP2A1 (NM_012692.1) 
  DS ATCTTAGCCAGGCCATCTCC   
rCYP2B1 US CGCATGGAGAAGGAGAAGTCGAACC Will amplify 151bp fragment of rat CYP2B1 (NM_001134844.1 ) 
  DS CGACATGGGGGTACTTGAGCATCAG   
rCYP2B2 US CGCCTGTTGGAGCTGTTCTA Will amplify 151bp fragment of rat CYP2B2 (NM_001198676.1) 
  DS ACTTCTCCTCTCTCATCCATGC   
rCYP2B3 US CCCTTCTCCATAGGAAAGCGTA Will amplify 269bp fragment of rat CYP2B3 (NM_173294.1) 
  DS CCAGCAGGTCTCCCAGAATC   
rCYP2C6 US CTGTGACCAACCAGCTAAAGTCCAG Will amplify 82bp fragment of rat CYP2C6 (XM_003748910.1) 
  DS CTCCATGCGGGCTAGGCCCT   
rCYP2C7 US AGATGTGAAGAACATCAGCCA Will amplify 84bp fragment of CYP2C7 (NM_017158.2) 
  DS GGCTGTGAGCCCAAATACAG   
rCYP2C11 US CTGCCATGGATCCAGTCCTAGTCC Will amplify 88bp fragment of rat CYP2C11 (NM_019184.2 ) 
  DS TTCCCTCTCCCAAAGCTCTGTCTCC   
rCYP2C12 US TGTGAGCACTCCTGCATTTCAGG Will amplify 317bp fragment of rat CYP2C12 (NM_031572.1) 
  DS AGAGCAAAAGTGCAAATCTCAGCGT   
rCYP2C13 US CCCACTTTCCAGATGCGCTTCA Will amplify 165bp fragment of rat CYP2C13 (NM_138514.1) 
  DS CCGAAGCTGTGAGAAGAAGGAAGG   
rCYP2E1 US TCGACTACAATGACAAGAAGTGT  Will amplify 525bp fragment of rat CYP2E1 (NM_031543) 
  DS CAAGATTGATGAATCTCTGGATCTC    
rCYP3A1/23 US TGGCCCAGTGGGGATTATGGGG Will amplify 183bp fragment of rat CYP3A1/23 (NM_013105.2) 
  DS GGGACAGGTTTGCCTTTCTCTTGCC   
rCYP3A2 US TGGCAAGGTCTGTGATGGAAC Will amplify 72bp fragment of rat CYP3A2 (NM_153312.2) 
  DS ACCAGATGTGGATGGAGATGG   
rCYP3A2 US ACCCGTCTGGATTCTAAGCA Will amplify 73bp fragment of rat CYP3A2 (NM_153312.2) - used for qPCR 
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  DS TGGAATTATTATGAGCGTTCAGC   
mCYP3A11 US GGATCACACACACAGTTGTAGGGAG  Will amplify 194bp fragment of mouse CYP3A11 (NM_007818.3) 
  DS GCAGAGGTTTGGGCCCAGGAA    
rCYP3A18 US GGAGGCCTGAACTGCTGAAGGAG Will amplify 166bp fragment of rat CYP3A18 (NM_145782.1) 
  DS AAGGCACAGGTTTGGGTCCAGGA   
rCYP3A19 US GCCCTGAAAGGTTCAGCAAG Will amplify 282bp fragment of rat CYP3A19 (NM_147206.2) 
  DS AGGCCATTCTACATCAAGCTCC   
rCYP4A1 US TGCACCATGAGCGTCTCTGCACT Will amplify 85bp fragment of rat CYP4A1 (NM_175837.1) 
  DS GACCAAGCACGGAGGCCACTT   
rCYP4A2 US AGCTCCAAAGCTTTTACTCCAGA  Will amplify 219bp fragment of rat CYP4A2 ( NM_001044770.2) 
  DS TGCCGATTGTCCCAAGACTC    
rCYP4A3 US GGAGGAGCAAGGAACTGCAT  Will amplify 225bp fragment of rat CYP4A3 (NM_175760.2) 
  DS TATTGCAGGCAGCAGACCTC    
mCYP7A1 US TGCGAAGGCATTTGGACACAGA Will amplify 163bp fragment of mouse CYP7A1 (NM_007824.2) 
  DS AGGAAGGCCCGGAGGTCTCA   
mCYP8B1 US CCCCGGCAGGTTCTTTGCCC  Will amplify 119bp fragment of mouse CYP8B1 (NM_007742.3) 
  DS AGCGCCTTGGGTCAATGGGG    
mCYP27A1 US GGCTGGGGTGGACACGACAT Will amplify 116bp fragment of mouse CYP27A1 (NM_024264.4) 
  DS TCCCGAAGGGCACCACACCA   
hFOXA2 US CACTTGAGTCCCAGCCTGA Will amplify 333bp fragment of human FOXA2 (BC011780.2) 
  DS GTCGTTGAAGGAGAGCGAGT   
rmhGAPDH US TGACATCAAGAAGGTGGTGAAG Will amplify 243bp of rat GAPDH (NM_017008.3)(also human and mouse) 
  DS TTGTCATACCAGGAAATGAGCT   
hHNF1α US ACAGCTTGGAGCAGACATCC Will amplify 55bp fragment of human HNF1α (BC104910.1) 
  DS ATGAGCATAGTCTGCGGGAG   
rhHNF4α US ACATGGACATGGCCGACTAC Will amplify 202bp fragment of human HNF4α (NM_178849.2)(also rat) 
  DS CTCGAGGCACCGTAGTGTTT   
mMDR1a US GGAACAGCGGTTTCCAGGAGCTG Will amplify 136bp fragment of mouse MDR1a (NM_011076.2) 
  DS CCATCACGACCTCACGTGTCTCT   
mMDR2 US AGCGAGAAACGGAACAGCACGG Will amplify 175bp fragment of mouse MDR2 (NM_008830.2) 
  DS AGCTATGGCCATGAGGGTGCC   
rMMP-2 US GCACCGTCGCCCATCATCAAGT Will amplify 55bp fragment of rat MMP2 (NM_031054.2) 
  DS TTGCGGGGAAAGAAGTTGTAGT   
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mMRP2 US CGTGCGCTCTCCTCCCAGACT Will amplify 167bp fragment of mouse MRP2 (NM_013806.2 ) 
  DS CACAGCCGACAGGGGGTCGT   
rMRP2 US GCGCCCTGGGTGACTGACAA Will amplify 164bp fragment of rat MRP2 (NM_012833.1) 
  DS GTCCTGCCCACTACGCCGAC   
mNTCP US ATCCAAGCTGCAGACGCACCA Will amplify 248bp fragment of mouse NTCP (NM_001177561.1) 
  DS AGCATCTTCTGTTGCAGCAGCCT   
rNTCP US GCATCATGCCCCTCGCTGCT  Will amplify 164bp fragment of rat NTCP (NM_017047.1) 
  DS GGTGGTCATCACGATGCTGAGGT    
rPAPSS1 US CTCTCTTACCACTCGGCCTC  Will amplify 313bp fragment of rat PAPSS1 (NM_001106471.1) 
  DS AAGTGTAGCACGGAATGCCA    
rPAPSS2 US CCGTGTTACTCCCTGGATGG Will amplify 600bp fragment of rat PAPSS2 (NM_001106375.2 ) 
  DS AAAGCCTTTGAGCGGAGTGG   
rPPARα US CGGGGATCTTAGAGGCGAGCCAA  Will amplify 126bp fragment of rat PPARα (NM_013196.1) 
  DS GCGGGCCACAGAGCACCAAT    
rPXR US GCTCCTGCTGGACCCGTTGA Will amplify 115bp fragment of rat PXR (NM_052980.2) 
  DS GCCAGGGCGATCTGGGGAGAA   
rRXRα US TCTTCATCCCTGAGCTCTCCA Will amplify 263bp fragment of rat RXRα (NM_012805.2) 
  DS TTCATGGGTGAGTTGAGCTGG   
rRXRβ US GACAGCTCCTCCCCAAATCC Will amplify 213bp fragment of rat RXRβ (NM_206849.3) 
  DS GGAGTTAATCTGAGGGCTGC   
hSGK1F US TCTCCTCCTTCATCCACAGCTTTCA Will amplify 211bp fragment of human SGK1F (CAI19718) 
  DS TGGACGACGGGCCAAGGTTG   
rSULT1A1 US ACACATCTGCCCCTGTCCT Will amplify 77bp fragment of rat SULT1A1 (NM_031834.1) 
  DS GCATTTCGGGCAATGTAGA   
rSULT1B1 US CGAGATGTTATTACCTCTAAAGTTCCA Will amplify 88bp fragment of rat SULT1B1 (NM_025513.1) 
  DS GAGTTTTCTTCAAGAGTTCAACACC   
rSULT1C2 US TCTGCCCTTGAGGTATCCAG Will amplify 90bp fragment of rat SULT1C2 (NM_133547.4) 
  DS GCGGCTGTAATCTGCTCAA   
rSULT1C2A US TCTGCCCTTGAGGTATCCAG Will amplify 87bp fragment of rat SULT1C2A (NM_001013177.2) 
  DS CAGGGAAGAAGGTTTAGTTCCA   
rSULT1C3 US GGTACCCTGGGAGAATACATTG Will amplify 84bp fragment of rat SULT1C3 (NM_031732.2) 
  DS CCACCATCCCTTTACATGGT   
rSULT1D1 US CCTCGACTGGTGAAGACACA Will amplify 87bp fragment of rat SULT1D1 (NM_021769.1) 
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  DS CCGTGCCACATAAATCATCTT   
rSULT1E1 US GAGAAATTTATGGAAGGGCAAG Will amplify 103bp fragment of rat SULT1E1 (NM_012883.1) 
  DS CATAGAACATAAACAAAACACGTGAA   
rSULT2A1 US TGGGGTAATTCAACTCTTGTGA Will amplify 102bp fragment of at rat SULT2A1 (NM_131903.1 ) 
  DS GATGTGCTCAAACCATGATCC   
rSULT2A2 US TCTTCAGTTCCAAGGCCAAG Will amplify 118bp fragment of rat SULT2A2 (NM_001025131.1) 
  DS GTTCCCAGCGAGTCTGGTT   
rSULT2A6 US AAGACAACTCTTGCGAAGAAGC Will amplify 96bp fragment of rat SULT2A6 (NM_012695.3) 
  DS GATGTGCTCAAACCATGATCC   
rSULT2B1 US GGTGATTTACTTGGGCCGGA  Will amplify 420bp fragment of rat SULT2B1 (NM_001039665.1) 
  DS CAGTCGCCACTGATCCCTTT    
rSULT2B12 US GGTGATTTACTTGGGCCGGA  Will amplify 420bp fragment of rat SULT2B12 (NM_001039665.1) 
  DS CAGTCGCCACTGATCCCTTT    
rSULT4A1 US CGGAAGTTGCTTGGAAACAG Will amplify 60bp fragment of rat SULT4A1 (NM_031641.1) 
  DS CATCTCACTCCTCGGCTCTC   
rSULT5A1 US CTCCAGAAGGACCTAACTTTGC Will amplify 69bp fragment of rat SULT5A1 (NM_001106194.1) 
  DS AATGGTTGAGCGAGGTTCC   
rSULT6B1 US TCCGAGCTTTGGATGCCTTT Will amplify 608bp fragment of rat SULT6B1 (NM_001192017.1) 
  DS CTGGGATTTTGCTCGCATCG   
rTGFβ1 US CGAGCCCGAGGCGGACTACT Will amplify 73bp fragment of rat TGFβ1 (NM_021578.2) 
  DS ATAGATTGCGTTGTTGCGGTCCACC   
rTGFβ2 US TTCAGAATCGTCCGCTTCGAT Will amplify 114bp fragment of rat TGFβ2 (NM_031131.1) 
  DS TTGTTCAGCCACTCTGGCCTT   
rTIMP1 US GACCACCTTATACCAGCGTT Will amplify 60bp fragment of rat TIMP1 (NM_053819.1) 
  DS GTCACTCTCCAGTTTGCAAG   
rVimentin US CAGGCCACCTCGTCCTTCGAAG Will amplify 84bp fragment of rat vimentin (NM_031140.1 ) 
   DS TGTGCCGGAGCCACCGAACAT   
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Appendix B. Published papers 
